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8Chapter 1
RISK ASSESSMENT OF CHEMICALS
In the past century, major events such as the industrial revolution and World War I and II took 
place, which resulted in a significant increase of the development and production of 
chemicals. Many of these chemicals are beneficial for our life as they for example facilitate 
the production of crops as fertiliser or protect them from pests, they are used as 
pharmaceuticals, applied to produce a wide variety of consumer goods, or are used in 
chemical synthesis. Consequently, chemical exposure has become ubiquitous in daily life, 
from the moment of conception until death. Exposure to chemicals, however, may also lead 
to adverse health effects. A classical example is the synthetic hormone diethylstilbestrol 
(DES) which was prescribed to millions of women around the world, predominantly in the 
period of 1940 till late 1970s (Troisi et al. 2007), to prevent miscarriages and premature 
labour (National Toxicology Program 2011). It was considered safe and effective until the 
United States Environmental Protection Agency (EPA) advised physicians in 1971 to 
discontinue prescribing DES due to a link to a rare vaginal cancer in female offspring (Anon. 
1972). Now, millions of people, both DES mothers and their (grand)children suffer from or are 
at increased risk to a variety of adverse health effects, like vaginal and cervical cancer 
(Verloop et al. 2010), breast cancer (Hoover et al. 2011; Titus-Ernstoff et al. 2001), infertility 
(Senekjian et al. 1988; Verloop et al. 2010) and urogenital abnormalities (Klip et al. 2002). 
This event and many other incidences reported in the previous century have initiated a more 
thorough pre-market testing and safety evaluation of novel chemicals.
Over time, dozens of regulations and directives on the safety of compounds have come 
into force within Europe, like the European regulation on food additives (EC 2008), the 
European regulation on pesticides (EC 2009a) and the directive on pharmacovigilance (EC 
2010). In Europe, health and safety tests for industrial chemicals did not become compulsory 
until 1981 (Čihák, 2009). As a result, more than 100,000 chemicals have been marketed in 
Europe prior to 1981, which have not yet been (fully) tested on safety (Čihák, 2009). A more 
or less similar situation is encountered in the US; since the late 1970s about 84,000 
industrial chemicals that are manufactured and/or processed in the USA are listed on the US 
Toxic Substances Control Act (TSCA) inventory (EPA 2015), but chemical companies were not 
obliged to provide specific toxicological evaluations although this information may be required 
by the EPA (National Research Council 2006). From the time the TSCA was enacted in 1976 
until 2009, additional toxicity information was required for only less than 200 chemicals 
(GOA 2013), leaving a large number of chemicals for which no adequate toxicological data 
are available. Insight into the possible health effects of these chemicals is therefore highly 
desirable. With the enforcement of the European Registration, Evaluation, Authorisation and 
restriction of CHemicals (REACH) regulation in 2007 (EC 2007), the EU aims to collect 
chemical safety information of chemicals that are produced or imported at levels > 1 tonne/
C
C
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yr, in the period from 2007-2018. The estimated number of chemicals to be registered under 
REACH lays within 68,000-100,000 (Rovida and Hartung 2009).
Traditionally, human health risk assessment consists of four steps, the hazard 
identification, dose-response assessment, exposure assessment and risk characterisation 
(National Research Council 1983), and enables estimation of the probability of adverse 
health effects in humans due to a chemical exposure. At the current state-of-the-art both the 
hazard identification and the dose-response assessment of chemicals rely heavily on the 
results of in vivo toxicity studies in experimental animals. To be able to fill the data gaps on 
the safety information of industrial chemicals, millions of animals would be required. Rovida 
and Hartung (2009) estimated that for the implementation of REACH, 114 million vertebrate 
animals might be needed. The greatest contribution to the total number of animals required 
has been estimated to come from three toxicity tests only, namely the developmental toxicity 
screening test (28.13%), the two-generation reproduction toxicity test (31.95%) and the long-
term fish toxicity test (26.62%) (Rovida and Hartung 2009). The use of such a high number of 
experimental animals for safety testing of chemicals is generally regarded unethical, and not 
acceptable from a financial point of view (Rovida and Hartung 2009) and it would also require 
an enormous capacity of laboratories to carry out that many animal tests within the proposed 
period of time (IEH 2001). Because of these drawbacks, the application of alternatives to 
animal experiments is enforced within REACH (EC 2007) and the Cosmetic Products 
Regulation (EC 2009b). Moreover, a US National Research Council report on toxicity testing 
in the 21st century (National Research Council 2007) describes a transition in toxicity testing 
from relying on apical endpoints determined in in vivo studies towards application of in vitro 
tests to assess perturbations of toxicity pathways that are relevant for human biology. These 
initiatives promote that the safety evaluation of chemicals is evolving from using standalone 
animal toxicity tests towards the application of innovative non-animal based in vitro 
approaches to predict toxicity.
Over the past decades many efforts have been undertaken to develop alternatives to 
animal testing for a wide range of toxicological endpoints and parameters. In vitro toxicity 
assays are mainly used to screen and prioritise chemicals for further toxicity testing. 
Translation of in vitro toxicity data to the in vivo situation is an important, but limiting step for 
the use of in vitro toxicity outcomes in the regulatory risk assessment of chemicals, as in vitro 
derived outcomes of toxicity screening data do not always reflect in vivo toxicity ranking 
values (Blaauboer 2010). Moreover, the potential of in vitro tests to provide adequate 
quantitative toxicity values for the hazard and risk assessment of chemicals is limited. An 
important reason underlying this limitation is that an in vitro assay cannot provide a complete 
in vivo dose-response curve from which a point of departure (PoD) for risk assessment, like 
the no observed adverse effect level (NOAEL) or the 95% lower confidence limit of the 
benchmark dose (BMDL), can be derived. To overcome this constraint, in vitro toxicity tests 
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could be combined with physiologically based kinetic (PBK) modelling (Forsby and Blaauboer 
2007; Louisse et al. 2010; Verwei et al. 2006). PBK models describe the absorption, 
distribution, metabolism and excretion (ADME) of a compound and may provide the link 
between in vitro derived toxicity data and in vivo toxicity values. Information describing the 
ADME characteristics can be obtained from in vivo kinetic studies, which have formed the 
basis for many PBK model parameters (Clewell and Clewell III 2008; Krewski et al. 1994). 
Along with the development of in vitro toxicity assays, in vitro and in silico approaches 
describing ADME processes have received increasing attention over the past years and may 
be used to parameterise PBK models (Rietjens et al. 2011). Combining in vitro toxicity data 
with PBK models, using in silico and in vitro derived kinetic parameters and information 
reported in the literature can be a next step to optimally contribute to a replacement, 
reduction and refinement (3Rs) of animal testing for the qualitative and quantitative safety 
assessment of chemicals.
Deriving human guidance values for chemicals is an important step for the risk assessment 
of chemicals and as outlined above frequently relies on animal data. Besides that alternatives 
to animal testing are required for ethical and financial reasons, alternative approaches might 
also provide better toxicity estimates for the human situation. At present, for non-genotoxic 
compounds PoDs derived from animal toxicity studies are extrapolated to human guidance 
values by applying default uncertainty factors that account for the inter- and intraspecies 
kinetic and dynamic differences (IPCS 2005). The default uncertainty factors often used 
amount to 10 for interspecies differences and another factor 10 for intraspecies variation 
(IPCS 2010). The interspecies safety factor is composed of a factor of 100.6 (=4.0) accounting 
for kinetic differences and 100.4 (=2.5) for dynamic differences, where the intraspecies safety 
factor is composed of a factor of 100.5 (=3.16) accounting for human interindividual variability 
in toxicokinetics and a factor 100.5 (=3.16) for human interindividual variability in 
toxicodynamics (IPCS 2005). The EPA and the United States Food and Drug Administration 
(FDA) use allometric scaling to account for interspecies differences. Two methods are often 
applied, namely allometry based on differences in body size (US FDA 2005) and allometry 
based on differences in physiological parameters (US EPA 2005) for which a body weight 
based allometric exponent of 2/3 and 3/4 is used, respectively. After applying intra- en 
interspecies uncertainty factors, the resulting guidance value can be applied for the general 
population, depending on the use of the chemical. However, these general factors do not 
always adequately resemble compound specific interindividual kinetic and dynamic 
differences. For example, response to environmental chemicals can vary between individuals 
or population groups as a result of multiple factors, i.e. age, life style, genotype, disease 
status and use of drugs. Insight into the sensitivity towards chemicals within the human 
population may be valuable as it can help to define specific groups that might be at higher 
risk, and thereby facilitate the risk assessment of compounds. Combining PBK modelling 
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with a statistical sampling technique (i.e. Monte Carlo simulation) may allow to evaluate 
variability and/or uncertainty in model inputs to variability and or uncertainty in model 
outputs, which potentially allows to quantify interindividual variability in chemical induced 
toxicity (Bois et al. 2010).
AIM OF THIS THESIS
The aim of the present thesis was to demonstrate the potential of a combined in vitro PBK 
based approach to translate in vitro data to in vivo toxicity values for rat and human predicting 
in vivo dose-response curves that allow definition of a PoD for risk assessment. This 
translation was carried out by applying PBK-based reverse dosimetry, using in silico and in 
vitro defined kinetic parameters, and by combining the in vitro PBK approach with Monte-
Carlo simulations to assess interindividual variability.
The toxicity endpoint chosen for the studies was developmental toxicity because in vivo 
assays for this endpoint require one of the highest numbers of experimental animals in 
toxicity testing. Simple phenolic congeners were selected as model compounds based on the 
availability of in vitro and in vivo data for this endpoint.
DEVELOPMENTAL IN VITRO TOXICITY TESTING
Currently, several methods to predict human developmental toxicity are listed in the EURL 
database on alternative methods to animal experimentation (DM-ALM) (ECVAM DB-ALM 
2014). Different species or tissue fractions or cells from different organisms, including mice 
and rats are used. Despite the fact that these assays are recorded in the database on 
alternative methods DM-ALM, they differ with respect to their contribution to the 3Rs. For 
example, in the whole embryo culture (WEC) assay, the frog embryo teratogenesis assay-
xenopus (FETAX) test and the chicken embryotoxicity test, whole embryos are used (in 
culture), while the murine embryonic stem cell test (EST) uses a permanent cell line 
(Spielmann et al. 2006). Moreover, the alternatives included in the database on alternative 
methods DM-ALM cover a variety of (developmental) endpoints, i.e. effects of chemicals on 
differentiation, morphology, viability and/or functional parameters. So far the EST, WEC assay 
and micromass (MM) test are scientifically validated by ECVAM. From these three assays, the 
EST is the only test that does not require experimental animals, as it uses a permanent 
mouse cell line which makes it a promising assay for high-throughput screening of compounds 
(Spielmann et al. 2006). Therefore, the EST was chosen to assess the embryotoxic potency 
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of phenols in vitro in the present thesis. The differentiation assay of EST studies the 
embryotoxic potential of chemicals and is based on the assumption that chemicals block the 
spontaneous development of embryonic cells into beating cardiomyocyte clusters (Seiler et 
al. 2006). It is presumed that it covers critical endpoints in embryotoxicity (Adler et al. 2011). 
Based on different (pre)validation test that were performed it was stated that the EST was a 
reliable in vitro method to test embryotoxicity in vitro (Seiler et al. 2006). However, another 
validation study reported a low predictivity of the assay (Marx-Stoelting et al. 2009).
PBK MODELLING
PBK modelling is a mathematical technique to describe the ADME of a compound in an 
organism. In a PBK model, organs and tissues are represented as compartments, which are 
defined by anatomical (i.e. organ and tissue weights), physiological (i.e. blood flows), physico-
chemical (i.e. blood:tissue coefficients) and kinetic (i.e. metabolic constants) parameters 
(Chiu et al. 2007; Krewski et al. 1994). The concentration of a compound and/or its 
metabolites in the compartment of interest in time is calculated using a set of mass-balance 
differential equations (Krewski et al. 1994; Rietjens et al. 2011). 
Traditionally, PBK models have been applied to estimate the internal exposure to a 
chemical, i.e. a blood or tissue concentration, after being externally exposed for example orally 
or via inhalation. This type of prediction is called forward dosimetry (Clewell et al. 2008). The 
inverse, estimating external dose levels based on internal concentrations is called reverse 
dosimetry (Clewell et al. 2008) and was applied in the present thesis to translate in vitro 
effect concentrations to in vivo external dose levels in our so-called in vitro PBK approach.
PBK models can be developed for different species, for specific populations and even for 
individuals. When PBK models are linked with Monte Carlo simulations, then the impact of 
interindividual variation regarding for example physiological or biochemical parameters, on 
the distribution of internal (plasma) concentrations of a compound across a population can 
be simulated.
PBK MODEL PARAMETERISATION
Parameterisation of PBK models is an essential aspect of constructing a PBK model, because 
it can greatly affect the outcomes of the model. PBK model parameter values may be obtained 
from different sources. Anatomical and physiological parameter values for the species to be 
modelled (e.g. rat, mouse, human) are to a large extent available in the literature (Brown et 
al. 1997; Delp et al. 1998; ICRP 2003), especially when this concerns anatomical and 
physiological values that should represent the average of a population. In contrast, in vivo 
derived physico-chemical and kinetic data are scarce because in vivo ADME studies have not 
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regularly been conducted. Moreover, due to restrictions on animal testing under recent 
regulations like REACH (EC 2007) and the Cosmetic Products Regulation (EC 2009b) 
alternative approaches to predict physico-chemical and kinetic parameters are essential. 
Some key parameters in PBK modelling are discussed below.
Partition coefficients are physico-chemical parameters that are used in PBK models to 
estimate the distribution of a chemical over the specific body compartments or blood, such 
as for example the partitioning of a chemical between liver tissue and plasma. In vivo derived 
values for partition coefficients are obtained by taking the ratio of measured in vivo tissue 
and plasma concentrations at steady state conditions. An alternate approach is to determine 
these values in vitro, applying separation techniques including vial equilibration (Jepson et al. 
1994; Murphy et al. 1995), ultra filtration (Tremblay et al. 2012), dialysis (Pacifici and Viani 
1992) or solid-phase microextraction (Artola-Garicano et al. 2000), which accomplish 
partitioning of the test chemical between two or more compartments that represent the 
matrices of interest, for example the tissue and blood. Chemical analysis of the compartments 
at equilibrium provides information to calculate the partition coefficients. In addition to these 
in vitro approaches, numerous algorithms that estimate a chemical specific partition 
coefficient for certain compartments have been proposed in the past decades. Some have 
been established empirically (Meulenberg and Vijverberg 2000), while others are 
mechanistically defined using descriptors including the octanol-water partition coefficient 
and protein binding (Berezhkovskiy 2004; DeJongh et al. 1997; Payne and Kenny 2002; 
Poulin et al. 2001; Poulin and Krishnan 1996a; Poulin and Krishnan 1996b; Poulin and Theil 
2000; Rodgers et al. 2005; Rodgers and Rowland 2006).
Frequently used kinetic data in PBK models include the oral absorption coefficient and 
kinetic constants for biotransformation reactions of a chemical. Non-animal based systems 
to study intestinal permeation include cell based drug transport studies (Alqahtani et al. 
2013; Balimane and Chong 2005), isolated membrane vesicles (Hillgren et al. 1995), the 
Parallel Artificial Membrane Permeability Assay (PAMPA) (Kansy et al. 1998) and ex vivo and 
in situ models, for instance everted gut sacs (Wilk-Zasadna et al. 2015). Information on 
metabolism may be predicted using hepatocytes (Vellonen et al. 2014), tissue-slices (De 
Graaf et al. 2010), subcellular fractions like microsomes (Punt et al. 2008), or embryonic and 
induced pluripotent stem cells (Mann 2015; Takebe et al. 2013), each with its specific 
benefits and drawbacks (Wilk-Zasadna et al. 2015). In silico approaches to predict metabolism 
vary from rule-based expert systems that predict chemical sites liable for metabolism and the 
resulting metabolites (T’Jollyn et al. 2011), to Quantitative Structure-Activity Relationships 
(QSARs) to estimate metabolic constants such as Km and Vmax (Pirovano et al. 2014). The 
availability of alternative methods to quantify ADME characteristics, however, depends on the 
tissue, or barrier studied as well as the species.
Despite recent developments in non-animal approaches to estimate ADME properties, 
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PBK models for toxicological risk assessment purposes have often been developed based on 
animal data. Thus, exploring the development of PBK models that are (only) based on in vitro 
and in silico approaches, as was carried out in the present thesis may provide new 
perspectives for advancing PBK modelling as a method in alternatives to animal testing.
Selecting an applicable approach or assay to parameterise a PBK model requires 
consideration about the purpose of the PBK model, the age group, gender and species to be 
modelled, the physico-chemical properties of the compound of interest, the predictive power 
of the ADME assay and its applicability domain. For instance, to select the appropriate 
algorithm for predicting a partition coefficient, the species and the tissues to be modelled, as 
well as the chemical lipophilicity should be considered (Payne and Kenny 2002). Parameters 
generated with in silico or in vitro approaches may often not directly represent the in vivo 
system, and hence extrapolation of in vitro data to the in vivo situation (IVIVE) is imperative, 
to enable use of the generated output in the PBK model.
 
GENERAL OUTLINE OF THE IN VITRO PBK
APPROACH USING REVERSE DOSIMETRY
The in vitro PBK approach applied in the present thesis is schematically represented in Figure 
1 and encompasses 5 steps. The first step is the establishment of an in vitro concentration-
response curve defined by effective concentrations (ECx) of the test compound in vitro. For 
this purpose, different concentrations of a chemical are tested in an in vitro toxicity assay 
that is regarded to represent a specific in vivo toxicity outcome. In the present thesis this was 
the EST. This assay provided a series of ECx values from which a concentration-response 
curve could be derived.
The second step is the development of a PBK model describing kinetic properties of the 
test compound in vivo, including the derivation of the required PBK model parameters. The 
present thesis took into account the principle of parsimony for the development of the PBK 
models, meaning that models should be as simple as possible but with sufficient explanatory 
power to fulfil their purpose (Clewell and Clewell III 2008). In the present thesis, model 
compartments were selected based on the target tissue of the toxicant and discriminating 
ADME properties that affect the fate of the test compound. Other tissues were lumped 
together in one compartment. Anatomical and physiological parameter values were obtained 
from literature. Physico-chemical and kinetic parameters were mainly derived with in vitro 
and in silico approaches to contribute to the 3Rs in the most optimal way.
Step three encompasses evaluation of the PBK model. The performance of the PBK model 
can be evaluated by comparing plasma concentrations predicted with the PBK model, with in 
vivo plasma concentrations of the compound reported in literature. For this purpose, PBK 
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model predictions were performed by applying similar dose administrations as reported in 
the in vivo studies used for the evaluation. Evaluation of the PBK models also comprised a 
sensitivity analysis to identify the sensitivity of the model outcome to changes in parameter 
values or model structures and aid the model interpretation and the decision if additional 
testing (of parameters) is required.
In the fourth step, in vitro ECx values are translated into in vivo external dose levels (EDx) 
generating dose-response curves for the toxic endpoint of interest in vivo, using PBK model 
based reverse dosimetry (Figure 1). 
Figure 1 Principle of the in vitro PBK-based reverse dosimetry approach applied in the present thesis to predict 
developmental toxicity in vivo. Key elements of the approach that are visualised are (a) establishment of in vitro 
effect concentrations with the EST, (b) development of a PBK model, (c) parameterisation of the model using in 
vitro and in silico data, (d) applying reverse dosimetry and hence (e) generating in vivo effective dose levels and a 
dose-response curve.
a
b
c
d
e
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For the reverse dosimetry step, in vitro ECx values are set equal to internal plasma or tissue 
concentrations. Before applying this step, the influence of in vitro biokinetic processes i.e. 
evaporation or binding of the test chemical to components of the in vitro test system, like 
plastic or serum albumin should be identified as this may affect the bioavailability of a test 
compound in vitro and hence the ECx values. Extrapolating in vitro effect concentrations 
towards values equivalent to in vivo ECx values should be made, whenever possible. Use of 
the (corrected) in vitro ECx values in the PBK model when applying PBK-based reverse 
dosimetry, will provide in vivo external dose levels (EDx), from which a dose-response curve 
and hence a PoD or an effective dose level for the safety assessment of the compound under 
study can be derived.
In the final step, the in vitro PBK approach is evaluated by comparing the predicted dose-
response curves and the PoD with in vivo data obtained from the literature.
PROBABILISTIC RISK ASSESSMENT AND 
MONTE CARLO SIMULATION
In the present thesis PBK modelling was also combined with Monte Carlo simulations to 
obtain insight in interindividual variation within the human population. This is of interest 
given that risk is a probability to develop an adverse health effect after being exposed towards 
a chemical (IPCS 2004). 
For human health risk assessment, it has been recommended to distinguish uncertainty 
from individual variability (National Research Council 1994). The estimation of risk may be 
subject to uncertainties which may have different origins in the four step paradigm of risk 
assessment. For example, uncertainty may arise from experimental procedures, sampling 
and storage conditions of the chemical, definition of the adversity of the effect, model 
selection to define a PoD, extrapolation of animal data to human, and definition of exposure 
to the chemical (National Research Council 1994; Ramsey 2009). Variability can be defined 
as the spread of the true value of a quantified variable and is a property of a population, 
where uncertainty is the contribution to the estimated distribution that comes from imperfect 
knowledge (Kelly and Campbell 2000).
Monte Carlo is a statistical sampling technique to evaluate variability and/or uncertainty 
in model inputs to variability and or uncertainty in model outputs. Model inputs can be 
defined by probability distributions. In Monte Carlo simulations, situations or events (i.e. an 
exposure assessment) are simulated many times (i.e. 1000 times) thereby randomly sampling 
a parameter value from its probability distribution. Such a sampling can be performed for a 
single parameter as well as for multiple parameters in one simulation. The result of applying 
Monte Carlo simulations is an output distribution (i.e. a distribution of estimated exposures).
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In the present thesis, the Monte Carlo simulation technique was linked to the PBK model for 
phenol (Figure 2) to obtain insight in interindividual variation in phenol induced development 
toxicity within the human population. Samples were randomly drawn repeatedly from 
distributions representing human interindividual variability in input parameters of the PBK 
model (i.e. metabolic constants and oral absorption coefficient). The input data sets 
generated by these Monte Carlo simulations were entered in the PBK model. After performing 
the PBK model calculations, an output distribution was generated representing variability in 
the phenol plasma concentrations for the human population. Differences in the phenol 
plasma concentrations for the average and the sensitive individual were used to define a 
chemical specific adjustment factor (CSAF) for interindividual kinetic differences, which is an 
alternative to the default uncertainty factor that accounts for human interindividual variability 
in toxicokinetics (IPCS 2005). The CSAF can be applied to the PoD to derive a safe guidance 
value for the risk assessment of chemicals (IPCS 2005).
 
Figure 2 Schematic representation of the combination of Monte Carlo simulations with PBK modelling. The solid 
arrows indicate repeated drawings of samples from distributions of specified input parameters of the PBK model, 
generating a model output distribution after performing the PBK model calculations.
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MODEL COMPOUNDS OF THE PRESENT THESIS: 
PHENOLS
To demonstrate the potential of a combined in vitro PBK model based approach to translate 
in vitro toxicity data to in vivo toxicity values and define a PoD for risk assessment the studies 
presented in the thesis used a series of phenol model compounds. Phenolic compounds are 
a wide class of compounds that are naturally present, i.e. in food, or are produced synthetically 
and are ubiquitous in our environment. Phenolic compounds contain an aromatic ring bearing 
one or more hydroxyl groups (Weber and Weber 2010). Phenols can be classified as simple 
phenols and polyphenols based on the number of phenol units in the molecule (Khoddami et 
al. 2013). The simplest form of a phenolic compound is hydroxybenzene generally referred to 
as phenol (Figure 3), which is a high volume production chemical with an annual production 
volume of about 9 million tons in 2008 world-wide (Weber and Weber 2010). The phenols 
selected for the present thesis are phenol and simple phenols with a substituent in the para 
position (Table 1). These compounds were selected based on their potential developmental 
toxicity reported in in vivo models (Argus 1997; Kavlock 1990) and/or in vitro models 
(Bernardini et al. 1996; Chapman et al. 1994; Oglesby et al. 1992; Paisio et al. 2009) and/
or based on the fact that developmental toxicity was identified as the critical effect for 
defining guidance values for these compounds (Environment Agency 2009; WHO 1994).
 
Figure 3 Chemical structure of phenol.
Table 1 Chemical name, p-substituent and CAS number of phenols used in the present thesis.
Chemical name p-substituent CAS
phenol  108-95-2
p-fluorophenol  371-41-5
p-heptyloxyphenol  13037-86-0
p-mercaptophenol  637-89-8
p-methylketophenol  99-93-4
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ABSORPTION, DISTRIBUTION, METABOLISM AND EXCRETION OF PHENOLS
In vivo studies in rat and man reported a rapid uptake of phenol via the oral, inhalation and 
dermal routes (Hughes and Hall 1995; Piotrowski 1971). Dermal absorption was also reported 
for p-heptyloxyphenol in rats (Hughes and Hall 1997). Phenol is mainly transported in plasma, 
partly bound to albumin or other macromolecules (Liao and Oehme 1981) and is retained 
mainly in the highly perfused tissues, although concentrations were low (Hughes and Hall 
1995; Liao and Oehme 1981).
Due to the presence of the hydroxyl moiety on the aromatic ring, the phenols selected for 
the present thesis may undergo direct conjugation catalyzed by sulfotransferases (SULT) and 
uridine diphosphate glucuronyltransferases (UGT) requiring the cofactors 
3’-phosphoadenosine-5’-phosphosulfate (PAPS) and uridine 5’-diphosphoglucuronic acid 
(UDPGA), respectively (see Figure 4). Generally, these conjugations serve as a detoxification 
step and represent the major metabolic pathways of these phenols. In vivo, phase I 
hydroxylation of phenol mainly occurs at high concentrations and is known to occur via 
cytochromes P450 producing hydroquinone (Hiser et al. 1994). However, this is not a major 
metabolic pathway and hydroquinone has been found in urine as its glucuronide conjugate 
(Hiser et al. 1994).
Depending on the substituent on the phenol ring, other metabolic conversions may occur, 
i.e. elimination of the halogen may lead to the formation hydroquinone or benzoquinone 
which consecutively may be rapidly converted to hydroquinone (Ohe et al. 1997), but these 
metabolic pathways are regarded as minor routes compared to the conjugation while the 
resulting metabolites may also be detoxified by conjugation. Commonalities that are often 
found in the metabolic pathways of the simple phenols selected in the present thesis are 
included in Figure 4. Glucuronidation and sulfation of phenol have been identified as the 
major elimination pathways both in rodents (Capel et al. 1972; Edwards et al. 1986; Koster 
et al. 1981; Mulder and Meerman 1978) and in man (Capel et al. 1972; Hiser et al. 1994). 
First pass conjugation of phenol in rat was identified in the intestine, liver and the pulmonary 
system (Kothare and Zimmerman 2002; Powell et al. 1974), although pulmonary first pass 
metabolism has been questioned given that Dickinson and Taylor (1996) could not 
demonstrate this in vitro or in vivo. Metabolism of phenol and p-substituted phenols may also 
occur in the kidney as glucuronidation of p-nitrophenol was identified in kidney homogenates 
in vitro (Machida et al. 1982).
Excretion of phenol, mainly as conjugates, occurs in rat and human predominantly via 
urine (Capel et al. 1972; Hiser et al. 1994; Hughes and Hall 1995) and is, upon single oral 
and intravenous dosing, nearly complete within 12 hours (Hughes and Hall 1995; Hughes 
and Hall 1997). This was also found for phenol and a group of p-substituted phenols including 
p-heptyloxyphenol, after dermal and intraperitoneal administration of these compounds in 
young female rats (Hughes and Hall 1997), although p-heptyloxyphenol was retained in small 
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amounts in the carcasses (7-10% of the dose) after ip injection after 120 hours (Hughes and 
Hall 1997). This study also showed that excretion of p-heptyloxyphenol also occurs partly via 
faeces, though excretion via urine was reported to be still greater. The glucuronide conjugate 
of p-heptyloxyphenol may be subject to biliary secretion and hence elimination via the faeces, 
because its molecular weight is higher than 300 Da (Hughes and Hall 1997). Biliary excretion 
was observed in vivo for the glucuronide conjugate of p-methylketophenol, which has a 
molecular weight of 312 Da (Machida et al. 1982).
Figure 4 Commonalities in metabolic pathways of phenol and p-substituted phenols. The R represents the p-substituent 
included in Table 1. SULT and UGT represent sulfotransferases and uridine diphosphate glucuronyltransferases 
which are responsible for direct conjugation of the phenols with a glucuronide or sulfate moiety representing the 
major metabolic pathways. The reaction indicated by the asterisk represents hydroxylation of phenol by CYP450, 
accompanied by dehalogenation in the case of p-fluorophenol resulting in the formation of hydroquinone or 
benzoquinone that can subsequently be chemically reduced to hydroquinone, which are regarded minor metabolic 
pathways (see text for more details).
OUTLINE OF THIS THESIS
The aim of the present thesis was to demonstrate the potential of a combined in vitro PBK 
model based approach to translate in vitro toxicity data to in vivo toxicity values for rat and 
human predicting in vivo dose-response curves that allow definition of a PoD for risk 
assessment. Chapter 1 provides background information on alternatives to animal testing, 
gives a brief description of PBK modelling, Monte Carlo simulations and a short overview of 
some important ADME characteristics of phenols, the model compounds of the present 
thesis. This chapter also outlines the in vitro PBK-based reverse dosimetry approach to 
translate in vitro effective concentrations towards in vivo toxicity data. Chapter 2 describes 
the results of the EST which were used to identify the in vitro relative embryotoxic potency of 
the selected phenolic congeners. These results were compared to the outcomes of the ex 
vivo WEC assay and in vivo developmental toxicity values for the phenols, to provide insight 
into the applicability of the EST as an alternative for in vivo developmental toxicity testing. 
Chapter 3 describes the development of the PBK model of phenol and the extrapolation of in 
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vitro ECx values obtained in the EST to an in vivo dose-response curve, applying PBK-based 
reverse dosimetry. The prediction was evaluated against available in vivo toxicity data. In 
chapter 4 it was investigated whether the in vitro PBK approach was able to correctly predict 
the developmental toxic potency of the selected series of phenolic congeners in vivo. In 
chapter 5 we demonstrated a modelling approach that integrated in vitro toxicity data, PBK 
modelling and Monte Carlo simulations to derive chemical specific safety factors that cover 
interindividual human kinetic variation, with phenol induced developmental toxicity as the 
endpoint of interest. Chapter 6 presents the discussion of the results obtained within the 
present thesis and suggestions for future research.
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CHAPTER 2
Relative embryotoxic potency of 
p-substituted phenols in the 
embryonic stem cell test (EST) 
and comparison to their toxic 
potency in vivo and in the whole 
embryo culture (WEC) assay
Marije Strikwold, Ruud A Woutersen, Bert Spenkelink, Ans Punt, Ivonne MCM Rietjens
Based on: Toxicology Letters (2012) 213:235-242
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ABSTRACT
The applicability of the embryonic stem cell test (EST) as an alternative for in vivo embryotoxicity 
testing was evaluated for a series of five p-substituted phenols. To this purpose, the potency 
ranking for this class of compounds derived from the inhibition of cardiomyocyte differentiation 
in the EST was compared to in vivo embryotoxic potency data obtained from literature and to 
the potency ranking defined in the in vitro whole embryo culture (WEC) assay. From the results 
obtained it appears that the EST was able to identify the embryotoxic potential for p-substituted 
phenols, providing an identical potency ranking compared to the WEC assay. However, the 
EST was not able to predict an accurate ranking for the phenols compared to their potency 
observed in vivo. Only phenol, the least potent compound within this series, was correctly 
ranked. Furthermore, p-mercaptophenol was correctly identified as a relative potent congener 
of the phenols tested, but its ranking was distorted by p-heptyloxyphenol, of which the toxicity 
was overestimated in the EST. It is concluded that when attempting to explain the observed 
disparity in potency rankings between in vitro and in vivo embryotoxicity, the in vitro models 
should be combined with a kinetic model describing in vivo absorption, distribution, 
metabolism and excretion processes of the compounds.
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INTRODUCTION
Embryotoxicity is considered a critical step in reproductive toxicity (Adler, 2011). For this 
endpoint, so far, three scientifically validated rodent based in vitro assays are available, 
which have been evaluated for discriminating between non, weak and strong embryotoxic 
compounds (Genschow et al. 2002). These assays are the postimplantation rat whole-embryo 
culture test (WEC), the limb bud micromass test and the embryonic stem cell test (EST). Each 
of these assays has its advantages and limitations. Briefly, in the WEC, embryo’s dissected at 
gestational day (GD) 10 are cultured and exposed to the test compound for two days, 
whereupon they are examined and evaluated for developmental anomalies (ECVAM, 2010a). 
An advantage of the WEC is that the model system comprises a whole organism. A drawback, 
however, resides in the fact that it only covers a limited period of organogenesis (Augustine-
Rauch et al. 2010). Both, the limb bud micromass test and the EST are more simplified 
methods to evaluate embryotoxicity compared to the WEC. In principle, the limb bud 
micromass test studies the interference of a compound with the formation of foci of 
chondrocytes in vitro, but still requires embryos, though less than the WEC (ECVAM, 2010b). 
The EST is based on the principle that chemicals may affect the spontaneous development of 
embryonic cells into beating cardiomyocyte clusters (Seiler et al. 2006). An important 
advantage of the EST, compared to both the WEC and the limb bud micromass test, is the use 
of a permanent cell line (Spielmann et al. 2006), permitting nearly indefinite propagation of 
the embryonic stem cells in vitro, thereby greatly supporting reduction, refinement, and 
replacement (3 Rs) in animal testing. Moreover, this feature allows high-throughput screening 
of chemical compounds (Spielmann et al. 2006), which makes the EST a promising tool to 
screen compounds on potential embryotoxicity.
In a validation study lead by the European Centre for the Validation of Alternative Methods 
(ECVAM), the EST demonstrated a good correlation between in vitro and in vivo data, providing 
a correct classification of 78% of a test set of twenty chemicals into three distinct embryotoxic 
classes (non, weak and strong embryo toxicants) (Genschow et al. 2004). However, in a 
second study only two of thirteen additional selected chemicals were correctly classified with 
the EST, which raises concern about the applicability of the prediction model that was applied 
in both studies to classify compounds in non, weak and strong embryo toxicants (Marx-
Stoelting et al. 2009). An explanation for this poor predictivity might be the absence of a 
carefully defined applicability domain and the limited number of compounds that was used to 
develop the prediction model, thereby restricting the application of the EST for regulatory 
purposes (Marx-Stoelting et al. 2009). 
To overcome this limitation, additional information on the performance of the EST with 
different chemical classes is needed (de Jong et al. 2011a). Therefore, the aim of the present 
study was to evaluate the applicability of the EST for a series of p-substituted phenols, a novel 
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chemical class to be studied with the EST, as an alternative for in vivo embryotoxicity testing.
Phenol is a high production volume chemical with an annual production of nearly 9 million 
tons world-wide in 2008 (Weber and Weber, 2010). Phenol is used as an intermediate in the 
chemical industry and as a disinfectant, slimicide and in medicinal drugs (ATSDR, 2008). 
Many phenols, including p-substituted phenols, are applied in pesticides, resins, textiles, 
dyes and/or drugs. In addition, 4-methylketophenol is a natural occurring and chemically 
synthesised flavouring compound (FAO, 2010). Several studies demonstrated an embryotoxic 
potential of phenol and/or p-substituted phenols in vivo (Argus, 1997; Kavlock, 1990) and in 
vitro (Chapman et al. 1994; Oglesby et al. 1992).
In the present study, results obtained for a selected series of phenols in the EST, were 
compared to the in vivo benchmark dose (BMD10) values derived for their effects reported in 
in vivo developmental toxicity studies as well as to outcomes already reported in the literature 
for their effects in the WEC assay. This in order to evaluate the performance of the EST for this 
novel chemical class not tested before in this in vitro assay for embryotoxicity.
MATERIALS AND METHODS
COMPOUNDS AND CELLS
Phenol (99%), p-fluorophenol (99%), p-heptyloxyphenol (97%), p-mercaptophenol (97%), 
p-methylketophenol (99%), p-hydroxyphenol (99%), p-aminophenol (99%), ascorbic acid, 
glutathione and ß-mercaptoethanol were purchased from Sigma Aldrich (Steinheim, 
Germany). Methanol (HPLC supra-gradient) was obtained from Biosolve (Valkenswaard, The 
Netherlands). Dimethylsulfoxide was obtained from Acros Organics (Geel, Belgium). Murine 
embryonic stem cells (ES-D3 cells) were kindly provided by Johnson & Johnson (Beerse, 
Belgium). Dulbecco’s Modified Eagle Medium (DMEM), L-glutamine, non-essential amino 
acids and penicillin and streptomycin are from Gibco and were purchased from Fisher Emergo 
(Landsmeer, The Netherlands). Foetal calf serum was obtained from Lonza (Verviers, Belgium) 
and mouse leukemia inhibitory factor from Chemicon International (Temecula, CA).
PHENOL STABILITY
The chemical stability in time of phenol and six p-substituted phenols in ES-D3 cell culture 
medium was tested prior to experiments with the EST. Stability of the compounds was tested 
at concentrations to be tested in the EST, which were initially selected based on in vitro 
cytotoxicity data from literature (Kendig and Tarloff, 2007; Selassie et al. 2005; Verma et al. 
2003; Zhou et al. 2009). These final test concentrations were 3.16 mM for phenol, 1.0 mM 
for p-fluorophenol, p-mercaptophenol and p-aminophenol, 0.024 mM for p-heptyloxyphenol, 
0.5 mM for p-methylketophenol and 0.316 mM for p-hydroxyphenol. ES-D3 cell culture 
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medium with the test compound, but without cells, was maintained in 24 well plates under 
similar test conditions as applied in the differentiation assay of the EST (for details see 
Sections Cell culture and Differentiation assay). Samples were taken on days 0, 1, 2 and 5 
and analysis of the compound in culture medium was performed on a Waters Alliance HPLC-
system using an Alltima C18, 5 µm column, 150 mm x 4.6 mm (Grace Alltech, Breda, The 
Netherlands). The mobile phase was made of nanopure water (A) and pure methanol (B) 
using a gradient (A:B) of 100:0 for the first 10 min, changing to 90:10 in 5 min and then to 
10:90 within another 5 min, maintaining this ratio for 2 min, then changing to 100:0 in 1 min 
and maintaining this ratio for 10 min. The flow rate was 1 ml/min. Phenol, p-fluorophenol, 
p-heptyloxyphenol, p-mercaptophenol, p-methylketophenol, p-aminophenol and p-hydroxy-
phenol were detected and quantified based on their peak areas at their maximum wavelength, 
using a photodiode array detector.
CELL CULTURE
Embryotoxicity of phenol and four p-substituted phenols (Figure 1) was assessed using the 
murine embryonic stem cell differentiation assay (ES-D3 cells) performed essentially as 
previously described (De Smedt et al. 2008). Briefly, ES-D3 cells, which were stored in liquid 
nitrogen, were thawed and cultured for 3 days in ES-D3 culture medium, consisting of 
Dulbecco’s Modified Eagle Medium, supplemented with 20% (v/v) foetal calf serum, 2 mM 
L-glutamine, 1% (v/v) non-essential amino acids, penicillin/streptomycin (50 U/ml / 50 µg/
ml) and 0.1 mM ß-mercaptoethanol. Cells were maintained undifferentiated by adding 1000 
U/ml mouse leukemia inhibitory factor.
 
Figure 1 Chemical structure, chemical name and CAS number of phenol and four p-substituted phenols used in 
the present study.
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DIFFERENTIATION ASSAY
The differentiation assay was started by culturing 20 µl drops (45 drops totally) of an 
embryonic stem cell suspension (3.75x104 cells/ml medium) on the inner side of the lid of a 
96 well microtiter plate (Corning, The Netherlands) according to the hanging drop technique 
allowing cells to form embryoid bodies. After 3 days, embryoid bodies were transferred to 6 
cm non-adherent petri dishes (Greiner Bio-one, Hungary) and incubated for 2 days. Then, one 
embryoid body was placed in each well of a 24 well tissue culture plate (one plate per test 
concentration) and cultured for 5 more days. After that, differentiation of the embryoid bodies 
into contracting cardiomyocytes was evaluated visually with an Olympus CKX41 inverted 
microscope. During culturing, cells were constantly kept in a 5% CO2-humidified atmosphere 
at 37°C and were continuously exposed to the test compound. Stock solutions and compound 
dilutions were prepared in dimethylsulfoxide and added to ES-D3 culture medium. The final 
dimethylsulfoxide concentration in culture medium was 0.25% (v/v) and a solvent control 
was tested in each experiment. ES-D3 medium including the compound was refreshed on 
days 0, 3 and 5 of the differentiation assay.
The differentiation assay was considered valid if a blank resulted in beating cardiomyocyte 
clusters in at least 21 out of 24 wells. The inhibition of differentiation by the test compound 
was defined and presented as the fraction of wells with undifferentiated embryoid bodies in 
a 24 well plate. For each phenol, multiple independent assays were performed (n=2-5 as 
indicated), using different test concentrations (Figure 2).
SELECTION OF IN VIVO AND IN VITRO TOXICITY DATA
A literature search was performed to identify available in vivo and in vitro studies on 
reproductive and developmental toxicity of phenol and the p-substituted phenol model 
compounds of the present study. A study was selected if it included at least three dose 
groups, because this would enable analysis by the benchmark dose (BMD) approach and 
possible establishment of a BMD value. Developmental endpoints were considered relevant 
if the compound showed a dose or concentration depended effect and a BMD value could be 
derived. In addition, in vivo maternal effects were evaluated, when available from the selected 
developmental toxicity studies.
DATA COMPUTATION
For each phenol that was tested in the EST, in vitro concentration-response curves for 
embryotoxicity were derived to calculate benchmark concentrations at which 50 percent 
(BMC50) of the embryoid bodies did not differentiate into contracting cardiomyocytes. To this 
purpose, different dichotomous concentration-response models were fitted to the 
embryotoxicity data obtained with the EST. The data of the independent assays were 
combined prior to the curve-fitting. Models included in the evaluation were the gamma, (log) 
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logistic, (log) probit, multistage and the Weibull model. For each BMC calculation an extra risk 
at a benchmark response above background was considered (Davis et al. 2011). The 
performance of each model fit was consecutively evaluated for the global goodness-of-fit 
(p>0.1), the model with the smallest scaled residual at the concentration-response curve 
closest to the calculated BMC50 and a visual inspection of the fitted concentration-response 
curves (Davis et al. 2011). In case no goodness-of-fit with p>0.1 was obtained for any model, 
an additional curve-fitting was performed using average response values for each 
concentration tested. If the model-fit of two or more models was accepted according the 
criteria described above, then the model with the smallest Akaike’s Information Criterion 
(AIC) was regarded superior (Davis et al. 2011). Hence, the BMC50 was selected from the 
model that provided the best fit. 
For continuous in vivo data a benchmark response of 10% adverse effect of the studied 
maternal and developmental toxicity endpoints was used (Barnes et al. 1995). Continuous 
data were fit to the exponential, polynomial, power, linear, and hill models. The dose-response 
curves were included in further evaluation if they showed a significant (p<0.05) dose 
dependent response and if the variance (constant or non-homogeneous) was adequately 
modelled (p>0.05). Subsequently, the evaluation of the model fit was performed according to 
the same criteria as described for the dichotomous models. Finally, the BMD10 was selected 
from the model that provided the best fit.
All benchmark dose and benchmark concentration calculations were performed with the 
Environmental Protection Agency’s (EPA) Benchmark Dose Software (BMDS) version 2.2. 
Concentration-response curves were plotted with GraphPad Prism (version 5, GraphPad 
Software, San Diego, CA) applying a four-parameter logistic fit.
POTENCY RANKING
Phenols tested in the EST were ranked for embryotoxic potency according to their BMC50 
value, from the one with the highest to that with the lowest toxic potency. This ranking was 
compared to in vitro embryotoxic potency (ranking) data obtained from literature and to 
ranking based on BMD10 values derived in the present study from in vivo data on developmental 
toxicity of the phenols reported in the literature. In addition, embryotoxicity was compared to 
maternal toxicity.
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Figure 2 Concentration-response curves for phenol, p-fluorophenol, p-heptyloxyphenol, p-mercaptophenol and 
p-methylketophenol. Each figure represents the inhibition of differentiation of the embryoid bodies (EBs) by the 
compound at the specified concentrations. Different symbols represent independent assays.
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RESULTS
STABILITY OF THE TEST COMPOUNDS
Results from the chemical stability tests of the phenols are presented in Figure 3. From these 
data it can be derived that the compounds p-heptyloxyphenol, p-mercaptophenol and 
p-methylketophenol, were stable during the 5 days of incubation. Phenol and p-fluorophenol 
showed some decrease in the test concentration in time. For phenol 75, 62 and 27% of the 
original test concentration was detected in culture medium after 1, 2 and 5 days of incubation, 
respectively, with an area under the curve (AUC0-5days) from 0 to 5 days amounting 57.9% of 
what would be expected without decrease in the initial concentration. For p-fluorophenol 
these values amounted to 86, 74 and 39% with an AUC0-5days amounting 68.5% of what would 
be expected without decrease in the initial concentration. Stability was regarded sufficient to 
include these compounds in the EST. Both, p-hydroxyphenol and p-aminophenol could not be 
detected after 1 day of incubation, probably due to auto-oxidation of these compounds. To 
prevent auto-oxidation, both ascorbic acid and glutathione were added to the culture medium 
at 1 mM and 5 mM, respectively. However, both glutathione and ascorbic acid appeared to be 
toxic to ES-D3 cells at these concentrations (data not shown). Hence, p-hydroxyphenol and 
p-aminophenol were not included in the EST.
 
Figure 3 Chemical stability expressed as the percentage of the initial test concentration (t=0) of phenol (◇), 
p-fluorophenol (▽), p-heptyloxyphenol (×), p-mercaptophenol (△), p-methylketophenol (□), p-aminophenol (O) 
and p-hydroxyphenol (■) left in ES-D3 assay medium, in time (day).
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Table 1 BMC50 values of phenols tested in the EST as determined by a BMD analysis of the data of Figure 2, 
ranked from high to low potency.
Phenol BMC50 (mM)
p-heptyloxy 0.00038
p-mercapto 0.035
p-methylketo 0.12
p-fluoro 0.31
phenol 0.59a
a Model fit: 0.05<p<0.1.
DIFFERENTIATION OF EMBRYONIC STEM CELLS TO BEATING
CARDIOMYOCYTES
Figure 2 presents the concentration-response curves for the phenols tested in the EST. From 
these results it appears that each phenol inhibited differentiation of ES-D3 cells into beating 
cardiomyocytes in a concentration dependent manner. Both, p-mercaptophenol and 
p-methylketophenol show a steep concentration-response curve. The BMC50 values derived 
from the concentration response data of the different phenols are presented in Table 1. The 
most potent phenol tested is p-heptyloxyphenol, followed by p-mercaptophenol, 
p-methylketophenol, p-fluorophenol and phenol. The choice of the dose-response model and 
the benchmark response value appeared not to affect the ranking (data not shown). The 
difference in the BMC50 values of the least and the most potent chemical, phenol and 
p-heptyloxyphenol respectively, is three orders of magnitude. The difference between the 
BMC50 value of phenol and the BMC50 values of the other p-substituted phenols is less, 
namely, 16.9, 4.9 and 1.9-fold for p-mercaptophenol, p-methylketophenol and p-fluorophenol 
respectively. Figure 4 graphically presents these potency differences and compares them to 
the potency differences derived from the data reported in the literature for these phenols in 
the WEC and in vivo assay as described in the next sections.
POTENCY RANKING WEC ASSAY
Phenol, p-fluorophenol and p-heptyloxyphenol have been tested in the WEC assay by Oglesby 
et al. (1992) and assessed on both growth retardation (somite number, crown rump length 
and DNA content) and structural defects (fore and hind limb bud absence, hypoplasia of 1st 
arch, bifurcated tails and total tail defects). In general, the potency ranking for phenol, 
p-fluorophenol and p-heptyloxyphenol was similar for each of the endpoints tested in the WEC 
assay (Oglesby et al. 1992). A few phenols did not cause a toxic effect for some of the 
endpoints. The most potent of the three compounds in the WEC assay was p-heptyloxyphenol, 
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followed by p-fluorophenol and phenol. Based on the concentrations needed to reduce the 
somite number by 10% relative to the concurrent control (Oglesby et al. 1992), a 31.2-fold 
potency difference between the most and the least toxic chemical in the WEC assay was 
calculated, and a 4.1-fold potency difference between phenol and p-fluorophenol. The first 
potency difference is smaller compared to the potency difference in the EST while the latter 
is somewhat larger (Figure 4).
Oglesby et al. (1992) obtained a different potency ranking for the phenols tested in a WEC 
assay co-cultured with hepatocytes compared to the WEC system without hepatocytes (Table 
2). The presence of hepatocytes diminished toxicity for p-heptyloxyphenol and p-fluorophenol, 
but enhanced toxicity for phenol (Oglesby et al. 1992). For the endpoints total tail defects and 
reduction in somite number this resulted in an altered ranking, which became phenol, 
p-fluorophenol and p-heptyloxyphenol (Oglesby et al. 1992). Modelling the free concentration 
instead of the total concentration did not change the ranking for p-heptyloxyphenol and 
phenol (Oglesby et al. 1992).
 
Figure 4 Potency of p-substituted phenols relative to phenol expressed as a potency ratio (potency ratio = potency 
phenol / potency p-substituted phenol), specified for litter biomass on postnatal day 6 in vivo (BMD10), the EST 
(BMC50) and the WEC assay (based on reduction in somite number by 10% relative to the concurrent control 
(Oglesby et al. 1992)). No potency data are available for p-mercaptophenol and p-methylketophenol from the WEC 
assay.
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Table 2 Summary of toxic potency ranking, from high to low potency, of phenol, p-fluorophenol, p-heptyloxyphenol, 
p-mercaptophenol and p-methylketophenol tested in the EST, in vivo (postnatal day 6) and in the WEC assay, with 
a specification of the embryotoxic endpoints considered. Additionally, a toxic potency ranking is included for the 
WEC assay in the presence of hepatocytes and based on the free concentration. 
ESTa In vivob In vivob In vivoc WECd WECd + 
hepatocytes
WECd 
free conc.
Inhibition of 
differentiation
Change litter 
size
Reduction 
litter 
biomass
Perinatal loss Diverse  
(see text)
Total tail 
defects & 
somite 
number
3 endpointse
p-heptyloxy p-mercapto p-mercapto p-mercapto p-heptyloxy phenol p-heptyloxy
p-mercapto p-fluoro p-fluoro p-methylketo p-fluoro p-fluoro phenol
p-methylketo p-heptyloxy p-methylketo p-heptyloxy phenol p-heptyloxyf
p-fluoro p-methylketo p-heptyloxy phenol
phenol phenolg phenol p-fluoroh
 
a Ranking based on BMC50 as derived from the EST from the present study.
b Ranking based on BMD10, as derived from in vivo data from Kavlock (1990).
c Ranking according Kavlock (1990).
d Ranking according Oglesby et al. (1992).
e Endpoints considered are reduction in somite number, crown-rump length and total DNA content.
f No incidence was obtained for p-heptyloxyphenol on total tail defects.
g No significant dose-related trend could be fit.
h No perinatal loss observed at highest dose group for p-fluorophenol.
IN VIVO TOXICITY DATA
Table 3 presents a summary of the in vivo developmental toxicity data for phenol. From this 
overview it emerges that for phenol, the most common critical developmental endpoint in 
vivo is reduced foetal body weight. A number of studies reported the incidence of 
malformations due to phenol (Argus, 1997; Jones-Price et al. 1983a; Jones-Price et al. 
1983b; Kavlock, 1990; Narotsky and Kavlock, 1995). In all but one study (Jones-Price et al. 
1983a), developmental effects were accompanied by maternal effects, mostly by a decrease 
in maternal weight change. In general, the developmental no observed adverse effect levels 
(NOAELs) reported for phenol in the different studies are in agreement with each other. 
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Table 3 Summary of in vivo developmental toxicity data of phenol described in the literature.
Species and strain Exposure 
day(s)
Dose 
(mg/kg bw/day)a
Developmental 
endpoint
Developmental 
NOAELb 
(mg/kg bw/day)
Reference
Sprague-Dawley rat GD 11 0, 100, 333, 
667, 1000
Malformationsc 
reported at two 
highest dosesd
333 Kavlock 
(1990)
Sprague-Dawley rat GD 6-15 0, 30, 60, 120 Decreased average 
foetal bw/litter
60 Jones-Price 
et al. 
(1983a)
Sprague-Dawley rat GD 6-15 0, 60, 120, 360 Decreased foetal bw
Decreased 
ossification sites 
metatarsalse
120 Argus 
(1997) 
Fischer rat GD 6-19 0, 40, 53.3 Increased prenatal 
loss
Reduced litter size
2 cases of kinked
tails in one litterd
40 Narotsky 
and Kavlock 
(1995)
Sprague-Dawley rat 10-11 
weeks 
prior to 
mating 
through 
weaning
0, 200, 1000, 
5000 ppm (= 0, 
20, 93, 350 mg/
kg/d)
Decreased pup 
survival
Decreased bw/
growth delay
Increased organ to 
bw ratios
Delay in landmarks 
of sexual maturation
93 Ryan et al.
(2001)g
CD-1 mice GD 6-15 0, 70, 140, 280 Decreased average 
foetal bw/litter
Increased incidence 
in cleft palate at high 
dosef
140 Jones-Price 
et al. 
(1983b)
 
a In each study phenol was administered by oral gavage, except in the study of Ryan et al. (2001) at which phenol 
was administered via drinking water.
b NOAELs were taken from cited studies, except the NOAEL from the study of Kavlock (1990) which is derived in 
the present study based on malformations.
c Hindlimb paralysis and/or short kinky tails.
d Not analysed on statistical significance.
e Significant effect, but biological significance questioned.
f Not statistical significant.
g Effects possibly related to decreased maternal water intake due to flavour aversion.
One in vivo study in rats was available on developmental effects for the other phenolic 
congeners, including phenol as well (Kavlock, 1990). In this rat study, in which compounds 
were administered orally at GD11, all five phenols were classified as active developmental 
toxicants (Kavlock, 1990). Developmental toxicity endpoints quantitatively assessed included 
perinatal loss, change in pup weight, litter size, and litter biomass. For the latter two endpoints 
dose-response curves with a significant dose-related trend were obtained enabling calculation 
of a BMD10 value, with the exception of phenol for the endpoint litter size for which no 
significant dose-related trend could be established (Table 4). Table 2 summarizes the potency 
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ranking based on the BMD10 values obtained and in addition the potency ranking for perinatal 
loss from Kavlock (1990). From this overview it appears that each in vivo endpoint considered 
resulted in a different potency ranking (Table 2). Though, at each endpoint, p-mercaptophenol 
was the most potent compound and phenol the least toxic, except for perinatal loss where 
phenol is the second least toxic compound in the potency ranking. The ranking for 
p-methylketophenol, p-heptyloxyphenol and p-fluorophenol differs between the in vivo 
endpoints in a non-systematic way (Table 2). The potency difference between phenol and 
p-substituted phenols tested in vivo is less than the potency difference observed in the EST 
(Figure 4).
From the developmental toxicity study from Kavlock (1990), dose-response curves and 
BMD10 values for maternal weight change were obtained as well (Table 4). For each phenol, 
except for p-methylketophenol, a significant dose-response relationship could be established. 
In general, embryotoxicity occurs at similar (p-mercaptophenol) or somewhat higher dose 
levels (5.7, 2.0 and 1.5-fold higher for p-heptyloxyphenol, p-fluorophenol and phenol 
respectively) than maternal toxicity.
Table 4 BMD10 values (mg/kg) of phenols for maternal effect 72 h after dosing and developmental effects on 
postnatal day 6, calculated from in vivo data from Kavlock (1990), ranked from high to low developmental potency 
of the endpoint litter size.
BMD10 (mg/kg)
Maternal
BMD10 (mg/kg)
Developmental
Phenol Weight change Litter size Litter biomass
p-mercapto <333a <333a <333a
p-fluoro 369 719 747
p-heptyloxy 168 946 951
p-methylketo >1000b 979 932c
phenol 667a >1000b >1000a
a Data not adequate for BMD modelling. Instead, the NOAEL is presented.
b No significant dose-related trend could be fit. Instead, the maximum tested dose is presented.
c Model fit: 0.05<p<0.1.
DISCUSSION
The aim of the present study was to evaluate the applicability of the EST for a series of 
p-substituted phenols, as an alternative for in vivo embryotoxicity testing. The EST showed 
concentration dependent response curves for the inhibition of differentiation of the embryoid 
bodies for all tested compounds, demonstrating the embryotoxic potential of the phenols. 
The test concentration of both phenol and p-fluorophenol in the EST decreased in time. As 
the reported BMC50 values for inhibition of differentiation of the embryoid bodies were 
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derived from the initial total test concentrations (t=0), the actual BMC50 might be lower than 
the concentration reported in this study for these two compounds. In the EST, phenol is the 
least toxic compound followed by p-fluorophenol. Hence, a lower BMC50 of these compounds 
in vitro could potentially affect the potency ranking of the phenols. It is unknown, however, if 
the toxic effects of phenol and p-fluorophenol in vitro occur due to a peak concentration or as 
the result of a prolonged exposure above a certain concentration. In addition, the critical 
exposure period in the 10-day EST is also unknown. Therefore, correcting the initial BMC50 
towards an actual effective BMC50 in vitro was not possible and hence not applied in the 
present study. However, correcting the initial BMC50 for the percentage of the compound that 
was stable for 5 days using the AUC0-5, could provide insight in the effect of the chemical loss 
on the potency. This correction resulted in the reduction of BMC50 values from 0.59 mM 
towards 0.34 mM for phenol and from 0.31 mM towards 0.21 mM for p-fluorophenol. After 
this correction, phenol remained the least toxic compound, followed by p-fluorophenol, which 
is equal to the ranking based on the initial concentration. Even a correction for the maximum 
decrease, as was measured on day 5, would not alter the potency ranking. Hence, the potency 
ranking as presented in the present study is considered valid.
The potency ranking of the phenols, based on the BMC50 values derived from the EST, is 
identical to the potency ranking from the WEC assay of Oglesby et al. (1992). This finding is 
in accordance with Louisse et al. (2011) who found a similar potency ranking between both 
in vitro test systems for a series of retinoids. However, for a series of six 1,2,4-triazoles, de 
Jong et al. (2011a) found only a moderate correlation between the potency of the tested 
compounds in the EST and the WEC assay. It was found that p-heptyloxyphenol is relatively 
more potent in the EST compared to the WEC assay. This may (partly) be explained by 
differences in serum content between both in vitro assays, which is 20% in the EST and 50% 
in the WEC assay. Moreover, it has been shown that p-heptyloxyphenol readily binds to serum 
albumin and may accumulate in the embryo in the WEC assay possibly due to its high 
lipophilicity (Fisher et al. 1993). Similar phenomena might occur in the EST and, in conjunction 
with the lower serum content in the EST than the WEC assay, may explain the relative high 
toxicity of p-heptyloxyphenol in the present EST study.
In order to evaluate the applicability of the EST as an alternative for in vivo embryotoxicity 
testing, the potency of the phenols in the EST was compared to the potency of the compounds 
in vivo. It was found that the potency ranking in the EST differs from the in vivo developmental 
toxicity potency ranking for perinatal loss, reduction litter biomass and change litter size. 
None of these three in vivo endpoints was best mimicked by the EST. Only phenol, the least 
potent compound from the phenols tested, was correctly ranked when compared to in vivo 
litter biomass and litter size. Furthermore, p-mercaptophenol was correctly identified as a 
relative potent congener within the series of phenols, but its ranking was distorted by 
p-heptyloxyphenol, of which the toxicity was overestimated in the EST. Again, differences in 
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serum albumin levels, which are higher in vivo in the rat than in the EST (Verwei et al. 2006), 
may cause the difference in the ranking for p-heptyloxyphenol. Moreover, the ranking for 
p-methylketophenol, p-heptyloxyphenol and p-fluorophenol differs between the in vivo 
endpoints in a non-systematic way. The disparity in potency ranking between the EST and in 
vivo embryotoxicity is in accordance to what has been found for two other chemical classes, 
namely a series of 1,2,4-triazoles (de Jong et al. 2011a) and a series of retinoids (Louisse et 
al. 2011). However, the EST predicted a correct potency ranking for a series of glycol ether 
alkoxy acid metabolites compared to the potency ranking of parent glycol ether compounds 
in vivo (de Jong et al. 2009). A good predictive property of the EST was also found for valproic 
acid analogues (de Jong et al. 2011b; Riebeling et al. 2011).
The relative poor predictivity of the EST for the embryotoxic potency in vivo for the 
p-substituted phenols tested might also be due to differences in biotransformation between 
the in vitro and the in vivo system. In the present study, only parent phenolic compounds were 
tested as the ES-D3 cells are expected to have no or hardly any metabolic capacity. However, 
in the in vivo situation, maternal metabolism can play a key role in (de)activating the 
compound before reaching the embryo. For phenol and p-substituted phenols the major 
metabolic pathways in vivo are sulfation and glucuronidation reducing toxicity of the phenols, 
whereas cytochrome P450 mediated bioactivation may result in the formation p-hydroxyphenol 
(Bollard et al. 1996; Capel et al. 1972; Hoffmann et al. 1999; Koster et al. 1981; Mulder and 
Meerman, 1978). The latter compound appeared to be the most potent compound of the 
p-substituted phenols tested in the WEC assay (Oglesby et al. 1992). It was not possible, 
however, to test the latter compound in the EST due to a rapid auto-oxidation of the compound 
and the toxicity of anti-oxidants, which could prevent auto-oxidation. From data of Oglesby et 
al. (1992) it appeared that adding a metabolic system to the in vitro WEC assay, to mimic 
maternal metabolism in vivo, could not overcome the disparity between embryotoxicity in 
vitro and in vivo for the phenols. In the WEC assay co-cultured with hepatocytes, phenol 
became more potent for the endpoints total tail defects and reduction in somite number, 
while the toxic potency of p-heptyloxyphenol and p-fluorophenol was diminished by the 
hepatocytes (Oglesby et al. 1992). The diminished potency of the latter two compounds may 
reflect the in vivo situation where glucuronidation and sulfation result in detoxification. 
However, the increased potency of phenol in the co-cultured system is not in agreement with 
the in vivo potency ranking where phenol is the least potent compound. A possible explanation 
for this observation may be differences between in vitro kinetics and in vivo kinetics. To 
illustrate this, from an in vitro incubation experiment of 1 h with 3 mM phenol using freshly 
isolated rat hepatocytes (Schrenk and Bock, 1990) the formation of 19.3% p-hydroxyphenol, 
29.8% phenylsulfate and 41.4% phenylglucuronide was derived. However, the fraction of the 
toxic metabolite p-hydroxyphenol (measured as p-hydroxyphenol conjugates) formed in vivo in 
the rat is much lower, namely 3% in 24-hour urine (Capel et al. 1972), providing a possible 
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explanation for the difference between the potency ranking in the WEC assay co-cultured with 
hepatocytes and the in vivo situation. Instead, combining in vitro embryotoxicity data with 
kinetic modelling of in vivo absorption, distribution, metabolism and excretion (ADME) 
processes is expected to more closely mimic the in vivo embryotoxicity as has been 
demonstrated recently for other developmentally toxic model compounds (Louisse et al. 
2010; Verwei et al. 2006).
The BMD10 values for embryotoxic effects in vivo were similar or somewhat higher than the 
BMD10 values for reduction in maternal weight change, except for methylketophenol which 
showed a lower developmental BMD10. These findings might raise the question whether 
embryotoxic effects observed in vivo are due to indirect maternal effects or are induced by a 
more direct action of the compound. In line with the in vivo maternal-developmental 
correlations observed in this study, a positive correlation was found between four of seven 
embryotoxic endpoints for phenols in the WEC assay and maternal weight reduction in vivo by 
Oglesby et al. (1992), who pointed out that this correlation might reflect some general 
mechanisms, but stated that the maternal and embryotoxic endpoints are clearly dissimilar. 
This is supported by the different physico-chemical properties that were able to predict 
maternal and developmental toxicity in vivo for a large group of p-substituted phenols 
(Kavlock, 1990). Furthermore, it is important to take into account that in vivo kinetics could 
greatly reduce the concentration actually reaching the embryo, and hence the embryotoxic 
effect in vivo. This demonstrates the necessity to combine in vitro embryotoxicity data with in 
vivo ADME processes, which could be achieved by extrapolating in vitro effect concentrations 
towards in vivo dose levels, using physiologically based kinetic models.
In conclusion, the EST was able to identify the embryotoxic potential for phenol and 
p-substituted phenols, providing an identical potency ranking compared to the WEC assay. 
However, the EST was not able to predict an accurate ranking for the phenols compared to 
their potency observed in vivo and hence is not yet able to serve as a standalone assay to 
replace animal testing, even not for the purpose of prioritising a closely related group of 
chemicals on their embryotoxicity like the p-substituted phenols. The reason for this disparity 
might be the kinetic difference between the in vitro and the in vivo system. Therefore, it is 
essential to combine in vitro embryotoxicity data with kinetic modelling of in vivo ADME 
processes in the evaluation of the true in vivo embryotoxic potential of a compound, thereby 
enhancing the power of the EST in the potency ranking and risk assessment of this class of 
chemicals. To this purpose, our laboratory is currently investigating whether combining in 
vitro toxicity levels obtained from the EST together with a physiologically based kinetic model 
for phenol, would actually lead towards a better prediction of in vivo embryotoxicity of these 
compounds.
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CHAPTER 3
Combining in vitro embryotoxicity 
data with physiologically based 
kinetic (PBK) modelling to define in 
vivo dose-response curves for 
developmental toxicity of phenol in 
rat and human
Marije Strikwold, Bert Spenkelink, Ruud A Woutersen, Ivonne MCM Rietjens, Ans Punt 
Based on: Archives of Toxicology (2013) 87:1709-1723
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ABSTRACT
In vitro assays are often used for the hazard characterisation of compounds, but their 
application for quantitative risk assessment purposes is limited. This is because in vitro 
assays cannot provide a complete in vivo dose-response curve from which a point of departure 
(PoD) for risk assessment can be derived, like the no observed adverse effect level (NOAEL) 
or the 95% lower confidence limit of the benchmark dose (BMDL). To overcome this constraint, 
the present study combined in vitro data with a physiologically based kinetic (PBK) model 
applying reverse dosimetry. To this end, embryotoxicity of phenol was evaluated in vitro using 
the embryonic stem cell test (EST), revealing a concentration dependent inhibition of 
differentiation into beating cardiomyocytes. In addition, a PBK model was developed on the 
basis of in vitro and in silico data and data available from the literature only. After evaluating 
the PBK model performance, effective concentrations (ECx) obtained with the EST served as 
an input for in vivo plasma concentrations in the PBK model. Applying PBK-based reverse 
dosimetry provided in vivo external effective dose levels (EDx) from which an in vivo dose-
response curve and a PoD for risk assessment were derived. The predicted PoD lies within 
the variation of the NOAELs obtained from in vivo developmental toxicity data from the 
literature. In conclusion, the present study showed that it was possible to accurately predict 
a PoD for the risk assessment of phenol using in vitro toxicity data combined with reverse 
PBK modelling.
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INTRODUCTION
In vitro toxicity assays play an important role in screening chemicals for their possible hazards 
and prioritising them for further toxicity testing. The implementation of in vitro assays in 
quantitative risk assessment, however, is limited. An important reason underlying this 
limitation is that in vitro assays cannot provide a complete in vivo dose-response curve from 
which a point of departure (PoD) for risk assessment can be derived, like the no observed 
adverse effect level (NOAEL) or the 95% lower confidence limit of the benchmark dose 
(BMDL). To overcome this constraint, toxicological in vitro data can be combined with 
physiologically based kinetic (PBK) modelling, applying reverse dosimetry (Louisse et al. 
2010; Verwei et al. 2006). With PBK-based reverse dosimetry, external dose levels are 
estimated from internal concentrations, i.e. plasma or tissue concentrations, using a PBK 
model describing the kinetics of a compound. Concentration-response information obtained 
from an in vitro assay, represented by different effective concentrations (ECx), may serve as a 
surrogate for in vivo internal effect concentrations in the PBK model. Applying PBK-based 
reverse dosimetry will then provide external effective dose levels (EDx) from which an in vivo 
dose-response curve and a PoD for risk assessment can be derived. Identifying whether this 
in vitro PBK approach with reverse dosimetry can actually be applied in quantitative risk 
assessment of chemicals, requires insight into its predictive performance for different 
compounds (Rietjens et al. 2011; Punt et al. 2011).
The objective of the present study was to demonstrate the capability of the in vitro PBK 
approach to predict in vivo dose-response curves and hence a PoD for risk assessment from 
experimentally derived in vitro toxicity data, with phenol as the selected model compound. 
PBK models for rat and human were developed on the basis of only in vitro and in silico data 
and data available from the literature to contribute to the 3Rs principle for the replacement, 
reduction and refinement of animal testing in the most optimal way.
Phenol is a high production volume chemical and is an important compound in many 
production processes, like the manufacturing of bisphenol-A and phenolic resins (Weber and 
Weber 2010). Phenol is present in various commercially available (household) products and 
has a number of clinical applications as well (ATSDR 2008; Landau 2007; Kheder and Nair 
2012). Exposure to phenol can occur occupationally, domestically as well as clinically, i.e. via 
inhalation, ingestion of contaminated drinking water, or via dermal contact (ATSDR 2008). 
The compound is also a major intermediate metabolite of benzene and exposure can 
therefore also occur due to benzene exposure (Rothman et al. 1998). Uptake of phenol itself 
occurs rapidly via all routes (Hughes and Hall 1995). Animal studies revealed adverse effects 
on the kidney, liver, and the immunological and neurological system upon exposure (Bruce et 
al. 2001). Moreover, several studies demonstrated the embryotoxic potential of phenol in 
vivo (Argus 1997; Kavlock 1990) and in vitro (Chapman et al. 1994; Oglesby et al. 1992; 
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Strikwold et al. 2012). In vivo developmental toxicity has been used as endpoint to derive a 
PoD for the risk assessment of phenol (Baars et al. 2001; Environment Agency 2009; WHO 
1994). In the present study, it will be evaluated whether such a PoD could also be adequately 
predicted with the combined in vitro PBK approach using the in vitro embryonic stem cell test 
(EST) for determining the embryotoxic potential of phenol.
 
MATERIALS AND METHODS
COMPOUNDS AND BIOLOGICAL MATERIALS
Phenol (99%), tetra-n-butylammonium bromide, phenylglucuronide (≥99%), ammonium 
acetate (≥ 98%), sulfamic acid (99.3%), uridine 5’-diphosphoglucuronic acid (UDPGA), 
alamethicin (≥98%), sulfatase (from Helix pomatia), 3’-phosphoadenosine-5’-phosphosulfate 
(PAPS) and tris(hydroxymethyl)aminomethane (Tris) (≥99.9%) were purchased from Sigma 
Aldrich. Dimethyl sulfoxide (DMSO) (≥99.9%) was obtained from Acros Organics (Geel, 
Belgium), acetonitrile (ULC/MS grade) and methanol (HPLC supra-gradient) from BioSolve 
(Valkenswaard, The Netherlands), and trifluoroacetic acid (TFA) (≥99.8%) from J.T. Baker 
(Philipsburg, NJ, USA). Glacial acetic acid, sodium acetate trihydrate (99.5%), hydrochloride 
acid (37%) pyridine and magnesium chloride hexahydrate (≥ 99%) were purchased from VWR 
International GmbH (Darmstadt, Germany).
Pooled liver microsomes and cytosol from male Sprague-Dawley rats were obtained from 
BD Biosciences Gentest (Woburn, MA, USA). Pooled small intestinal microsomes and pooled 
small intestinal, kidney and lung cytosols, all from male Sprague-Dawley rats, and pooled 
human mixed gender small intestinal microsomes and cytosols were obtained from BioPredic 
(Rennes, France). Pooled male rat kidney and lung microsomes, pooled human mixed gender 
liver microsomes and cytosol, and pooled human mixed gender lung and kidney S9 were 
obtained from XenoTech (Lenexa, KS, USA).
SYNTHESIS OF PHENYLSULFATE
Phenylsulfate was synthesised as the potassium salt, from phenol and sulfamic acid in 
pyridine according to the method of Yamaguchi (1959). The synthesised phenylsulfate was 
required as a reference standard to quantify phenylsulfate from the incubation experiments, 
using LC-ESI-MS/MS. The product of synthesis was analysed by a Waters Alliance HPLC 
system using a Supelcosil LC-18 25 cm x 4.6 mm 5 μm column connected to a photodiode 
array detector (PDA, Waters). The isocratic eluent consisted of methanol and nanopure water 
(50:50) containing 0.05 M tetra-n-butylammonium bromide and 0.2% (v/v) acetic acid, and 
elution was performed at a flow of 0.8 ml/min. The amount of phenylsulfate in the synthesised 
product was quantified by the comparison of HPLC-PDA data to those for phenylglucuronide, 
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which has similar UV characteristics. Peak areas of phenylsulfate and phenylglucuronide 
were quantified at a wavelength of 262 nm. The retention times of phenylglucuronide and 
phenylsulfate were 4.6 and 9.9 min, respectively. 
GENERAL OUTLINE IN VITRO PBK APPROACH
The in vitro PBK approach to predict in vivo dose-response curves and a PoD for risk 
assessment using in vitro toxicity data consisted of the following steps: (1) establishment of 
in vitro effective concentrations (ECx) of phenol in the EST, (2) development of PBK models 
describing in vivo kinetic properties of phenol in rat and human and derivation of PBK model 
parameters, (3) evaluation of the PBK models, (4) translation of in vitro ECx into in vivo 
external dose levels (EDx) generating dose-response curves for developmental toxicity in rat 
and human and deriving a PoD for risk assessment, and (5) evaluation of the in vitro PBK 
approach.
IN VITRO EMBRYOTOXICITY DATA AND THE AREA UNDER THE CURVE OF PHENOL 
IN THE EST
Embryotoxicity data of phenol derived using the murine embryonic stem cell differentiation 
assay (ES-D3 cells) by Strikwold et al. (2012) were used as a starting point for the in vitro PBK 
approach to translate in vitro embryotoxicity data to in vivo toxicity values. The assay 
encompassed five independently performed experiments in which the inhibition of 
differentiation of ES-D3 cells into beating cardiomyocyte clusters was the toxicity endpoint 
that was studied. Cytotoxicity in ES-D3 cells and fibroblasts, which represent additional 
endpoints in the validated EST when used for embryotoxic potency classification (Genschow 
et al. 2004), was not quantified and is not required for the present study, since the aim was 
to convert a concentration-response curve of an in vitro developmental toxicity endpoint to an 
in vivo dose-response curve. 
A compound may exert its toxic effect either by the peak concentration in blood (Cmax) or by 
its concentration in blood over a specific time period, represented by the area under the 
blood concentration-time curve (AUC). The current study evaluated both metrics in the in vitro 
PBK approach. The area under the curve of phenol in the 10-day EST (AUC0-10d) was obtained 
by measuring the course of the phenol concentration in the cell culture medium of the EST. 
This was evaluated for two test concentrations, namely 0.2 and 0.6 mM phenol. To this end, 
the embryonic stem cell differentiation assay was performed as described by Strikwold et al. 
(2012), but DMEM containing phenol red was replaced by phenol red-free DMEM to prevent 
interference of peaks in the chromatogram of phenol during analysis. Samples of the EST 
culture medium were taken immediately after refreshing the culture medium at days 3 and 5 
of the EST and at t= 0, 1, 2, 4 and 24 h after starting the EST, then followed by a time interval 
of 24 h for the remaining test period. The samples were stored at -20°C until analysis of the 
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phenol concentration by UPLC-PDA (see Quantification of phenol, phenylglucuronide and 
phenylsulfate section).
IN VITRO ASSAYS FOR GLUCURONIDATION AND SULFATION OF PHENOL BY RAT 
AND HUMAN TISSUE SAMPLES
At first, the ability of rat and human tissue samples to glucuronidate and/or sulfate phenol 
was identified using incubations in 50 mM Tris-HCl buffer (pH 7.4 including 10 mM MgCl2) 
with liver, intestinal, kidney and lung tissue fractions (microsomes, cytosol or S9) containing 
(final concentrations) 1 mg protein/ml, 10 mM UDPGA or 0.6 mM PAPS, for a maximum of 2-h 
incubation.
Subsequently, incubations with pooled rat and pooled human microsomes, cytosol or S9 
were performed to determine kinetic constants, namely the maximum enzyme reaction rate 
(Vmax) and the Michaelis-Menten constant (Km), for glucuronidation and sulfation of phenol for 
the metabolising organs. Conditions were optimised to obtain linear metabolism reaction 
rates with respect to incubation time and protein concentration and non-limiting cofactor 
levels were applied. 
For glucuronidation, the rat incubation mixtures consisted of 50 mM Tris-HCl buffer (pH 
7.4) with 10 mM MgCl2, containing (final concentrations) 2 mM UDPGA and 0.2 mg microsomal 
protein/ml for incubations with rat liver microsomes and 10 mM UDPGA and 0.7, 0.8, and 0.8 
mg microsomal protein/ml for incubations with rat small intestinal, lung, and kidney 
microsomes, respectively. The incubation mixtures with human microsomes or S9 consisted 
of 50 mM Tris-HCl buffer (pH 7.4) with 10 mM MgCl2, containing (final concentrations) 10 mM 
UDPGA and 0.8 mg microsomal or S9 protein/ml, except for the incubations with human liver 
tissue fractions for which 0.5 mg microsomal protein/ml was used. To obtain maximum 
glucuronidation activity, the microsomes were activated by preincubating the incubation 
mixture with 0.025 mg/ml alamethicin added from a 200 times concentrated stock solution 
in methanol, during 15 min on ice (Fisher et al. 2000). Subsequently, the incubations were 
started after a 1-min preincubation at 37°C by the addition of the substrate phenol from a 
200 times concentrated stock solution in DMSO and left in a shaking water bath of 37°C for 
10, 20, 20 and 45 min for incubations with rat liver, intestinal, kidney and lung microsomes, 
respectively. Incubations with human liver microsomes were carried out for 10 min and those 
with human intestinal microsomes and kidney S9 for 45 min. The reactions were terminated 
by the addition of ice-cold acetonitrile (20% v/v). Subsequently, the reaction mixtures were 
put on ice. In the blank incubation mixtures, UDPGA was omitted.
For sulfation, the incubation mixtures consisted of 50 mM Tris-HCl buffer (pH 7.4), containing 
(final concentrations) 0.4 mM PAPS and 0.2 mg cytosolic protein/ml for incubations with rat 
liver cytosol and 0.4 mg cytosolic protein/ml for incubations with human liver cytosol and 
human intestinal cytosol. After a 1-min preincubation at 37°C, the reactions were started by 
Binnenwerk Proefschrift Marije Strikwold def.indd   52 05-04-16   16:32
53
PBK-based reverse dosimetry to predict developmental toxicity of phenol in rat and human
3
the addition of the substrate phenol from a 100 times concentrated stock solution in DMSO 
and left in a shaking water bath of 37°C for 30 min for incubations with rat liver cytosol and 
20 min for incubations with human liver and intestinal cytosol. The reactions were terminated 
by the addition of ice-cold acetonitrile (20% v/v). Subsequently the reaction mixtures were 
put on ice. In the blank incubation mixtures, PAPS was omitted.
The formation of phenylsulfate in the sulfation assays was confirmed by enzymatic 
deconjugation using sulfatase. A 60 μl volume of 0.1 M sodium acetate (pH 5.2) and 6 μl of 
sulfatase (400 units/ml) were added to 90 μl of the incubation mixtures of the sulfation 
assays (that was not stopped by the addition of ice-cold acetonitrile) and incubated overnight 
in a shaking water bath at 37°C. Control samples were treated under the same conditions, 
but without sulfatase.
QUANTIFICATION OF PHENOL, PHENYLGLUCURONIDE AND PHENYLSULFATE
Samples of the EST culture medium were thawed after which ice-cold acetonitrile was added 
(50% v/v). Subsequently, the samples were vortexed and left on ice for 20 min after which 
they were centrifuged at 10,000 g for 10 min. The samples of the incubation mixtures of the 
glucuronidation assay were centrifuged for 5 min at 14,000 rpm. Next, 3.5 µl of the 
supernatant of each sample was analysed by UPLC (Waters Acquity) using a Waters BEH C18 
1.7 µm column, 2.1 x 50 mm, with nanopure water (0.1% TFA) (A) and pure acetonitrile (B) 
applying a gradient elution. The start condition was 100:0 (A:B), changing to 90:10 from 1 to 
2 min, then to 10:90 from 2 to 4 min, remaining at this ratio for 0.5 min and then rapidly 
declining to the start condition. The flow rate was 0.6 ml/min. Peaks of phenol and 
phenylglucuronide were detected with a photodiode array detector (PDA, Waters) at a 
wavelength of 270 and 266 nm, respectively. The retention times of phenol and 
phenylglucuronide were 2.6 and 2.4 min, respectively. Phenol and phenylglucuronide were 
quantified based on their peak areas using a linear calibration curve (R2>0.999) prepared 
from commercially available reference compounds. 
The incubation mixtures from the sulfation assay were centrifuged at 14,000 rpm for 5 
min, after which 5 µl of the supernatant of each sample was analysed by LC-ESI-MS/MS. 
High-performance liquid chromatography separation (PerkinElmer 200 series, Waltham, MA, 
USA) was performed using a Zorbax Extend-C18 column, 2.1 x 50 mm, 3.5 µm, with Zorbax 
guard column. The mobile phase consisted of 5 mM ammonium acetate solution (A) and 
methanol (B). The start condition was 80:20 (A:B) for 2 min, changing to 5:95 in 0.1 min and 
kept at this elution for 2.4 min, and then declining to the start condition in 0.1 min, which was 
maintained for 2.9 min. A flow rate of 0.2 ml/min was applied and the retention time of 
phenylsulfate was 1.51 min. The LC effluent was split using a valve (Valco Instruments Co. 
Inc.) to divert the effluent to waste for the period that phenylsulfate was not eluting to prevent 
contamination of the ionisation source. The HPLC was connected to an API-3000 triple-
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quadrupole mass spectrometer with a turbo ionspray (Applied Biosystems, Foster City, CA, 
USA). Nitrogen gas was used as the nebuliser gas. Sample analysis was performed in the 
negative ionisation mode, using multiple reaction monitoring (MRM). Transitions for phenylsulfate 
with m/z 173→93 and 173→80 (Kikuchi et al. 2010) were monitored and used for 
quantification and identity confirmation, respectively. The ionspray voltage was -4200 V, the 
nebuliser gas pressure was 10 psi, the curtain gas pressure was 8 psi, the collision gas 
pressure was 5 psi, and the ion source temperature was 350°C. The declustering potential 
was -37 V, the focussing potential -200 V, the entrance potential -12 V, and the collision cell 
exit potential -15 V. The collision energies were -34 and -26 eV for transitions 173→93 and 
173→80, respectively. The dwell time was 25 ms. Phenylsulfate was quantified based on its 
peak area using a linear calibration curve (R2>0.997) prepared from the in the present study 
synthesised phenylsulfate. The data were processed with the Analyst software, version 1.5 
(Applied Biosystems). 
 
Figure 1 Schematic presentation of the PBK model for phenol in rat and human.
PBK MODEL RAT AND HUMAN
A perfusion rate-limited distribution was used to describe the disposition of unconjugated 
phenol and its metabolites between plasma and tissue, an assumption that is in line with 
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data reported for rats exposed to phenol (Liao and Oehme 1981). The conceptual structure 
of the PBK model for unconjugated phenol is illustrated in Figure 1. A set of differential 
equations describes the kinetics of unconjugated phenol (supplementary data A). Liver, small 
intestine, kidney and lung were identified as metabolising organs in the present study. The 
liver was divided in 3 metabolic zones namely (1) the periportal zone, (2) the midzone and (3) 
the perivenous zone. Sulfation was assigned to be evenly distributed across the zones and 
glucuronidation was assigned to zone 3 (Pang et al. 2008). Fat was not included as a separate 
compartment, because relative low concentrations of phenol appear in fat containing tissues 
(Liao and Oehme 1981) and due to corresponding calculated partition coefficients with the 
other body tissues (data not shown). Therefore, fat was lumped together with all other body 
tissues. Simple phenolic compounds may readily pass the placental barrier (Abu-Qare et al. 
2000; Gray and Kavlock 1990). Therefore, the concentration reaching the embryo was set 
equal to the maternal plasma concentration and no separate embryonic compartment was 
distinguished. Following exposure, a high recovery of phenol in urine has been reported, 
predominantly as phenol metabolites (Hiser et al. 1994; Capel et al. 1972; Weitering et al. 
1979). Only minor excretion of unconjugated phenol was observed via faeces and no or 
hardly any via exhalation (Hiser et al. 1994). Hence, metabolism was considered as the only 
excretion pathway in the present PBK model. At high-dose levels, phenol has been reported 
to be partly converted to hydroquinone, which is excreted as hydroquinone glucuronide (Hiser 
et al. 1994). The formation of hydroquinone is not included in the present model as it is not 
expected that hydroquinone contributes to the developmental toxicity of phenol. Namely, 
hydroquinone was not developmental toxic at low doses in vivo (Blacker et al. 1993; Krasavage 
et al. 1992; Murphy et al. 1992), only at a single high dose of 333 mg/kg bw (Kavlock 1990), 
but such a high level will probably not be reached due to the limited formation of hydroquinone 
after phenol exposure. Kinetic model calculations were performed applying Rosenbrock’s 
algorithms for solving stiff systems (Berkeley Madonna, version 8.3.18, UC Berkeley, CA, USA).
All physiological parameters were obtained from Brown et al. (1997), except the fraction 
of blood flow to small intestine, which for rat was calculated using reported blood flow rates 
for the specific parts of the splanchnic system by Delp et al. (1998), whereas for human the 
value was taken from ICRP (2003). Physiological parameters are outlined in Table 1. Both, rat 
and human tissue:plasma partition coefficients were calculated by the algorithm of 
Berezhkovskiy (2004) requiring information on plasma protein binding, lipophilicity and acid-
base properties. The olive oil:water partition coefficient was used to calculate the adipose 
tissue:plasma partition coefficient, and the octanol:water partition coefficient was used for 
the non-adipose tissues. The unbound fraction of phenol in plasma was 0.59 for the rat (Liao 
and Oehme 1981) and 0.47 for human (Judis 1982). The log Kow (pH 7.4) was 1.46 and the 
pKa was 9.99, which were obtained from the CHEMFATE database (http://esc.syrres.com/
esc/chemfate.htm). The olive oil:water partition coefficient was calculated from the Kow 
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using the algorithm reported by Poulin and Theil (2002). The tissue:plasma partition 
coefficients for rat and human are presented in Table 2.
Table 1 Physiological data for rat and human applied in the PBK model.
Physiological parameter Rat Human
Percentage of body weight
Small intestine 1.4 0.91
Liver 3.4 2.57
Kidney 0.70 0.44
Lung 0.50 0.76
Arterial blood 1.85 1.98
Venous blood 5.55 5.93
Body remaining 77.6 76.0
Cardiac output (l/h/kg bw0.74) 15.0 15.0
Percentage of cardiac output
Small intestine 7.5 10
Liver (without flow from small intestine) 17.5 12.7
Kidney 14.1 17.5
Body remaining 60.9 59.8
Table 2 Calculated tissue:plasma partition coefficients for rat and human.
Tissue Partition coefficient
Rat Human
Liver 0.97 1.13
Small intestine 1.18 1.26
Kidney 0.99 0.93
Lung 1.09 0.67
Body remaining 0.92 0.98
Kinetic parameters, namely Vmax and Km, were derived from the in vitro metabolism data 
obtained in the present study. To this end, the in vitro data were fit to the Michaelis-Menten 
equation (GraphPad Prism 5.0 software, San Diego, CA, USA). The in vitro-derived Vmax values 
(nmol/min/mg protein) were scaled to the in vivo situation using reported protein yields for 
the liver, small intestine, kidney and lung (Table 3). The in vivo Km values were assumed to 
equal the in vitro Km values. The oral uptake rate (ka) of phenol via small intestine was 7.62/h 
(Humphrey et al. 1980) for the rat. The same oral uptake rate value was applied in the human 
PBK model.
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Table 3 Microsomal and cytosolic protein yields (mg/g organ) of different organs for rat and human. 
Organ tissue fraction Rat (mg/g) Reference Human (mg/g) Reference
Liver microsomes 38 Chiu and Ginsberg (2011) 32 Barter et al. (2007)
Liver cytosol 87 Chiu and Ginsberg (2011) 80.7 Cubitt et al. (2011)
Intestinal microsomes 2.4 Van de Kerkhof et al. (2007) 20.6 Cubitt et al. (2009)
Intestinal cytosol - 18 Gibbs et al. (1998)
Kidney microsomes 16 Bong et al. (1985) 16a
Lung microsomes 20 Medinsky et al. (1994) -
a
 Value of rat kidney microsomes.
EVALUATION OF THE PBK MODEL PERFORMANCE
The performance of the PBK model for rat was examined by means of comparing predicted 
plasma concentrations of phenol with reported in vivo plasma levels. For the rat, this was 
evaluated for both the oral and the intravenous (IV) route of administration and at different 
dose levels, using in vivo rat data for phenol available from the literature (Table 4). The 
performance of the human PBK model was not evaluated due to the lack of data on the 
disposition of phenol in humans.
SENSITIVITY ANALYSIS OF THE PBK MODEL
For both the rat and human PBK models, a local parameter sensitivity analysis was carried 
out to identify influential parameters; each parameter was changed in turn keeping the other 
ones constant (Chiu et al. 2007). To this purpose, normalised sensitivity coefficients (SC) 
were calculated with respect to the maximum venous plasma concentrations of unconjugated 
phenol (Cmax) using the algorithm:
where C is the initial value of the model output, and C’ is the output after a 1% parameter 
change. P is the initial parameter value and P’ is the parameter value modified by an increase 
of 1%. The sensitivity analysis was conducted for an oral exposure to a single dose of 1.5 and 
150 mg/kg bw.
TRANSLATION OF IN VITRO-DERIVED EMBRYOTOXICITY DATA TO AN IN VIVO POD 
FOR RISK ASSESSMENT
PBK reverse dosimetry was conducted to predict in vivo dose-response curves from in vitro 
concentration-response data. To this purpose, each nominal effective concentration (ECx) of 
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phenol tested in the EST by Strikwold et al. (2012) was set equal to the maximum plasma 
concentration of unconjugated phenol (Cmax) in the PBK model. In a second approach, the 
area under the curve of phenol in the 10-day EST (AUC0-10d) was set equal to the in vivo AUC 
of phenol in plasma. No correction was applied to in vitro embryotoxic effect levels to account 
for different concentrations of free phenol in the EST culture medium and in plasma caused 
by different albumin levels in these matrices, since it was found that in vitro cytotoxicity of 
phenol tested with the fibroblast-like embryonic mouse cell line Balb/c 3T3 clone A31 was 
not affected by differences in bovine serum albumin levels reflecting the in vitro and in vivo 
situation (Gülden et al. 2002). Applying PBK-based reverse dosimetry with in vitro ECx (or AUC 
response data) as an input for in vivo plasma levels provides in vivo effective dose levels 
(EDx). From these EDx values, an in vivo dose-response curve and a BMDL05 (95% lower 
confidence limit of the benchmark dose at 5% benchmark response) were derived, using the 
Environmental Protection Agency’s (EPA) Benchmark Dose Software (BMDS) version 2.2, 
applying the model that provided the best fit as described previously (Strikwold et al. 2012). 
EVALUATION IN VITRO PBK APPROACH
In vivo dose-response curves for the rat predicted with the in vitro PBK approach were 
compared to individual data points representing the fraction of embryos affected at different 
experimental doses obtained from in vivo developmental toxicity studies (Table 5). To this 
purpose, the average continuous data for foetal weight/litter as reported by Argus (1997) 
were dichotomised using a 5% reduction in the foetal body weight from the mean foetal body 
weight/litter of the control group as a cut-off point. Based on this point, each foetal body 
weight/per litter was assigned affected or not affected, from which the fraction affected was 
calculated. In addition to this evaluation, the in vivo BMDL05 predicted with the in vitro PBK 
approach was compared to NOAELs obtained from in vivo developmental toxicity studies from 
the literature.
To provide a sound evaluation of the in vitro PBK approach, exposure routes and scenarios 
(i.e. oral intake) from in vivo developmental toxicity studies for the rat available from literature 
(Table 5) were applied to the in vitro PBK approach. In most studies, phenol was tested during 
several consecutive days administering a single daily oral dose. As phenol was rapidly 
eliminated (<2 h) at a dose <350 mg/kg bw, only one single oral administration was modelled 
with the PBK model for unconjugated phenol. In the study of Ryan et al. (2001), rats were 
dosed via drinking water. The intake of drinking water by rats occurs in bouts (Zorrilla et al. 
2005). The oral intake of phenol was calculated using a maximum intake amount of 6.6 ml 
water per bout (Zorrilla et al. 2005) multiplied by the concentration of phenol in drinking 
water to obtain maximum peak concentrations. Accumulation of phenol that could result 
from quick successive drinking water bouts was not considered.
Binnenwerk Proefschrift Marije Strikwold def.indd   58 05-04-16   16:32
59
PBK-based reverse dosimetry to predict developmental toxicity of phenol in rat and human
3
RESULTS
IN VITRO EMBRYOTOXICITY DATA AND THE AREA UNDER THE CURVE OF PHENOL 
IN THE EST
Phenol inhibited differentiation of ES-D3 cells into beating cardiomyocytes in a concentration-
dependent fashion (Figure 2). The in vitro BMC50 (benchmark concentration at 50% level of 
response) was 590 μM and the BMC1-99 ranged from 70 to 1520 μM (Strikwold et al. 2012). 
It was found that the phenol concentration in the EST culture medium decreased rapidly 
in the first few hours of the EST resulting in hardly any exposure from day 0-3 in the EST. In 
the remaining days, phenol was relatively stable (Figure 2). The decrease of the phenol 
concentration in time follows a similar course for phenol concentrations of 0.2 and 0.6 mM 
and was on average 39% of the nominal concentration. The nominal AUC0-10d of each 
concentration tested in the EST was reduced by 39% to calculate the actual AUC0-10d, which 
then served as the surrogate for the in vivo plasma AUC in the PBK model.
 
Figure 2 a Concentration-response curve for phenol representing the inhibition of differentiation of the embryoid 
bodies (EBs) at the specified concentrations, as previously obtained by Strikwold et al. (2012). Different symbols 
represent independent assays. b Course of the phenol concentration in the EST in time, tested at initial 
concentrations (t = 0) of 0.2 mM (♦) and 0.6 mM (●). Symbols represent mean values ± SD.
IN VITRO KINETIC DATA FOR RAT AND HUMAN
Analysis of the incubations with phenol revealed that rat liver, small intestinal, kidney and lung 
microsomes were able to metabolise phenol towards phenylglucuronide and that rat liver 
cytosol was capable of forming phenylsulfate. For human samples, the incubations with phenol 
showed that liver and small intestinal microsomes and kidney S9 were able to glucuronidate 
phenol to phenylglucuronide and that both human liver and human small intestinal cytosol 
were able to form phenylsulfate. Sulfation was not detected in incubations with rat small 
intestinal cytosol, rat kidney and lung cytosol, and not with human kidney and lung S9 up to 2 
h of incubation, neither was glucuronidation detected in incubations with human lung S9.
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In each incubation with the relevant tissue fractions (microsomes, S9 or cytosol), metabolism 
followed Michaelis-Menten kinetics (Figure 3). The apparent Km, Vmax and the catalytic 
efficiencies (Vmax(app)/Km) of the tissue fractions are presented in Table 6, as well as the scaled 
Vmax(app) and the scaled catalytic efficiencies (scaled Vmax(app)/Km). In general, the scaled 
catalytic efficiencies (ml/h/g organ) for glucuronidation and sulfation of phenol obtained 
from human tissue fractions were lower compared to values obtained from rat tissue 
fractions. It appeared that the scaled catalytic glucuronidation efficiency was higher than the 
scaled catalytic sulfation efficiency for both rat and human liver, while the scaled catalytic 
sulfation efficiency in human intestinal tissue fraction was higher compared to the scaled 
catalytic glucuronidation efficiency. The liver was found to be the main metabolising organ for 
phenol in both rat and human. Rat liver tissue expressed a scaled catalytic glucuronidation 
efficiency of 440 ml/h/g liver, which is 6.4-fold higher compared to kidney tissue and 35.7- 
and 160.7-fold higher compared to lung tissue and small intestinal tissue, respectively. The 
ranking of human organs based on their scaled catalytic efficiencies is almost similar to the 
rat organs, identifying the liver as the main metabolising organ expressing a scaled catalytic 
efficiency of 59 ml/h/g liver, followed by kidney and small intestine that showed a 9.1- and a 
23.0-fold lower catalytic efficiency compared to the liver. The scaled catalytic efficiency for 
sulfation in rat liver tissue was 636 ml/h/g liver and occurred with a relatively high affinity 
and low capacity resulting in saturation of this pathway at low doses. Human liver cytosol 
expressed a scaled catalytic sulfation efficiency of 17 ml/h/g liver, which is 1.4 times higher 
than the scaled catalytic efficiency determined with human intestinal cytosol. In case the 
catalytic efficiencies (ml/h/g liver) were scaled to a whole organ (ml/h/organ) using organ 
weights, then the ranking between the organs based on their catalytic efficiency would 
remain the same, both for rat and human (data not shown).
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Figure 3 Concentration-dependent formation of phenylglucuronide (a and c) and phenylsulfate (b and d) by liver 
(●), small intestine (▲), kidney (■) and lung (▼) in incubations with relevant rat (a and b) and human (c and d) 
tissue fractions (microsomes, cytosol or S9). Individual symbols represent mean activities of ≥ 3 measurements ± SD. 
Table 4 Specifications of in vivo kinetic studies of phenol published in the literature and applied to evaluate the 
developed PBK model for phenol.
Species and strain Body 
weight 
(kg)
Exposure route Dose 
(mg/kg 
bw/d)
Cmax PBK / 
Cmax in vivo
AUCPBK / 
AUCin vivo
Remarks Reference
Fischer 344 rat
(male)
0.191
0.175
Oral 1.69
147
1.56
0.86
4.28
1.09
Bolus dose, 
volume ad-
ministration 
5 ml/kg
Hiser et 
al. (1994)
Sprague-Dawley rat
(male)
0.263 Intraduodenal 0.4
1.5
4.5
15
- b 1.30
1.02
0.61
0.42
Cassidy 
and Hous-
ton 
(1984)
Sprague-Dawley rat
(male)
0.263 IV 0.4
1.5
4.5
15
- b 1.49
1.48
1.21
1.05
0.01-h infu-
sion (as-
sumption)
Cassidy 
and Hous-
ton 
(1984)
Wistar rat
(male)
0.286a IV 1.5 1.00 1.20 0.167-h infu-
sion, volume 
administra-
tion 10 ml/kg
Dickinson 
and Taylor 
(1996)
a Mean of the reported range of 0.241-0.330 kg.
b No in vivo data available for first few minutes after dosing; therefore, no reliable Cmax could be obtained from the 
in vivo data.
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EVALUATION OF THE PBK MODEL PERFORMANCE
Figure 4 shows plasma concentration-time curves for unconjugated phenol in the rat 
predicted with the developed rat PBK model together with in vivo kinetic data obtained from 
the literature. The kinetic data show that phenol is rapidly absorbed in the body, resulting in 
a high peak concentration, after which phenol is readily excreted from the body, both at low 
and high doses. Figure 4 reveals that the PBK model accurately predicts the time course of 
changes in plasma concentrations of phenol for the oral route and for the IV route at the 
specified doses. The difference between the predicted and observed Cmax for a single oral 
dose of 1.69 and 147 mg/kg bw was 1.56- and 0.86-fold, respectively, and for 10-min IV 
infusion of 1.5 mg/kg bw, there was no difference (1.0-fold) (Table 4). In addition, the 
difference between the AUC predicted with the PBK model for phenol and the AUC values 
obtained from the corresponding studies was small for most of the concentrations tested 
(Table 4). Only at the low single oral dose of 1.69 mg/kg bw, the model tends to overpredict 
the AUC expressing a 4.28-fold difference between the AUC predicted with the PBK model 
and the observed AUC obtained from the study of Hiser et al. (1994) (Table 4).
Figure 4 Plasma concentration-time profiles for phenol in rat predicted with the PBK model (solid lines) and 
published in vivo values (▲) after a single oral dose of 1.69 and 147 mg/kg bw (a) (Hiser et al. 1994) and after IV 
dosing of 1.5 mg/kg bw with an infusion rate of 0.167/h (b) (Dickinson and Taylor 1996) and 0.4 mg/kg bw with 
presumed infusion rate of 0.01/h (c) (Cassidy and Houston 1984). a shows mean values ± SD.
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Table 5 In vivo developmental toxicity data of phenol obtained from the literature, used to evaluate the in vitro PBK 
approach.
Species and strain Exposure 
day(s)
Dose
(mg/kg bw/d)a 
Developmental 
endpoint
Developmental 
NOAEL 
(mg/kg bw/d)
Reference
Sprague-Dawley rat GD 11 0, 100, 333, 667, 
1000
Malformationsb 
reported at two 
highest dosesc
333 Kavlock 
(1990)
Sprague-Dawley rat GD 6-15 0, 30, 60, 120 Decreased average 
foetal bw/litter
60 Jones-Price 
et al. 
(1983a)
Sprague-Dawley rat GD 6-15 0, 60, 120, 360 (3 
doses/d; 0, 20, 40, 
120 mg/kg bw/dos-
age)
Decreased average 
foetal bw/litter
120
(40)
Argus 
(1997)
Fischer rat GD 6-19 0, 40, 53.3 Reduced live pups/
litter and fraction 
litters fully resorbed
40 Narotsky 
and 
Kavlock 
(1995)
Sprague-Dawley rat 10-11 
weeks 
prior to 
mating 
through 
weaning
0, 200, 1000, 5000 
ppm
 (= 0, 20, 93, 350 
mg/kg bw/d)
Fraction of offspring 
nonlive postnatal 
day 4 and postnatal 
day 7-21
70 (males)
93 (females)
Ryan et al. 
(2001)d
CD-1 mice GD 6-15 0, 70, 140, 280 
(final study)
0,100, 200, 230, 
260, 275, 300, 400 
(preliminary study)
Decreased average 
foetal bw/litter
Fraction foetuses 
malformed
140 Jones-Price 
et al. 
(1983b)
a In each study phenol was administered by oral gavage, except in the study of Ryan et al. (2001) in which phenol 
was administered via drinking water.
b Hindlimb paralysis and/or short or kinky tails.
c Not analysed on statistical significance.
d Effects possibly related to decreased maternal water intake due to flavour aversion.
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SENSITIVITY ANALYSIS OF THE PBK MODEL
The sensitivity analysis (supplementary data B) revealed that the intestinal absorption 
coefficient, the volume of the liver, the maximum glucuronidation and sulfation rate in the 
liver and the liver cytosolic protein yield were the most influential parameters in the rat PBK 
model expressing normalised sensitivity coefficients >1. The normalised sensitivity 
coefficients of most of the PBK model parameters were not dose-dependent, except for 
parameters related to sulfation in the rat liver (cytosolic protein yield and the Michaelis-
Menten parameters Km and Vmax), which were more influential on Cmax at low oral dose levels 
compared to high oral dose levels.
The sensitivity analysis of the human PBK model revealed that the intestinal absorption 
coefficient, the volume of the intestine, the microsomal protein yield in the intestine and the 
maximum glucuronidation rate in the intestine were the most influential parameters in the 
model, expressing normalised sensitivity coefficients >1. The normalised sensitivity 
coefficients of several parameters of the human PBK model were dose-dependent, namely 
those for the body weight, the volume of the liver and the volume of the small intestine, the 
blood flow to the small intestine, the intestinal absorption coefficient, and parameters related 
to metabolism. Compared to the rat, parameters related to glucuronidation in human intestine 
were more influential at lower doses and parameters related to sulfation of phenol in the liver 
were not as influential in the human PBK model compared to the rat PBK model at low doses. 
These differences in sensitivity of the model parameters may be explained by the different 
catalytic efficiencies of the metabolising organs in rat and human.
TRANSLATION OF IN VITRO-DERIVED EMBRYOTOXICITY DATA TO AN IN VIVO POD 
FOR RISK ASSESSMENT
Figure 5 presents the predicted in vivo dose-response curves for developmental toxicity of 
phenol in the rat using the in vitro PBK approach, along with developmental toxicity data 
obtained from the literature. This figure shows that the predicted dose-response curves for 
the rat based on the Cmax of phenol closely mimic most of the in vivo developmental toxicity 
values obtained from the literature, which is not the case for the dose-response curve based 
on the AUC0-10d. The BMDL05 derived from the dose-response curve for rat based on the Cmax is 
93.5 mg/kg bw/d and the BMDL05 derived from the dose-response curve for rat based on the 
AUC0-10d is 1890 mg/kg bw/d. From here onwards, the BMDL05 derived from Cmax is considered 
because this value matches the in vivo data better than the BMDL05 derived from the AUC0-10d. 
The NOAELs for the rat obtained from the available in vivo developmental toxicity studies are 
presented in Table 5. A 0.3- to 2.3-fold difference was observed between the in the present 
study predicted BMDL05 and the in vivo-derived NOAELs. The predicted BMDL05 lies within the 
range of the reported PoDs obtained from in vivo developmental toxicity studies (Figure 6). 
The BMDL05 derived from the dose-response curve for human (Figure 5) based on the Cmax is 
26.9 mg/kg bw/d, which is 3.5-fold lower compared to the predicted BMDL05 for the rat.
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Figure 5 In vivo dose-response curves together with the 95% lower confidence limit for developmental toxicity of 
phenol in rat (a) and human (b) predicted by the in vitro PBK approach compared to in vivo developmental toxicity 
data reported in the literature. The solid lines represent the predicted dose-response curves based on the nominal 
test concentration of phenol relating Cmax to developmental toxicity, and the dashed lines represent the predicted 
dose-response curves relating the AUC0-10d of phenol to developmental toxicity. Symbols represent fraction of 
litters which had offspring with hindlimb paralysis and/or short or kinky tails (□) (Kavlock 1990), fraction of 
offspring nonlive postnatal day 4 (△) and fraction of offspring nonlive postnatal day 7-21 (×) (Ryan et al. 2001), 
fraction of litters with 5% reduction of foetal bw compared to average foetal bw/litter of the control group (▽) 
(Argus 1997), fraction litters fully resorbed (Ο), fraction nonlive pups per litter (compared to number of implants 
(average data)) (◇) (Narotsky and Kavlock 1995) and fraction foetuses malformed (+) (Jones-Price et al. 1983b). 
See Table 5 for specifications of the in vivo data.
 
Figure 6 95% lower confidence limit of the benchmark dose (BMDL05) for developmental toxicity of phenol in the 
rat predicted by the in vitro PBK approach (line) compared to NOAELs (●) obtained from in vivo developmental 
toxicity studies of phenol. See Table 5 for specifications of the in vivo data.
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DISCUSSION
The objective of the present study was to demonstrate the potential of a combined in vitro 
PBK approach to predict in vivo dose-response curves that allow definition of a PoD for risk 
assessment using in vitro-derived toxicity data combined with a PBK model, with phenol as 
the compound of interest. The current study demonstrated that combining in vitro toxicity 
data with a PBK model is a promising approach to derive safe exposure levels for the risk 
assessment of chemicals, predicting a BMDL05 that lies within the variation of NOAELs 
obtained from in vivo developmental toxicity data from the literature. The maximum observed 
difference was 0.3-fold between the in vitro PBK predicted BMDL05 of 93.5 mg/kg bw/d and 
the in vivo NOAELs with 333 mg/kg bw/d being the highest NOAEL. This result was achieved 
on the basis of in vitro and in silico data and data available from the literature only, thereby 
considerably contributing to the reduction, refinement and replacement (3Rs) in animal 
testing. In practice, there is a great demand for alternatives to animal experiments, as the 
use of animal testing is regulated in the new Cosmetic Products Regulation, which banned 
the testing of cosmetic ingredients on animals by March 2013 (EC 2009) and in the EU 
chemical legislation-Registration, Evaluation, Authorisation and restriction of CHemicals 
(REACH)-which states that animal testing may only be undertaken as a last resort (EC 2007). 
As only a few examples of the in vitro PBK approach are reported so far (Louisse et al. 2010; 
Verwei et al. 2006), more studies are required before the present approach can be regarded 
reliable and implemented in practice.
In most in vivo developmental toxicity studies, phenol was administered during several 
consecutive gestational days, resulting in a reduced foetal body weight. This adverse effect 
was not observed in the developmental screening study of Kavlock (1990) in which phenol 
was administered only on gestational day 11 up to a dose of 1000 mg/kg bw. Phenol is very 
rapidly eliminated from the body and does not accumulate after repeated daily dosing. The 
current study showed that the Cmax was an appropriate metric to predict in vivo developmental 
toxicity of phenol for most endpoints including reduction in foetal body weight. 
Physiological conditions of rat and human may change during pregnancy and may 
influence the kinetics of a compound. It has been reported that uridine diphosphate 
glucuronyltransferase (UDPGT) activity towards phenolic substrates in pregnant rats can be 
reduced by about 50% during pregnancy (Luquita et al. 2001). Glucuronidation is the 
dominant elimination pathway at higher dose levels of phenol. Using the approach developed 
in the present study it, was calculated that a 50% reduction of the Vmax for glucuronidation in 
the liver would result in a 1.6-fold lower BMDL05 of 58.9 mg/kg bw/d. This predicted BMDL05 
still lies well within the observed variation of the in vivo PoDs for developmental toxicity, 
though evaluating pregnancy specific kinetic changes may be valuable to refine model 
predictions. 
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Glucuronidation and sulfation conjugates were considered to be the most important phenol 
metabolites in the PBK models for rat and human in analogy with the metabolic profiles 
obtained from reported in vivo kinetic studies. Sulfation of phenol in rat small intestine could 
not be identified in vitro in incubations with tissue fractions that were positively screened for 
sulfation activity with genistein as the control substrate. However, sulfation of phenol was 
demonstrated in intestinal in situ perfusion studies in the rat (Kothare and Zimmerman 
2002; Powell et al. 1974) and in isolated rat intestinal cells and preparations (Shirkey et al. 
1979; Powell et al. 1974). This discrepancy, however, would not affect the predicted dose-
response curves (BMD1-99) and the PoD for phenol to a large extent, as the observed 
developmental toxic effect occurs at high doses, far above levels at which sulfation becomes 
saturated and at which the glucuronidation pathway dominates metabolism.
The predicted BMDL05 of 93.5 mg/kg bw/d for rat obtained using the in vitro PBK approach 
could theoretically be used as a PoD for risk assessment, applying a default uncertainty 
factor of 100, accounting for intra- and interspecies kinetic and dynamic differences (IPCS 
2005). This would result in a human guidance value for the general population of 0.93 mg/
kg bw/d. Applying the BMDL05 of 26.9 mg/kg bw/d obtained with the human in vitro PBK 
approach allows for elimination of an uncertainty factor of 100.6 that accounts for interspecies 
kinetic differences (IPCS 2005). This provides a guidance value of 1.07 mg/kg bw/d which is 
close to the guidance value of 0.93 mg/kg bw/d derived from the rat in vitro PBK approach. 
Thus, the interspecies kinetic differences elucidated with the present PBK model for rat and 
human are correctly covered with the default uncertainty factor for interspecies kinetic 
differences (IPCS 2005). 
The present study used the EST to assess the potential of phenol to cause developmental 
toxic effects in vivo. It should be noted, however, that the endpoint inhibition of cardiomyocyte 
differentiation tested in the EST cannot reflect the whole array of developmental toxic effects 
that can be induced by compounds, as some compounds interfere with processes that are 
not present in the 10-day EST and hence some effects may remain undetected. Therefore, 
additional test systems reflecting extra endpoints i.e. neural differentiation may be considered 
when applying this in vitro PBK approach in practice. In addition, there may be uncertainty 
whether the sensitivity of an in vitro test system towards the compound accurately reflects 
the sensitivity in vivo. Applying an extra uncertainty factor that accounts for these differences 
in sensitivity may therefore be considered in case the current in vitro PBK approach is applied 
for risk assessment purposes. Finally, it may be noted that the EST was not able to correctly 
rank a series of p-substituted phenols to their in vivo potency, except phenol itself (Strikwold 
et al. 2012). A reason may be the kinetic differences between the in vitro and the in vivo 
situation (Strikwold et al. 2012). Applying the current in vitro PBK approach to this series of 
p-substituted phenols may provide a promising strategy to elucidate this aspect in the future.
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Overall, this study shows that it is possible to accurately predict a PoD for the risk assessment 
of phenol, providing a PoD that lies within the range of the reported in vivo PoDs for 
developmental toxicity, using in vitro, in silico data and data from the literature only. It shows 
how combining different alternatives to animal testing such as in vitro and in silico methods 
can enlarge their application from screening and prioritising chemicals towards deriving safe 
exposure levels for the risk assessment of compounds. Although, the application of the 
presented in vitro PBK approach is still in its infancy, the positive results obtained in the 
present study may stimulate to explore its feasibility for other toxicological endpoints and a 
wide set of compounds.
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SUPPLEMENTARY DATA A
MASS BALANCE EQUATIONS AND PARAMETER SPECIFICATIONS OF THE PBK 
MODEL FOR PHENOL IN THE RAT
COMPOUND   ABBREVIATION
phenol    ph
phenylglucuronide   pg
phenylsulfate   ps
COMPARTMENT (TISSUE (T)) ABBREVIATION
Small intestine   I
Liver    L
Lung    P
Kidney    K
Remaing body   B
Arterial    A
Venous    V
VARIABLE UNIT ABBREVIATION
Blood flow rate to tissue l h-1 Q(T)
Cardiac output l h-1 QC
Concentration phenol in tissue or blood μM C(T)ph
Partition coefficient tissue:blood phenol - P(T)ph
Volume of tissue or blood l V(T)
Amount phenol in tissue or blood μmol A(T)ph
Maximum rate of formation metabolite (m) in tissue μmol h-1 Vmax(T)m
Michaelis-Menten constant for formation metabolite (m)  μM Km(T)m
in tissue 
Uptake rate phenol intestine h-1 ka
Amount phenol taken up from the gut lumen μmol Uptakeph
Amount phenol remaining in the gut lumen μmol AGLph
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SMALL INTESTINE
Uptake phenol from gut lumen
LIVER COMPARTMENT 1
LIVER COMPARTMENT 2
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LIVER COMPARTMENT 3
LUNG COMPARTMENT
KIDNEY COMPARTMENT
REMAINING BODY TISSUE
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ARTERIAL BLOOD COMPARTMENT
VENOUS BLOOD COMPARTMENT
 
SUPPLEMENTARY DATA B
 
Figure S1 Normalised sensitivity coefficients for parameters of the PBK model for rat (a) and human (b) based on 
Cmax values from a single oral dose of 1.5 mg/kg bw (black bars) and 150 mg/kg bw (grey bars). Normalised 
sensitivity coefficients ≥ 0.2 are presented. BW=body weight, VI=fraction small intestine, VL=fraction liver tissue, 
QI=fraction blood flow to small intestine, PB:P=partitioning coefficient body remaining:plasma, Ka=intestinal ab-
sorption coefficient, MPI=small intestinal microsomal protein yield, MPL=liver microsomal protein yield, CPL=liver 
cytosolic protein yield, VmaxLPS=unscaled maximum rate of sulfation of phenol in liver, VmaxIPG=unscaled 
maximum rate of glucuronidation of phenol in intestine, KmIPS=Michaelis-Menten constant for sulfation of phenol in 
small intestine, VmaxLPG=unscaled maximum rate of glucuronidation of phenol in liver, KmLPS=Michaelis-Menten 
constant for sulfation of phenol in liver, KmLPG=Michaelis-Menten constant for glucuronidation of phenol in liver. 
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ABSTRACT
In vitro derived toxicity outcomes do not always reflect in vivo toxicity values, which was 
previously observed for a series of phenols tested in the embryonic stem cell test (EST). 
Translation of in vitro data to the in vivo situation is therefore an important, but still limiting 
step for the use of in vitro toxicity outcomes in the safety assessment of chemicals. The aim 
of the present study was to translate in vitro embryotoxicity data for a series of phenols to in 
vivo developmental toxic potency values for the rat by physiologically based kinetic (PBK) 
modelling based reverse dosimetry. To this purpose, PBK models were developed for each of 
the phenols. The models were parameterised with in vitro derived values defining metabolism 
and transport of the compounds across the intestinal and placental barrier, and with in silico 
predictions and data from the literature. Using PBK-based reverse dosimetry, in vitro 
concentration-response curves from the EST were translated into in vivo dose-response 
curves from which points of departure (PoDs) were derived. The predicted PoDs differed less 
than 3.8-fold from PoDs derived from in vivo toxicity data for the phenols available in the 
literature. Moreover, the in vitro PBK-based reverse dosimetry approach could overcome the 
large disparity that was observed previously between the in vitro and the in vivo relative 
potency of the series of phenols. In conclusion, this study shows another proof-of-principle 
that the in vitro PBK approach is a promising strategy for non-animal based safety assessment 
of chemicals.
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INTRODUCTION
The safety evaluation of chemicals is currently evolving from using animal toxicity tests 
towards the application of innovative non-animal based in vitro approaches to predict toxicity. 
This development is encouraged by initiatives such as the European Registration, Evaluation, 
Authorisation and restriction of CHemicals (REACH) (EC 2007), the Cosmetic Products 
Regulation (EC 2009) as well as the US National Research Council report on toxicity testing 
in the 21st century (National Research Council 2007). For many years, in vitro toxicity assays 
have been used for hazard identification only, including for example the detection of 
genotoxicity, and the ranking and prioritisation of compounds for further in vivo toxicity 
testing (Gülden and Seibert 2005). Translation of in vitro data to the in vivo situation is an 
important but limiting step for the use of in vitro outcomes in the regulatory risk assessment 
of chemicals, as in vitro derived toxicity outcomes as such do not always reflect in vivo toxicity 
values (Blaauboer 2010; Punt et al. 2011). For example, in our study on the embryotoxic 
potencies of a series of phenols evaluated in vitro with the ES-D3 differentiation assay of the 
embryonic stem cell test (EST), it was concluded that the assay did not correctly rank the 
phenols according to their in vivo potency (Strikwold et al. 2012). Especially the toxicity of 
p-heptyloxyphenol was relatively higher in the EST than reported in in vivo studies in the 
literature as compared to the other phenols tested. In the EST p-heptyloxyphenol displayed a 
BMC50 that was more than 3 orders of magnitude lower than that of phenol whereas in vivo 
BMD10 values differed less than 3-fold (Strikwold et al. 2012). Kinetic differences between 
the in vitro and in vivo situation were hypothesised to provide a reason for the observed 
disparities (Strikwold et al. 2012).
Combining in vitro toxicity data with physiologically based kinetic (PBK) modelling applying 
reverse dosimetry has recently been shown to provide a promising approach to extrapolate in 
vitro concentration-response curves to in vivo dose-response curves from which points of 
departure (PoDs) for the risk assessment of chemicals can be derived (Louisse et al. 2010; 
Louisse et al. 2014; Strikwold et al. 2013). In this way kinetic differences between the vitro 
and in vivo situation can be taken into account and in vivo dose-response curves suitable for 
deriving a PoD for risk assessment can be obtained based on in vitro data. However, as PBK 
models are generally data intense and their development often time consuming (Loizou and 
Hogg 2011), their application is often hampered. Applying in silico predictions, i.e. Quantitative 
Structure-Activity Relationships (QSARs) and in vitro kinetic experiments may aid the 
development of PBK models by predicting input values for kinetic parameters required, 
thereby also facilitating non-animal based safety assessment of chemicals. 
For phenol, one of the congeners tested in our previous in vitro study on the embryotoxic 
potency of a series of phenols (Strikwold et al. 2012), in vitro PBK-based reverse dosimetry 
and subsequently dose-response modelling, provided a PoD that appeared to match the 
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range of in vivo derived PoDs (Strikwold et al. 2013). The aim of the present study was to 
translate in vitro embryotoxicity data for a series of phenols including p-heptyloxyphenol as 
previously obtained with the EST (Strikwold et al. 2012), to in vivo developmental toxicity 
values for the rat by PBK-based reverse dosimetry, using in silico and in vitro defined kinetic 
parameters. Ultimately, this should elucidate whether combining in vitro data with PBK 
modelling to predict in vivo values, can overcome differences that were observed between 
the in vitro and the in vivo relative potencies of different phenolic congeners, and especially 
whether this approach can overcome the deviating results for p-heptyloxyphenol. This may 
provide another proof-of-principle to assess the feasibility of this in vitro PBK approach for 
prospective toxicological safety evaluations of chemicals.
MATERIALS AND METHODS
COMPOUNDS AND MATERIALS
Phenol (99%), p-fluorophenol (99%), p-heptyloxyphenol (97%), p-methylketophenol (99%), 
antipyrine (≥ 99%), fluorescein, Tris(hydroxymethyl)aminomethane (Tris) (≥ 99.9%) and 
Dulbecco’s Modified Eagle’s medium (DMEM), uridine 5’-diphosphoglucuronic acid (UDPGA), 
alamethicin (98%), sodium taurocholate hydrate (97%), β-glucuronidase (Type 1x-A from 
Escherichia coli) and bovine serum albumin (≥ 98%) were obtained from Sigma Aldrich 
(Steinheim, Germany). Acetonitrile (ULC/MS grade) and methanol (HPLC supra-gradient) 
were obtained from BioSolve (Valkenswaard, The Netherlands), dimethylsulfoxide (DMSO) (≥ 
99%) from Acros Organics (Geel, Belgium). Trifluoroacetic acid (TFA), hydrochloride acid 
(37%), magnesium chloride hexahydrate, potassium phosphate (≥ 99%) and Transwell® 
inserts (0.4 µm pored polycarbonate membrane, 12 mm diameter) were purchased from 
VWR International GmbH (Darmstadt, Germany). Foetal calf serum (FCS) was puchased from 
HyClone-Perbio (Etten-Leur, The Netherlands). Penicillin, streptomycin, L-glutamine, minimal 
essential medium non-essential amino acids and trypsin / EDTA in PBS (final concentration 
0.025% / 0.01%) were obtained from Gibco (Paisley, Scotland). Phosphate buffered saline 
(PBS), and Hank’s balanced salt solution (HBSS), were obtained from Invitrogen (Breda, The 
Netherlands) and HEPES was from VWR (Radnor, USA).
BeWo choriocarcinoma cells subclone b30 were kindly provided by the Institute of Public 
Health of the Faculty of Health Sciences of the University of Copenhagen (Denmark) with 
permission from Dr. Alan Schwartz (Washington University, St Louis, MO). The provided cell 
line was confirmed to be mycoplasma negative. The colorectal adenocarcinoma (Caco-2) 
cells were obtained from ATCC (Middlesex, UK). Pooled liver microsomes from male Sprague-
Dawley rats were obtained from BD Biosciences Gentest (Woburn, MA, USA).
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GENERAL OUTLINE IN VITRO PBK APPROACH
The in vitro PBK approach to predict in vivo dose-response curves and a PoD for risk 
assessment using in vitro embryotoxicity data consisted of the following steps: (i) 
establishment of in vitro effective concentrations (ECx) of the phenols in the EST, (ii) 
development of PBK models describing in vivo kinetic properties of the phenols in rat 
including derivation of PBK model parameters, (iii) sensitivity analysis of the PBK models, (iv) 
translation of in vitro ECx values into in vivo external dose levels (EDx) generating dose-
response curves for developmental toxicity in rat and enabling the definition of a PoD for risk 
assessment and (v) evaluation of predictions performed with the in vitro PBK approach.
IN VITRO EMBRYOTOXICITY
Embryotoxicity data of phenol, p-fluorophenol, p-heptyloxyphenol and p-methylketophenol 
determined using the murine embryonic stem cell (ES-D3) differentiation assay of the EST by 
Strikwold et al. (2012), were used as a starting point for the in vitro PBK approach translating 
in vitro embryotoxicity data to in vivo toxicity values. The use of both the maximum 
concentration in foetal plasma (Cmax) and the Area Under the foetal plasma concentration-
time Curve (AUC) in the in vitro PBK approach was evaluated. The concentration of phenol 
and p-fluorophenol decreased in time in the EST culture medium (without cells) in a similar 
fashion, while p-methylketophenol and p-heptyloxyphenol were stable (Strikwold et al. 2012). 
Therefore, the AUC of the 10 day EST of p-methylketophenol and p-heptyloxyphenol was 
calculated by multiplying the test concentration by the duration of the experiment (AUC0-10d), 
while the calculated AUC0-10d for phenol and p-fluorophenol was reduced by 39% corresponding 
to the loss of phenol in the EST as reported by Strikwold et al. (2013).
 
Figure 1 Schematic representation of the PBK models of the phenols.
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RAT PBK MODEL STRUCTURES FOR PHENOLS
The rat PBK model for phenol developed by Strikwold et al. (2013) was used as a starting 
point to construct rat PBK models for the different phenols of the present study (Figure 1), 
with four major modifications. The first modification is that only liver glucuronidation of the 
phenolic compounds was taken into account in the present study to describe the metabolic 
conversions. This could be done because the sensitivity analysis of the previously developed 
PBK model of phenol by Strikwold et al. (2013), performed at an oral dose level of 150 mg/
kg bw which is consistent with high oral dose levels that were applied in in vivo toxicity studies 
of the phenols (Kavlock 1990), identified that glucuronidation of phenol in the liver is the 
most influential metabolic pathway in the model. Moreover, in vivo kinetic studies towards the 
metabolism of phenol confirm the importance of this route, showing that the glucuronide 
conjugate is the predominant metabolite formed at high oral dose levels (Hiser et al. 1994). 
Furthermore, the metabolic parameters Km and Vmax of sulfation were not identified as a 
sensitive parameter in the PBK model for phenol at high oral dose levels and the Vmax value 
for sulfation was very low (Strikwold et al. 2013), supporting the choice for glucuronidation as 
the metabolic and elimination pathway in the current PBK models. A second modification is 
that we have included in vitro transport experiments with Caco-2 cells to define the oral 
uptake constants of the different compounds of the present study, since the previously 
predicted plasma concentrations of phenol appeared to be quite sensitive to the oral 
absorption coefficient (ka). A third modification is that a fat compartment was included in the 
PBK models for the different phenolic compounds, because p-heptyloxyphenol may readily be 
distributed to adipose tissue due to its relatively high lipophilicity. Finally, a placental/foetal 
compartment was added to the PBK models, including transport of the compound from the 
mother to the embryos/foetuses and back by simple diffusion. For the placental/foetal 
compartment, the number of embryos in one litter was considered to be 12 and they were 
treated as one unit for which the physiological parameters were calculated. Foetal-maternal 
diffusion was set equal to maternal-foetal diffusion. To include maternal-foetal diffusion in 
the PBK model, apparent permeability coefficients (Papp) across placental BeWo cells 
cultivated in a transwell system were derived in vitro and subsequently converted to in vivo 
diffusion transplacental clearance rates (l/h) (see section In vitro placental transport study). 
The PBK models were defined with parameters representative for gestational day 11 (GD11), 
facilitating evaluation of the PBK model predictions with available in vivo developmental 
toxicity data for rats exposed to phenol or p-substituted phenol at GD11.
An overview of the PBK model algorithms, which are similar for all the phenols, is included 
in Supplementary data A. Kinetic model calculations were performed by applying Rosenbrock’s 
algorithms for solving stiff systems (Berkeley Madonna, version 8.3.18, UC Berkeley, CA, 
USA).
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PBK MODEL PARAMETER VALUES
Physiological parameters
In the PBK models, organ weights of the pregnant rat were kept equal to values of a non-
pregnant rat and placental and foetal weights were additionally included. The fractions of 
blood flow to the organs were set equal to that of the non-pregnant rat as well, although the 
fraction of blood flow to the compartment ‘body remaining’ was reduced to accommodate for 
the added blood flow to the placental/foetal compartment, with the total fraction not 
exceeding 1. Most physiological parameters were taken from Brown et al. (1997). The fraction 
of blood flow to the small intestine was calculated using reported blood flow rates for the 
specific parts of the splanchnic system by Delp et al. (1998). The volume of the placentas, 
the foetuses and the blood flow to the placentas were estimated by the algorithms of 
O’Flaherty et al. (1992). The volume of the foetuses included also the amniotic fluid volume 
of GD11 that was reported by Park and Shepard (1994) and Fisher (1993), because at this 
gestational day maternal-foetal exchange occurs via both the chorioallantoic placenta and 
the yolk sac placenta (Carney et al. 2004). All physiological parameters are presented in 
Table 1. 
Table 1 Physiological data for the rat applied in the PBK models of the phenols.
Parameter Percentage of body weighta Percentage of cardiac output
 Model compartments
   small intestine 1.4 7.5
   liver 3.4 17.5b
   adipose tissue 7.0 7.0
   arterial blood 1.85
   venous blood 5.55
   placentas 0.34
   body remaining 71.8 67.66
   Weight placentas (kg) 0.00079
   Weight foetuses and 0.00034
   amniotic fluid (kg)
(l/h/kg bw0.74)
Cardiac output 15
a Organ percentages of body weight without placenta and foetal compartment are reported because they were 
kept similar to non-pregnant rat values. The (weight of the) foetal-placental compartment is added separately. See 
text for more details.
b Without flow from small intestine.
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In silico predictions of physico-chemical and biochemical parameters
An overview of physico-chemical parameters that are used to predict biochemical and 
distribution parameters of the compounds are included in Table 2. Tissue plasma partition 
coefficients (Pt:p) were calculated using the algorithm of Berezhkovskiy (2004), which 
requires information on plasma protein binding, lipophilicity and acid-base properties (see 
Tables 2 and 3). The adipose tissue-plasma partition coefficients were calculated using the 
olive oil-water distribution coefficient (D*vo:wpH7.4) and the partition coefficients for the non-
adipose tissues were calculated with the n-octanol-water partition coefficient (Pow) for the 
non-ionised species at pH 7.4. The value of D*vo:wpH7.4 was calculated using log Po:w and pKa 
according to the algorithms reported by Poulin and Theil (2002). The unbound fraction of the 
compound in plasma was calculated with the Simcyp model (Simcyp 2015), after which these 
values were converted to the unbound fraction in tissue using the algorithm of Poulin and 
Theil (2002). The Pt:p values of the placental compartment were set equal to the predicted 
liver:plasma partition coefficient and the Pt:p of the embryonic/foetal unit was a volume 
weighted whole body:plasma partition coefficient, in which the adipose tissue was omitted 
because of the low amount of fat in foetal rat (Sarr et al. 2012). Partitioning of the compounds 
between red blood cells and plasma (Prbc:p) was predicted with the algorithms of Paixão et 
al. (2009), and was subsequently used to calculate the partition coefficient of the compounds 
between blood and plasma (Pb:p) using the following equation:
where HTC corresponds to a hematocrit fraction of 0.45.
Table 2 Physico-chemical properties of the phenols.
Parameter                phenol p-fluoro p-heptyloxy p-methylketo
MW (Da)a 94.11 112.10 208.30 136.15
Log Po:wa 1.54 1.84 4.41 1.40
pKaa 9.86 9.92 10.35 8.12
% ionised in serum (pH 7.4)b 0 0 0 16
 
a Values from ACD/Labs (2015).
b Calculated with Simcyp model (Simcyp 2015).
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Table 3 In silico predicted biochemical and distribution parameters of the phenols for the rat.
Parameter        phenol p-fluoro p-heptyloxy p-methylketo
Fu plasma (pH 7.4) (-)a 0.38 0.31 0.03 0.28
Partition coefficientsb
  liver:plasma 0.81 0.96 7.99 0.64
  intestine:plasma 0.97 1.20 11.57 0.74
  adipose:plasma 0.83 1.42 84.38 0.39
  placenta:plasmac 0.81 0.96 7.99 0.64
  foetus:foetal plasmad 0.76 0.89 6.92 0.61
  body remaining:plasma 0.75 0.87 6.67 0.61
  blood:plasmae 0.72 0.70 1.48 0.67
a Fraction unbound to plasma proteins (Fu). Calculated with Simcyp model (Simcyp 2015).
b Calculated with algorithms of Berezhkovskiy (2004).
c Assumed to be the same as the partition coefficient of the liver.
d Whole body:plasma partition coefficient without adipose tissue (volume weighted).
e Calculated with algorithms of Paixão et al. (2009).
In vitro intestinal transport study 
Caco-2 cells (passages 37-40) were cultured in DMEM containing 25 mM HEPES (pH 7.4) 
supplemented with 10% (v/v) heat-inactivated FCS, 4500 mg/l glucose, 2 mM L-glutamine, 
1% (v/v) minimal essential medium nonessential amino acids, 10,000 U/ml penicillin and 10 
mg/ml streptomycin and maintained in polystyrene cell culture flasks (Corning, Amsterdam 
The Netherlands) in a 5% CO2-humidified atmosphere at 37°C. Cells were harvested after 
exposure to a trypsin-EDTA solution. Next, the cells were seeded onto Transwell® inserts (0.4 
µm pored polycarbonate membrane, 12 mm diameter), at a density of 105 cells/cm2. Cell 
culture medium (0.5 ml and 1.5 ml in the apical and basolateral compartment, respectively), 
was changed every two days.
Compounds that were included in the transport experiments were phenol, p-fluorophenol, 
p-heptyloxyphenol, p-methylketophenol, antipyrine (passive transcellular control) and 
fluorescein (passive paracellular control) as well DMSO (solvent control). Stock solutions of 
the test compounds were prepared in DMSO, and tested at a final DMSO level in the transport 
buffer of 0.2%, except for p-heptyloxyphenol for which the final DMSO level was 0.5% due to 
the relatively lower solubility of this compound. 
Transport experiments were performed between day 20 and 23 post-seeding. Prior to the 
transport experiments, the cell culture medium was removed and cells were equilibrated in 
HBSS for 30-45 min in a 5% CO2-humidified atmosphere at 37°C. In these 45 min, the 
integrity of the cell monolayer was examined by measuring the Trans Epithelial Electrical 
Resistance (TEER) of the cell layer using a Millicell ERS-2 Volt-Ohm Meter (Millipore, USA). 
Only cell layers with a TEER value between 500-1000 Ω.cm2 were used for the transport 
experiments. The transport buffer for the apical compartment consisted of HBSS containing 
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10 mM HEPES (pH 6.5) and 10 mM sodium taurocholate and the transport buffer for the 
basolateral compartment consisted of HBSS (pH 7.4) with 30 mg/ml bovine serum albumin. 
At first, 1.5 ml pre-warmed (37°C) transport buffer was added to the basolateral compartment. 
Then, the transport experiments were started by adding 0.5 ml pre-warmed transport buffer 
containing the test compound (100 µM) to the apical compartment. After 60 min incubation 
in a 5% CO2-humidified atmosphere at 37°C, a 75 µl sample was taken from the basolateral 
compartment and then from the apical compartment. Each sample was added to 150 µl ice-
cold methanol, vortexed and put on ice immediately. The filters of the Transwell® inserts were 
washed one time with HBSS and two times with PBS, then cut out from the insert and added 
to 250 µl methanol 65% (v/v) and sonificated for 15 min by a Bandelin Sonorex RK100 
sonificator (Berlin, Germany). Samples were analysed by UPLC-PDA (see section Quantification 
of analytes) for the presence of the test compound and possible metabolites.
TEER values were also measured at the end of the transport experiment, during the first 
washing step and compared to the TEER values measured before the transport experiment in 
order to assess toxicity of the test compound to the cell monolayer. Caco-2 monolayers were 
omitted from further analysis when the TEER value was reduced more than 15% during the 
transport experiments (Wang et al. 2014). The Caco-2 transport studies encompassed four 
independently performed experiments including three replicates in each assay.
The apparent permeability coefficients (Papp) (cm/s) were calculated using the following 
algorithm:
where Papp is the apparent permeability coefficient (cm/s), ΔQ/Δt (nmol/s) is the amount of 
the test compound transported to the receiver chamber in a certain time period, A is the 
transwell membrane surface area (cm2) and C0 is the initial concentration of the test 
compound in the donor compartment (µM).
In order to assess the validity of the Papp calculations for this experiment, the linearity of 
transport from the apical to the basolateral side was verified by taking samples from the 
basolateral side at t=15, 30, 60 and 90 min, at a test concentration of 100 µM. The amount 
of sample (50 µl) withdrawn from the basolateral side was replaced by a similar amount of 
Caco-2 transport medium, which was accounted for in assessing the linearity. The recovery of 
the test compound in each transport experiment was calculated with a mass balance 
equation, taking into account the amount of the test compound in the apical and basolateral 
compartment and the amount in the cells and/or filter of the Transwell® insert.
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To extrapolate the in vitro derived apparent permeability coefficients (Papp) from the Caco-2 
transport experiments to in vivo oral absorption coefficients (ka), relative Papp ratios were 
calculated with phenol as the standard compound (Papp p-substituted phenol / Papp phenol), 
which were subsequently multiplied by the ka value for phenol of 7.62/h obtained from the 
rat in situ intestinal perfusion study of Humphrey et al. (1980).
In vitro placental transport study
BeWo cells (passages 28-31) were cultured in DMEM with 4500 mg/ml glucose and 
supplemented with 10% (v/v) heat-inactivated FCS, 2 mM L-glutamine, 10,000 U/ml penicillin 
and 10 mg/ml streptomycin and maintained in polystyrene cell culture flasks (Corning, 
Amsterdam The Netherlands) in a 5% CO2-humidified atmosphere at 37°C. Cells were 
harvested after exposure to a trypsin-EDTA solution. Next, the cells were seeded onto 
Transwell® inserts (0.4 µm pored polycarbonate membrane, 12 mm diameter), with a density 
of 105 cells/cm2. Cell culture medium (0.5 ml and 1.5 ml in the apical and basolateral 
compartment, respectively) was changed daily.
Transport experiments were performed 6 days post-seeding. The transport buffer 
consisted of HBSS with 30 mg/ml bovine serum albumin (apical compartment) and 10 mg/
ml bovine serum albumin (basolateral compartment) representing mid and late gestational 
maternal and embryonic/foetal rat plasma albumin levels, respectively (Honda et al. 2008; 
Mcmullin et al. 2008; Yeoh and Morgan 1974). The transport experiments were performed for 
the same compounds and according to the same method as described for the Caco-2 
transport experiments, except that only cell layers with a TEER value > 190 Ω.cm2 were used 
for the transport experiments. The BeWo transport studies encompassed four independently 
performed experiments including two replicates in each assay. Samples were analysed by 
UPLC-PDA (see section Quantification of analytes) for the presence of the test compound and 
possible metabolites. The apparent permeability coefficients were calculated using the same 
method as described for the Caco-2 transport experiments.
To extrapolate the in vitro derived apparent permeability coefficients (Papp) obtained from 
the BeWo transport experiments to in vivo transplacental clearance rates (CLPL), relative Papp 
ratios were calculated with antipyrine as the standard compound (Papp (p-substituted) phenol 
/ Papp antipyrine) which were subsequently multiplied by the transplacental maternal-foetal 
antipyrine clearance rate of 0.18 l/h. This antipyrine clearance rate was obtained by 
converting the reported antipyrine transplacental clearance value of 0.448 l/h/kg for the rat 
at GD20 (Varma and Ramakrishnan (1985) to a value for GD11 via allometric scaling to 
maternal body weight (O’Flaherty et al. 1992) using a maternal body weight for GD11 reported 
by Buelke-Sam et al. (1982).
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In vitro assays for glucuronidation of phenols by rat tissue 
The formation of glucuronide metabolites of the p-substituted phenols was investigated in 
incubations with rat liver microsomes. Incubation mixtures consisted of 50 mM Tris-HCl (pH 
7.4) and 10 mM MgCl2, containing (final concentrations) rat liver microsomes (0.2 mg protein/
ml) and 2 mM UDPGA. To obtain maximum glucuronidation activity, the microsomes were 
activated by preincubating the incubation mixture with 0.025 mg/ml alamethicin added from 
a 200 times concentrated stock solution in methanol, during 15 min on ice (Fisher et al. 
2000). Subsequently, the incubations were started after a 1-min preincubation at 37°C by 
addition of the substrate from a 200 times concentrated stock solution in DMSO and 
incubated in a shaking water bath at 37°C for 45 min. The reactions were terminated by 
addition of ice-cold acetonitrile (20% v/v). In the blank incubation mixtures, UDPGA was 
omitted. Samples were analysed by UPLC-PDA (see section Quantification of analytes). No 
reference standards of the glucuronide metabolites were commercially available. Hence, the 
metabolites were identified as follows. At first, retention times from the UPLC-PDA 
chromatograms of the parent compound of the blank incubation were compared with the 
retention times of newly appearing peaks in chromatograms of the incubation mixtures, as 
the glucuronide conjugates are expected to elute earlier compared with their parent 
compounds due do their increased hydrophilicity. Secondly, the formation of the suggested 
glucuronide conjugate was confirmed by enzymatic deglucuronidation with β-glucuronidase. 
To this purpose a volume of 10 µl of the incubation mixture of the glucuronidation assay (that 
was not terminated by the addition of ice-cold acetonitrile) was added to 90 µl of 200 mM 
potassium phosphate (pH 6.2). Then, 4 µl of glucuronidase (200 units/ml) was added and 
the mixtures were incubated for 60 min in a shaking water bath at 37°C. The reactions were 
terminated by addition of ice-cold acetonitrile (20% v/v) and were put on ice. Control samples 
were treated under the same conditions, but without glucuronidase.
After identifying the formation of the glucuronide conjugates for the p-substituted phenols, 
incubations with rat liver microsomes were performed to quantify kinetic parameters, which 
are the maximum enzyme reaction rate (Vmax) and the Michaelis-Menten constant (Km). The 
conditions of the incubation assays were optimised to obtain linear reaction rates with 
respect to incubation time and protein concentration and non-limiting cofactor levels were 
applied. The optimised incubation mixtures consisted of 50 mM Tris-HCl (pH 7.4) with 10 mM 
MgCl2, containing (final concentrations) 10 mM UDPGA and 0.1, 0.01 and 0.05 mg microsomal 
protein/ml for p-fluorophenol, p-heptyloxyphenol, and p-methylketophenol, respectively. To 
obtain maximum glucuronidation activity, the microsomes were activated by preincubating 
the incubation mixture with 0.025 mg/ml alamethicin added from a 200 times concentrated 
stock solution in methanol, during 15 min on ice (Fisher et al. 2000). Subsequently, the 
incubations were started after a 1-min preincubation at 37°C by addition of the substrate 
from a 200 times concentrated stock solution in DMSO and incubated in a shaking water 
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bath of 37°C for 10 min for p-fluorophenol and 2.5 min for p-heptyloxyphenol and 
p-methylketophenol, respectively. The incubation experiments encompassed three or four 
independently performed experiments for each phenol.
Kinetic constants for the glucuronidation of the p-substituted phenols were derived by 
fitting the data to the standard Michaelis-Menten equation;
in which [S] represents the substrate concentration, Vmax the maximum velocity and Km the 
Michaelis-Menten constant for the formation of the glucuronide metabolites. Data analysis 
was accomplished using GraphPad Prism 5.0 software (GraphPad, San Diego, CA, USA). For 
the PBK model, the in vitro derived Vmax values from rat liver microsomes were scaled to the 
in vivo situation using a reported microsomal protein yield of 38 mg/g rat liver (Chiu and 
Ginsberg 2011). The in vivo Km value was assumed to be the same to the in vitro Km value. 
Michaelis-Menten constants for phenol were taken from our previous study (Strikwold et al. 
2013). The present study assumed unrestricted metabolism despite the high plasma protein 
binding of p-heptyloxyphenol, because the rapid metabolic turnover is assumed to clear the 
chemical so avidly that protein binding may not be rate limiting.
QUANTIFICATION OF ANALYTES
Samples from the BeWo and Caco-2 transport experiments were centrifuged at 13,000 rpm 
at 5°C for 15 min. Next 7.5 µl of the supernatant of each sample was analysed by UPLC 
(Waters Acquity). Samples from the glucuronidation assays were centrifuged at 15,000 rpm 
at 5°C for 5 min. Subsequently, 3.5 µl of the supernatant of each sample was analysed by 
UPLC, except for the incubations with p-heptyloxyphenol of which 10 µl was analysed by 
UPLC. All samples, except those from transport studies with fluorescein, were analysed on a 
Waters BEH C18 1.7 µm column, 2.1 x 50 mm, with nanopure water (0.1% TFA) (A) and pure 
acetonitrile (B) applying a gradient elution. The start condition was 100:0 (A:B), changing to 
90:10 from 1 to 2 min, then to 10:90 from 2 to 4 min (or from 2 to 3 min when analysing 
samples for p-heptyloxyphenylglucuronide), remaining at this ratio for 0.5 min and then 
rapidly declining to the start condition. The flow rate was 0.6 ml/min. Peaks of the analytes 
were detected with a photodiode array detector (PDA, Waters). Analytes, except the 
glucuronide metabolites, were quantified with a linear calibration curve using peak areas 
obtained at the compounds’ maximum wavelength. The glucuronide metabolites were, due to 
the absence of commercially available reference compounds, quantified with the calibration 
curve and at maximum wavelengths of their parent compound. Differences in the UV 
absorbance between the parent and the glucuronide conjugate at the selected wavelength 
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were quantified by comparing the peak areas of the parent compound from three different 
concentrations of the calibration curve with the peak areas of corresponding concentrations 
of the glucuronide conjugate, which were obtained from a complete glucuronidation of the 
parent compound in a glucuronidation experiment of 2 h. A noticeable difference between 
the peak area of the parent compounds and the glucuronide (average of three tested 
concentrations) was only observed for p-fluorophenol (absorbance of conjugate was 2-fold 
lower compared to the parent) and this difference was used to correct the measured 
absorbance of the parent compound from each point of the calibration curve. Fluorescein 
was quantified with a fluorescence SpectraMax M3 microplate reader (Molecular Devices, 
USA) with excitation and emission at 495 and 538 nm, respectively.
SENSITIVITY ANALYSES OF THE PBK MODELS
For each PBK model a local sensitivity analysis was performed to determine influential 
parameters. To this purpose, each parameter was changed in turn keeping the other ones 
constant (Chiu et al. 2007). The normalised sensitivity coefficient (SC) was calculated using 
the algorithm:
where C is the initial outcome of the model, which in this case is the maximum foetal plasma 
concentration (Cmax). C’ is the output of the model after a 1% parameter change. P is the initial 
parameter value and P’ is the parameter value modified by an increase of 1%. The sensitivity 
analysis was conducted for an oral exposure to a single dose of 2 and 200 mg/kg bw.
TRANSLATION OF IN VITRO EFFECT CONCENTRATIONS IN THE EST TO IN VIVO 
EFFECT CONCENTRATIONS
In vitro concentration-response data obtained with the EST were translated to in vivo dose-
response values by applying PBK-based reverse modelling, performed as described by 
Strikwold et al. (2013) with some modifications. To correct for in vivo and in vitro differences 
in albumin and fat levels, each nominal in vitro effect concentration of p-heptyloxyphenol 
obtained from the EST from Strikwold et al. (2012) was translated to an in vivo effect 
concentration (ECx) according to the extrapolation rules of Gülden and Seibert (2003). In the 
extrapolation rule, a value of 0.99 was used for the fraction of p-heptyloxyphenol bound to 
albumin in the EST, which was obtained from a reported bound fraction of p-heptyloxyphenol 
in the culture medium of the whole embryo culture (WEC) assay (Fisher et al. 1993). In vivo 
albumin and fat levels that are used in the extrapolation rules were adjusted to values that 
correspond to embryos/foetuses during mid/late gestation. An in vivo lipid content of 0.11% 
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was applied based on foetal rat data (GD17) presented by Johansson (1983). An in vivo 
embryonic/foetal albumin level of 10 mg/ml was used representing albumin levels in mid 
and late gestation; GD10 (Yeoh and Morgan, 1974) and GD18 (Mcmullin et al. 2008). The 
vitro lipid fraction and albumin levels resembling the situation in the EST were 0.04% and 4.8 
mg/ml, respectively (Verwei et al. 2006). For the other phenols, no correction according the 
extrapolation rules of Gülden and Seibert (2003) was applied, since it was found that in vitro 
cytotoxicity of phenol tested with the fibroblast-like embryonic mouse cell line Balb/c 3T3 
clone A31 was not affected by differences in bovine serum albumin levels reflecting the in 
vitro and in vivo situation. It is assumed that this also applies for p-methylketophenol and 
p-fluorophenol as these compounds have a comparable log Po:w value as phenol, which is an 
important factor in albumin binding (Endo and Goss 2011).
Next, the maximum foetal plasma concentrations (Cmax) in the PBK model were set equal 
to the effect concentrations from the EST (which was corrected by the extrapolation rule of 
Gülden and Seibert (2003) in case of p-heptyloxyphenol). In addition, the foetal plasma AUC 
in the PBK model were set equal to the AUC0-10d from the EST. Applying in vitro PBK-based 
reverse dosimetry, provided in vivo effective dose levels (EDx) from which an in vivo dose-
response curve and a BMDL05 was derived using the Environmental Protection Agency’s (EPA) 
Benchmark Dose Software (BMDS) version 2.6. For each compound, the benchmark dose 
model selected was the one that provided the best fit determined as described by Strikwold 
et al. (2012).
EVALUATION OF THE DATA
The BMDL05 predicted with the in vitro PBK approach were compared to the BMDL05 (or NOAEL) 
derived from an in literature reported in vivo developmental toxicity study with rats that 
received phenol or p-substituted phenol at GD11 Kavlock (1990). The BMDL05 values of the in 
vivo study were derived using the BMDS version 2.6. For each compound, the benchmark 
dose model was selected that provided the best fit as described by Strikwold et al. (2012). In 
addition, potency ratios were calculated (potency phenol / potency p-substituted phenol) from 
potency data obtained with the in vitro PBK approach (BMDL05), and the in vivo developmental 
toxicity data (most critical in vivo endpoint) from Kavlock (1990) (BMDL05 or NOAEL).
RESULTS
IN VITRO EMBRYOTOXICITY
Phenol and the p-substituted phenols showed a concentration-response related inhibition of 
differentiation of ES-D3 cells into beating cardiomyocytes in the EST (Figure 2) identifying the 
embryotoxic potential of the different compounds (Strikwold et al. 2012). The highest difference 
Binnenwerk Proefschrift Marije Strikwold def.indd   91 05-04-16   16:32
92
Chapter 4
in embryotoxic potential in vitro was observed between phenol and p-heptyloxyphenol, with 
the BMC50 value being three orders of magnitude higher for phenol. The differences in BMC50 
values were much lower between phenol and the other p-substituted phenols, including 
p-fluorophenol and p-methylketophenol, namely 1.9-fold and 4.9-fold, respectively (Strikwold 
et al. 2012).
 
Figure 2 Concentration-response curves for phenol (grey line, □), p-fluorophenol (solid line, ᵡ), p-heptyloxyphenol 
(dashed line, ●) and p-methylketophenol (dotted line, ▼) representing the inhibition of differentiation of the 
embryoid bodies (EBs) by the compound. Data obtained from Strikwold et al. (2012).
IN SILICO PREDICTIONS OF BIOCHEMICAL AND DISTRIBUTION PBK MODEL
PARAMETERS
Physico-chemical parameters that are used for the prediction of PBK model parameters are 
outlined in Table 2 and the predicted biochemical and distribution model parameters are 
presented in Table 3. Notable differences between the compounds are the relatively high log 
Po:w value of 4.41 for p-heptyloxyphenol compared to log Po:w values < 1.84 for the other 
phenols. The tissue:plasma partition coefficients of p-heptyloxyphenol are substantially 
higher than those for the other phenols, especially the fat:plasma partition coefficient which 
is 84.4 for p-heptyloxyphenol and varies between 0.39-1.42 for the other phenols. The 
predicted fraction of phenols unbound to plasma albumin differs from 0.03 for 
p-heptyloxyphenol to 0.38 for phenol.
IN VITRO INTESTINAL TRANSPORT STUDY
Each phenol tested in the Caco-2 transport experiment showed a linear increase of the test 
concentration in the basal compartment for at least 60 min. The Papp values of the Caco-2 
experiments are presented in Table 4. Transport of each of the test compounds is rapid, and 
the Papp values differ at maximum only 1.3-fold between the test compounds, ranging from 
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51.9 10-6 cm/s for p-methylketophenol to 40.2 10-6 cm/s for p-heptyloxyphenol. The average 
mass recovery of antipyrine was 93.4%. The mass recovery of phenol, p-fluorophenol, 
p-heptyloxyphenol and p-methylketophenol was on average 80.2%, 78.2% 70.4% and 82.1%, 
respectively.
Table 4 Mean apparent permeability (Papp ± SD) obtained from Caco-2 and BeWo transport assays, predicted 
intestinal oral absorption coefficients (ka) and predicted rat transplacental clearance values (CLPL) for the test 
compounds.
Compound Papp_Caco-2
(10-6 cm/s)
kaa
(/h)
Papp_BeWo
(10-6 cm/s)
CLPLc
(l/h)
phenol 48.4 ± 8.6 7.62b 41.6 ± 3.4 0.19
p-fluorophenol 47.7 ± 13.8 7.52 34.2 ± 3.3 0.15
p-heptyloxyphenol 40.2 ± 3.9 6.34 5.9 ± 1.7 0.026
p-methylketophenol 51.9 ± 6.6 8.18 27.5 ± 1.7 0.12
antipyrine 42.7 ± 2.6 6.73 40.4 ± 3.2 0.18d
a Predicted oral absorption coefficient (see section Materials and methods).
b Uptake rate from in situ intestinal perfusion study in rat (Humphrey et al. 1980).
c Predicted rat transplacental clearance (see section Materials and methods).
d Transplacental clearance value obtained from in vivo rat study (Varma and Ramakrishnan 1985). (see section 
Materials and methods).
IN VITRO PLACENTAL TRANSPORT STUDY
Each phenol tested in the BeWo transport experiment showed a linear increase in 
concentration in the basal compartment for at least 60 min, after addition of the test 
compound to the apical side (final concentrations apical compartment 100 and 500 µM). The 
mass balances showed that > 90% of the mass of each compound was conserved in each 
transport experiment. The Papp values are presented in Table 4. Transport is rapid for each of 
the compounds, except for p-heptyloxyphenol which showed a Papp value of 5.9 10-6 cm/s, 
which is 6.8-fold lower than the Papp value of antipyrine. The Papp values for the other phenols 
were comparable to antipyrine, showing a 1.03-fold higher and 1.2- and 1.5-fold lower Papp 
value compared to the value of the reference compound antipyrine for phenol, p-fluorophenol 
and p-methylketophenol, respectively. The transport of the paracellular control fluorescein 
was on average 11-fold lower compared to the passive transcellular control antipyrine 
indicating the integrity of the monolayer. 
An interesting observation was that the Papp value for p-heptyloxyphenol obtained from the 
BeWo experiment was 6.8-fold lower than the Papp value from the Caco-2 experiment, while 
the Papp values for the other phenols were less than 2-fold lower in the BeWo assay and the 
Papp value from the BeWo experiment for antipyrine was only 1.1-fold lower than the Papp from 
the Caco-2 experiment. 
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IN VITRO GLUCURONIDATION OF P-SUBSTITUTED PHENOLS BY RAT LIVER
MICROSOMES
Results from the incubation experiments showed that rat liver microsomes were able to 
metabolise the p-substituted phenols to their glucuronide conjugates. Metabolism of the 
p-substituted phenols followed Michaelis-Menten kinetics (Figure 3). The apparent Km and 
Vmax values of the rat liver microsomes and the (scaled) catalytic efficiencies are presented in 
Table 5. The compound p-heptyloxyphenol was far more efficiently converted by liver 
microsomes than the other phenols. The scaled catalytic efficiency (l/h/g liver) for 
glucuronidation of p-heptyloxyphenol was 145-fold higher than that of phenol. The scaled 
catalytic efficiencies of p-fluorophenol and p-methylketophenol were respectively 1.7-fold and 
6.0-fold higher than that of phenol.
Table 5 Kinetic constants Km and Vmax ± SD, and catalytic efficiencies of the formation of the glucuronide 
metabolite of the phenols in rat liver microsomes.
Compound Km(app)a Vmax(app)b Catalytic 
efficiencyc
Scaled 
Vmax(app)d
Scaled catalytic 
efficiencye
phenol 465 ± 66 90 ± 4 0.19 205 0.44
p-fluorophenol 314 ± 16 101 ± 1.6 0.32 231 0.74
p-heptyloxyphenol 2.1 ± 0.6 60 ± 4.5 28.0 137 63.8
p-methylketophenol 138 ± 17 160 ± 4.4 1.16 365 2.65
a µM.
b nmol/min/mg microsomal protein.
c Vmax/Km (ml/min/mg protein in rat liver microsomes). 
d µmol/h/g liver.
e l/h/g liver.
a        b
   
Figure 3 Concentration-dependent formation of the glucuronide conjugate of phenol (♦), p-fluorophenol (▼), 
p-methylketophenol (■) (panel a) and p-heptyloxyphenol (●) (panel b) in incubations with rat liver microsomes. 
Individual symbols represent mean activities of 3-4 independently performed experiments ± SD.
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SENSITIVITY ANALYSIS
The results of the sensitivity analysis performed at a high oral dose of 200 mg/kg bw (Figure 
4) indicated that the most influential parameters for the phenol models are the volume of the 
liver, parameters related to glucuronidation in the liver (Vmax, Km and liver microsomal protein 
yield), the oral absorption coefficient, and the partition blood/plasma coefficient. The parameter 
Km was of higher influence in the models of p-methylketophenol and p-heptyloxyphenol than 
in the other phenol models. In the model for p-heptyloxyphenol, parameters related to the 
intestine (volume intestine, flow to intestine and partition coefficient intestinal tissue:plasma) 
are more influential than in the models of the other phenols. Parameters related to the 
foetal/placental compartment do not highly influence the model outcome.
In general, the model outcomes are sensitive to similar parameters at a low oral dose of 2 
mg/kg bw when compared to the analysis at 200 mg/kg bw. Parameters related to the 
intestine in the model for p-heptyloxyphenol are not of influence at a low dose of 2 mg/kg bw. 
Moreover, the values of sensitivity coefficients of the phenols for ka, derived at a low dose of 
2 mg/kg bw, are lower than the sensitivity coefficients derived at 200 mg/kg bw. The 
sensitivity coefficients for the microsomal protein content and the Vmax for glucuronidation in 
the liver for p-fluorophenol, p-heptyloxyphenol and p-methylketophenol are lower than the 
sensitivity coefficients for these parameters derived at 200 mg/kg bw, while the sensitivity 
coefficients for phenol and p-fluorophenol for Km are higher when compared to the sensitivity 
coefficients derived at 200 mg/kg bw.
a       b
 
Figure 4 Normalised sensitivity coefficients for parameters of the PBK model for phenol (white bars), p-fluorophenol 
(dark grey bars), p-heptyloxyphenol (black bars) and p-methylketophenol (light grey bars) based on foetal Cmax 
values from a single oral dose of 2.0 mg/kg bw (a) and 200 mg/kg bw (b). Normalised sensitivity coefficients ≥ 0.2 
are presented. VIc= fraction intestinal tissue, VLc=fraction liver tissue, VPL=volume placental tissue, QIc=fraction 
intestinal flow, QPLc= fractional placental flow, PI:P= partition coefficient intestine:plasma, PPL:P partition 
coefficient placenta:plasma, PFE:P=partition coefficient foetus:foetal plasma, PB:P=partition coefficient body 
remaining:plasma, PBL:P=partition coefficient blood:plasma, ka=oral absorption coefficient, MPL=liver microsomal 
protein yield, VmaxLPGc=unscaled maximum rate of glucuronidation of phenols in liver, KmLPG=Michaelis-Menten 
constant for glucuronidation of phenols in liver.
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TRANSLATION OF IN VITRO-EFFECT CONCENTRATIONS IN THE EST TO IN VIVO 
DOSE LEVELS
In a first step the in vitro concentrations of p-heptyloxyphenol were converted to equivalent 
plasma concentrations using extrapolation rules of Gülden and Seibert (2003). Only a very 
small difference was observed between the in vitro effect concentrations from the EST and 
the estimated equivalent plasma concentrations, with the latter being 2.1-fold higher than 
the in vitro effect concentrations. In a second step, the in vivo effect concentrations were 
translated to external in vivo oral dose values using the PBK models thus defining a dose-
response curve from which a PoD could be derived. The predicted dose-response curves 
based on Cmax or the AUC0-10d are presented in Figure 5. The BMDL05 values for the phenols 
predicted by the in vitro PBK approach using Cmax and the AUC0-10d from the EST as a dose 
metric for reverse dosimetry are outlined in Table 6, together with the BMDL05 values that 
were predicted from in vivo developmental toxicity data reported in literature. The in vivo 
experimental data and the PBK model based predictions were representative for exposure at 
GD11 since in the in vivo experimental study exposure was at GD11 and for the predictions 
the PBK model was defined using physiological parameters representative for GD11. 
Comparing the BMDL05 values that were predicted with the in vitro PBK approach with the 
BMDL05 values derived from in vivo data, indicates that the BMDL05 that is based on Cmax as 
a dose metric represents the in vivo BMDL05 better than the BMDL05 based on the AUC0-10d for 
phenol and p-fluorophenol, while for p-methylketophenol both the BMDL05 based on Cmax and 
AUC0-10d seem to represent the in vivo BMDL05 well. The difference between the BMDL05 
values predicted with the in vitro PBK approach based on Cmax of the EST as a dose metric and 
the BMDL05 values obtained with in vivo developmental toxicity data vary less than 3.8-fold 
for these three phenols. For p-heptyloxyphenol, however, the BMDL05 value based on AUC0-10d 
of the EST as a dose metric represents the in vivo BMDL05 somewhat better (1.9-fold 
difference) than the predicted BMDL05 based on Cmax (4.3-fold difference).
a     b
Figure 5 In vivo dose-response curves for developmental toxicity of phenol (solid black line), p-fluorophenol (solid 
grey line), p-heptyloxyphenol (dashed line) and p-methylketophenol (dotted line) in rat predicted by in vitro PBK-
based reverse dosimetry. Panel a represents the predicted dose-response curves based on the nominal test 
concentration of the phenols relating Cmax to developmental toxicity. Panel b represents the predicted dose-
response curves relating the AUC0–10d of the phenols to developmental toxicity.
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Table 6 BMDL05 values (mg/kg bw) for developmental toxicity of the phenols predicted with the in vitro PBK 
approach and BMDL05 values derived from in vivo developmental toxicity data reported in the literature.
in vitro PBK approach in vivo
Compound BMDL05_Cmax BMDL05_AUC BMDL05
(or NOAEL)a
phenol 88 1536 333
p-fluoro 129 1892 183
p-heptyloxy 113 257 484
p-methylketo 186 2170 632
a Derived from in vivo developmental toxicity data (most critical endpoint) from Kavlock (1990).
The potency ratios between phenol and p-fluorophenol, p-heptyloxyphenol and p-methyl-
ketophenol calculated based on the BMDL05 values obtained with the in vitro PBK approach 
are graphically presented in Figure 6, together with the potency ratios obtained from the in 
vivo developmental toxicity study of Kavlock (1990) and the EST. The difference between the 
most and the least potent test compound in the EST, p-heptyloxyphenol and phenol, was 
three orders of magnitude (Strikwold et al. 2012), which does not reflect the potency ratio 
obtained from the in vivo developmental toxicity study which shows a small potency difference 
between the phenols (maximum 0.5-fold for the potency ratio based on the in vivo BMDL05 or 
NOAEL). From Figure 6 it can be seen that the large difference in the toxic potency that was 
observed in the EST for p-heptyloxyphenol compared to phenol was greatly diminished, 
namely from 1553-fold in the EST to 0.8-fold in the in vitro PBK approach when based on the 
Cmax. The potency ratio between phenol and p-fluorophenol and p-methylketophenol was 
changed from 1.9 to 0.7-fold and from 4.9 to 0.5-fold, respectively.
 
Figure 6 Potency of p-substituted phenols relative to phenol expressed as a potency ratio (potency ratio = potency 
phenol/potency p-substituted phenol), specified for the in vitro PBK approach (BMDL05) using Cmax as dose metric, 
the in vivo data (most critical endpoint) from Kavlock (1990) (BMDL05 or NOAEL) and the EST (BMC50).
.
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DISCUSSION AND CONCLUSION
Translation of in vitro toxicity data to in vivo toxicity values is highly relevant in order to use in 
vitro data in the regulatory risk assessment of chemicals. In previous studies it was 
demonstrated that PBK-based reverse dosimetry converting in vitro concentration-response 
values to in vivo dose-response data could successfully be applied to predict a PoD for phenol 
(Strikwold et al. 2013), for all-trans-retinoic-acid (Louisse et al. 2014) and for some glycol-
ethers (Louisse et al. 2010). The aim of the present study was to investigate whether PBK-
based reverse dosimetry could be used to translate in vitro embryotoxicity data obtained with 
the EST for a series of phenols (Strikwold et al. 2012), to in vivo developmental toxic potency 
values for the rat, using only in silico and in vitro derived (kinetic) parameters and data from 
the literature, and if this approach could overcome differences in in vitro and in vivo relative 
potencies of different phenolic congeners observed by Strikwold et al. (2012). The PoDs 
predicted with the in vitro PBK approach differed only 3.8-fold from the PoDs derived from in 
vivo data from literature, when Cmax of the EST was considered to be the most appropriate 
dose metric for in vitro PBK-based reverse dosimetry for phenol and p-fluorophenol and the 
AUC0-10d for p-heptyloxyphenol, while both Cmax and AUC0-10d were appropriate metrics for 
p-methylketophenol. The large difference between the in vitro derived relative potency and 
the in vivo derived relative potency of p-heptyloxyphenol was reduced from 3 orders of 
magnitude for the EST data as such (Strikwold et al. 2012) to less than 2-fold after applying 
PBK-based reverse dosimetry to these EST data.
Results from our in silico and in vitro derived (kinetic) parameters, together with PBK 
modelling provide insight into the possible factors underlying the relative low toxic potency for 
p-heptyloxyphenol in vivo (Kavlock 1990) compared to the relatively high observed 
embryotoxic potency in vitro in the EST (Strikwold et al. 2012). This discrepancy may be due 
to three major factors that play a role in vivo but not in the EST in vitro model, including 1) the 
relatively rapid metabolism of p-heptyloxyphenol by glucuronidation, 2) the relatively low 
placental transport of p-heptyloxyphenol compared to the other phenols, and 3) the relatively 
high tissue:plasma partition coefficients of p-heptyloxyphenol. Of these three aspects, the 
rapid glucuronidation of the toxic parent compound p-heptyloxyphenol has the largest 
contribution to the improved relative potency prediction for this compound. The contribution 
of metabolism in diminishing the toxicity of p-heptyloxyphenol was also observed in the WEC 
assay where the embryotoxic potency of p-heptyloxyphenol was greatly reduced when 
hepatocytes were added to the WEC assay (Oglesby et al. 1992).
The affinity constant Km for glucuronidation of the phenols in the liver was found to be an 
influential kinetic parameter in the sensitivity analysis. The Km of p-heptyloxyphenol was 
much lower than the Km of the other tested phenols, resulting in a very rapid glucuronidation 
and elimination of the toxic parent compound. The high lipophilicity of p-heptyloxyphenol may 
explain the high affinity for the enzyme. 
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Transport across the placenta was determined with the BeWo cell line, and provided high Papp 
values for each of the test compound, except for p-heptyloxyphenol for which the Papp value 
was 7.1-fold lower compared with phenol. The high Papp values are in line with in vivo studies 
in rats reporting that simple phenolic compounds may readily pass the placenta (Abu-Qare et 
al. 2000; Gray and Kavlock 1990). In general, cellular permeability increases with increasing 
lipophilicity, until a certain threshold (Li et al. 2013; Waterhouse 2003; Wils et al. 1994). It 
has been demonstrated in vitro with intestinal cells that transport may decrease for 
compounds with an octanol:buffer distribution coefficient > 3000 (Wils et al. 1994), which 
corresponds to our observations for p-heptyloxyphenol (logP:ow = 25704 (ACD/Labs 2015) in 
the Caco-2 and the BeWo assays. Interestingly, the Papp value of p-heptyloxyphenol in the 
BeWo transport experiment was 7.1-fold lower than the Papp value of phenol while this was 
only 1.2-fold in the Caco-2 assay. The observed difference may be due to binding of 
p-heptyloxyphenol to albumin that is present in the apical medium of the BeWo assay but not 
in the apical medium of Caco-2 assay. These albumin levels were selected to reflect 
physiological conditions. The predicted Papp value in the BeWo assay for p-heptyloxyphenol 
may be somewhat lower than the in vivo value, as Li et al. (2013) observed that the relative 
Papp value of the highly albumin bound compound ketoprofen was 3.4-fold lower in the BeWo 
system with albumin, compared to the relative Papp determined with the ex vivo perfusion 
system that also included albumin. This difference possibly originates from differences in the 
fluid dynamics of both systems, which was static in the BeWo assay and is dynamic in the ex 
vivo perfusion system (Li et al. 2013).
Incorporating permeability data obtained from the BeWo transport system to semi-
quantitatively predict placental transfer in the PBK models in the present study, presents an 
approach that has not been applied in PBK modelling before. The BeWo transport system 
was evaluated to be a valuable in vitro model to predict transport of compounds across the 
placenta (Li et al. 2013). Nonetheless, this approach may be explored further, investigating 
the applicability domain of the BeWo assay with respect to different chemical classes, i.e. 
lipophilic compounds, as well as the time of pregnancy to augment its utility.
The present study predicted the embryotoxic potency of the phenols with physiological 
parameters in the PBK model selected for GD11 because for this time point in vivo 
developmental toxicity data for evaluation of the predictions were available. The EST was 
used to represent a sensitive in vitro endpoint for developmental toxicity (Genschow et al. 
2004), which ideally may represent the sensitivity of the embryo at the critical window for 
toxicity of the p-substituted phenols. Parameterisation of the PBK model for other gestational 
days is possible. Calculations with parameters adjusted to GD20 (data not shown) indicate 
little differences with GD11, providing a 1.04 to 1.8-fold higher BMDL05 value for predictions 
made with the PBK parameters for GD20 than for GD11 for the different phenols. Based on 
these results, the predictions for GD11 may be regarded to represent a sensitive period.
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In conclusion, PBK models were developed for a series of phenols, using in vitro, in silico data 
and data obtained from the literature only. Applying the in vitro PBK-based reverse dosimetry 
approach to overcome kinetic differences between the in vitro toxicity test system and the in 
vivo situation resulted in an improved prediction of the in vivo developmental toxic potency 
for this series of phenols. This approach has even overcome the large disparities that were 
observed between the in vitro and the in vivo relative potencies of p-heptyloxyphenol. 
Herewith, we provide another proof-of-principle that integrating in vitro toxicity data and PBK-
based reverse dosimetry may be a promising approach for prospective toxicological safety 
evaluations of compounds, without performing animal testing.
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SUPPLEMENTARY DATA A
MASS BALANCE ALGORITHMS AND PARAMETER SPECIFICATIONS OF THE PBK 
MODEL FOR PHENOL AND P-SUBSTITUTED PHENOLS IN THE RAT
The algorithms are similar for phenol, p-fluorophenol, p-heptyloxyphenol and p-methylketo-
phenol. An example for the compound phenol below is presented.
COMPOUND   ABBREVIATION
phenol    ph
phenylglucuronide   pg
COMPARTMENT (TISSUE (T)) ABBREVIATION
Small intestine   I
Liver    L
Fat    F
Placenta    PL
Foetus    FE
Remaing body   B
Arterial    A
Venous    V
Blood    BL
VARIABLE UNIT ABBREVIATION
Blood flow rate to tissue l h-1 Q(T)
Cardiac output l h-1 QC
Concentration phenol in tissue or blood μM C(T)ph
Partition coefficient tissue:plasma phenol - P(T)ph
Volume of tissue or blood l V(T)
Amount phenol in tissue or blood μmol A(T)ph
Maximum rate of formation metabolite (m) in tissue μmol h-1 Vmax(T)m
Michaelis-Menten constant for formation metabolite (m)  μM Km(T)m
in tissue  
Uptake rate phenol intestine h-1 ka
Amount phenol taken up from the gut lumen μmol Uptakeph
Amount phenol remaining in the gut lumen μmol AGLph
Clearance placenta l h-1 CLPL
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SMALL INTESTINE
Uptake phenol from gut lumen
LIVER COMPARTMENT
FAT COMPARTMENT
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PLACENTAL/FOETAL COMPARTMENT
Phenol in placental compartment
Phenol in foetal compartment
REMAINING BODY TISSUE
ARTERIAL BLOOD COMPARTMENT
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VENOUS BLOOD COMPARTMENT
Note: the maternal circulation is via blood, but exchange between mother and foetus is 
modelled to occur via plasma because that represents the BeWo system better. For the 
reverse dosimetry, the foetal plasma was set equal to the concentration in the EST.
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Development of a combined in 
vitro physiologically based kinetic 
(PBK) and Monte Carlo modelling 
approach to predict interindividual 
human variation in phenol induced 
developmental toxicity
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ABSTRACT
With our recently developed in vitro physiologically based kinetic (PBK) modelling approach 
we could extrapolate in vitro toxicity data to in vivo toxicity values applying PBK-based reverse 
dosimetry. This approach allows to make toxicity predictions directly for humans by taking 
human kinetic information into account. Ideally information on kinetic differences among 
human individuals within a population should also be considered. In the present study we 
demonstrated a modelling approach that integrated in vitro toxicity data, PBK modelling and 
Monte Carlo simulations to obtain insight in interindividual human kinetic variation and 
derive chemical specific adjustment factors (CSAFs) for phenol induced developmental 
toxicity as the endpoint of interest. The present study revealed that UGT1A6 is the primary 
enzyme responsible for the glucuronidation of phenol in humans followed by UGT1A9. Monte 
Carlo simulations were performed taking into account interindividual variation in 
glucuronidation by these specific UGTs and in the oral absorption coefficient which was 
shown to be another parameter with high influence on the phenol plasma concentrations 
predicted by the PBK model. Linking Monte Carlo simulations with PBK modelling, population 
variability in the maximum plasma concentration of phenol for the female human population 
could be predicted. This approach provided a CSAF for interindividual variation of 2.0 which 
covers the 99th percentile of the population. Based on this outcome, it was concluded that 
the default safety factor of 3.16 applied for interindividual human kinetic differences in the 
safety assessment of chemicals seems adequately protective. Dividing the dose-response 
curve data obtained with in vitro PBK-based reverse dosimetry, with the CSAF obtained for 
the 99th percentile provided a dose-response curve that reflects the consequences of the 
interindividual variability in phenol kinetics for the developmental toxicity of phenol. The 
strength of the presented approach is that it provides insight in the effect of interindividual 
variation in kinetics for phenol induced developmental toxicity, based on only in vitro and in 
silico testing.
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INTRODUCTION
The development of alternatives to animal testing is a subject of increasing importance. 
Especially a number of recent regulatory decisions within the EU have made the development 
of non-animal based approaches in chemical risk assessment more important (EC 2007; EC 
2009). In addition, alternatives to animal testing are also crucial for economic and ethical 
reasons and to meet the criticism about the human relevance of animal based safety tests. 
To enhance the development of non-animal approaches in risk assessment, we have recently 
developed an in vitro physiologically based kinetic (PBK) reverse dosimetry approach, which 
allowed prediction of in vivo developmental toxicity values for phenol and a series of p-substi-
tuted phenols from in vitro concentration-response curves obtained with the embryonic stem 
cell test (EST) (Strikwold et al. 2013; Strikwold et al. 2016). Within this approach in vitro 
toxicity data obtained with the EST were extrapolated to in vivo dose-response curves for 
developmental toxicity using in vitro PBK-based reverse dosimetry (Louisse et al. 2010; 
Louisse et al. 2014; Strikwold et al. 2013; Strikwold et al. 2016). The predicted points of 
departure (PoDs), that can be used as a starting point in the hazard and risk assessment of 
chemicals, differed less than 4-fold from the in vivo determined values (Strikwold et al. 2013; 
Strikwold et al. 2016). Similar promising results were obtained when applying this approach for 
a series of glycol ethers and for all-trans-retinoic-acid (Louisse et al. 2010; Louisse et al. 2014).
A major advantage of this in vitro PBK-based reverse dosimetry approach is that it provides 
the opportunity to make predictions directly for humans by taking PBK model parameters 
defined for humans into account. This implies that the in vitro PBK-based reverse dosimetry 
approach is not only relevant to reduce animal experiments but also to make the risk 
assessment more relevant to the human situation. Such human predictions are an important 
goal within the framework for toxicity testing in the 21th century as envisioned by the National 
Research Council (2007). 
Within our recent work, we made predictions on developmental toxicity of phenol for an 
average human female, applying the in vitro PBK-based reverse dosimetry approach for 
phenol (Strikwold et al. 2013). However, this model did not take into account interindividual 
human variation in sensitivity towards the toxic effects, which may occur as a result of 
differences in kinetic processes between individuals. Although a default safety factor of 3.16 
for interindividual human differences is often applied to account for such human variation in 
kinetics (IPCS 2005), having more detailed insights in possible interindividual variation might 
provide risk assessors with a reliable basis to derive human guidance values and assist in 
defining chemical specific adjustment factors (CSAFs). The aim of the present study was to 
demonstrate an approach that integrates in vitro toxicity data, PBK modelling and Monte 
Carlo simulations to assess the effects of human interindividual variation in kinetics for 
phenol induced developmental toxicity.
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Phenol is a high production volume chemical that is mainly metabolised by glucuronidation 
and sulfation. Results from a previously published PBK model for phenol indicated that the 
glucuronidation pathway is an important determinant for blood phenol concentrations 
(Strikwold et al. 2013). UGT1A6 and UGT1A9 are likely to be involved in the glucuronidation 
of phenol because many p-substituted phenols are a substrate for these UGT forms (Ethell et 
al. 2002). Moreover, at least SULT1A1 and SULT1A3 are involved in the sulfation of phenol 
(Dajani et al. 1999). Genetic differences and lifestyle factors may influence the expression 
and activity of these enzymes, and hence may significantly influence the metabolism of 
phenol and the sensitivity towards phenol induced developmental toxicity. The sensitivity 
analysis of the PBK model of phenol (Strikwold et al. 2013) revealed that the oral absorption 
coefficient (ka) and glucuronidation of phenol in the liver were parameters that influenced the 
maximum predicted phenol plasma concentration (Cmax) to a major extent and were therefore 
included in the evaluation of interindividual variation in the present study.
To enable prediction of the effect of interindividual human kinetic variation in sensitivity to 
phenol induced developmental toxicity, information on the metabolic variation in phenol 
glucuronidation was generated with in vitro kinetic experiments using two approaches. At 
first, phenol glucuronidation was quantified using subcellular liver fractions of ten female 
individuals, which is often used as a first step when information about interindividual variation 
is lacking. The kinetic constants obtained for each female were used to define ten subject 
specific PBK models based on our previously developed PBK model for phenol (Strikwold et 
al. 2013), from which differences in plasma phenol levels of the ten individuals were 
calculated. Secondly, a Monte Carlo simulation was performed to predict interindividual 
variation in phenol plasma levels. To this end the variation in phenol glucuronidation was 
modelled based on data from in vitro kinetic experiments using UGT isoforms and human 
variation in expression of these UGT enzymes described in literature. Variation in phenol 
plasma concentrations obtained with both approaches was compared to each other. So far in 
both approaches, only variation in phenol glucuronidation was taken into account, next to the 
use of average values for the other model parameters. In a next step interindividual variation 
for the oral absorption coefficient, which according to the sensitivity analysis (Strikwold et al. 
2013) also highly influenced the model outcome, was included in the Monte Carlo simulations 
as well. Based on the results obtained from the latter Monte Carlo simulation a CSAF (IPCS 
2005) was derived that accounts for interindividual differences in phenol kinetics within the 
human population. Possible consequences of the results obtained for risk assessment are 
discussed.
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MATERIALS AND METHODS
COMPOUNDS AND BIOLOGICAL MATERIALS
Phenol (99%), phenyl-β-D-glucuronide (≥ 99%), propofol (≥ 98%), propofol-β-D-glucuronide 
sodium salt (99.4%), serotonin (≥ 98%), Tris(hydroxymethyl)aminomethane (Tris) (≥ 99.9%), 
uridine 5’-diphosphoglucuronic acid (UDPGA) and alamethicin (98%) were obtained from 
Sigma Aldrich (Steinheim, Germany). Serotonin-β-D-glucuronide (97%) was obtained from 
Biozol (Eching, Germany). Acetonitrile (UPLC/MS grade) was obtained from BioSolve 
(Valkenswaard, The Netherlands), dimethylsulfoxide (DMSO) (≥ 99%) from Acros Organics 
(Geel, Belgium). Trifluoroacetic acid (TFA), hydrochloride acid (37%) and magnesium chloride 
hexahydrate were purchased from VWR International GmbH (Darmstadt, Germany).
SupersomesTM (baculovirus insect microsomal preparations) with individually expressed 
human UGT 1A1, 1A9 and 2B7 enzymes were purchased from BD Biosciences (Belgium). 
SupersomesTM (baculovirus insect microsomal preparations) with individually expressed 
human UGT 1A3, 1A4, 1A6, 1A7, 1A8, 1A10, 2B4, 2B10, 2B15, 2B17 enzymes and pooled 
female human liver microsomes (21 donors) were purchased from Corning (Woburn MA, 
USA). Ten individual female human liver S9 homogenates were obtained from XenoTech 
(Lenexa, KS, USA).
GLUCURONIDATION OF PHENOL BY POOLED FEMALE HUMAN LIVER MICROSOMES 
AND INDIVIDUAL FEMALE HUMAN LIVER S9
Incubations were performed to determine the kinetic constants, namely the maximum enzyme 
reaction rate (Vmax) and the Michaelis-Menten constant (Km) for phenol glucuronidation with 
female human liver fractions. The incubation mixtures consisted of 50 mM Tris-HCl buffer (pH 
7.4) with 10 mM MgCl2, containing (final concentrations) 10 mM UDPGA, 0.5 mg microsomal 
protein/ml for assays with pooled female human liver microsomes or 0.5 mg S9 protein/ml 
for assays with ten individual female human liver S9 homogenates. To overcome enzyme 
latency the incubation mixtures were pre-treated for 15 min on ice, with the poreforming 
peptide alamethicin (0.025 mg/ml) added from a 200 times concentrated stock solution in 
methanol. Then, incubations were started after a 1-min pre-incubation at 37 °C by the addi-
tion of the substrate phenol (final concentrations ranging from 200 to 4000 µM added from 
a 200 times concentrated stock solution in DMSO) and left in a shaking water bath of 37 °C 
for 10 min for the assays with pooled female human liver microsomes and with individual 
female human liver S9. The reactions were terminated with the addition of ice-cold acetonitrile 
(20% v/v) and subsequently put on ice. In the blank incubation mixtures, UDPGA was omitted. 
The ten human individual liver fractions were assumed to represent the female fertile popu-
lation. To enable the collection of ten female samples, also females aged 57 and 66 year 
were included, knowing that older age does not affect glucuronidation activity (Court 2010).
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GLUCURONIDATION OF PHENOL BY RECOMBINANT UGT ENZYMES
SupersomesTM with individually expressed UGT enzymes 1A1, 1A3, 1A4, 1A6, 1A7, 1A8, 1A9, 
1A10, 2B4, 2B7, 2B10, 2B15, 2B17 were screened on the ability to glucuronidate phenol. 
Incubations were performed in 50 mM Tris-HCl buffer (pH 7.4 including 10 mM MgCl2), 
containing (final concentrations) 0.5 mg protein/ml and 10 mM UDPGA. To overcome enzyme 
latency the incubation mixture was pre-treated for 15 min on ice, with the poreforming 
peptide alamethicin (0.025 mg/ml) added from a 200 times concentrated stock solution in 
methanol. Then, incubations were started after a 1-min pre-incubation at 37 °C by the 
addition of phenol (final concentration 1000 µM added from a 200 times concentrated stock 
solution in DMSO) and left in a shaking water bath of 37 °C for 45 min. The reactions were 
terminated with the addition of ice-cold acetonitrile (20% v/v) and subsequently put on ice. 
In the blank incubation mixtures UDPGA was omitted.
Kinetic constants Vmax, Km, the inhibition constant Ki or k, the latter representing the first-
order kinetic rate constant in the absence of saturation (for details see section Enzyme 
kinetic parameters) were determined for those UGT enzymes that showed a sufficient turn-
over in the screening study, including UGT1A6, UGT1A7, UGT1A8, UGT1A9 UGT2B7. The final 
phenol concentrations ranged from 200 to 8000 µM depending on the UGT enzyme studied 
and were added to the incubation mixture from 200 times concentrated stock solutions in 
DMSO. Other incubation conditions were similar as used for the screening assay, except that 
the incubation period was 30 min. Based on the kinetic curves and the kinetic constants 
obtained together with the scaled catalytic efficiency (Vmax/Km), the contribution of the 
different UGTs to phenol glucuronidation in vivo was further evaluated and UGTs that were 
expected to contribute the most to phenol glucuronidation at relevant plasma concentrations 
of phenol were included in the Monte Carlo evaluation. 
RELATIVE ACTIVITY FACTOR (RAF)
With the RAF approach (Crespi 1995) the glucuronidation activity of UGT enzymes can be 
scaled to female human liver microsomes enabling extrapolation of the in vitro determined 
activity to in vivo values. The Vmax values obtained from the in vitro incubations with 
recombinant enzymes (nmol/min/mg protein) were scaled to the in vivo situation (µmol/h/g 
organ) using this RAF approach (Crespi 1995), according to the following equation:
in which MPL represents the microsomal protein yield of 32 mg/(g liver) (Barter et al. 2007). 
RAFUGT corresponds to the ratio between the conversion of an enzyme specific probe substrate 
by the recombinant enzyme (SupersomesTM) and by pooled female human liver microsomes 
(HLM). The RAF is determined according to the following equation:
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in which, v represents the metabolic turnover of an enzyme specific probe substrate. The 
probe used to determine the RAF for UGT1A6 was serotonin (Krishnaswamy et al. 2003) and 
the probe for UGT1A9 was propofol (Court 2005). To determine the RAF values for UGT1A6 
and UGT1A9, incubations were performed as described for phenol glucuronidation using 
HLM or the SupersomesTM (both pre-treated with alamethicin to reduce enzyme latency), 
using a concentration of 0.1 mg protein/ml for HLM and 0.1 mg protein/ml SupersomesTM for 
serotonin with an incubation time of 30 min, and a concentration of 0.1 mg protein/ml for 
HLM and 0.1 mg protein/ml for SupersomesTM for propofol with an incubation time of 15 min. 
The applied final probe concentrations in the incubations were 4000 µM for serotonin and 25 
µM for propofol, taking into account recommendations about appropriate probe concentrations 
reported by Court (2005). In the blank incubation mixtures, UDPGA was omitted.
The performance of the RAF approach was evaluated by comparing the sum of scaled 
catalytic efficiencies (Vmax/Km) of the individual isoenzymes UGT1A6 and UGT1A9 to the 
scaled catalytic efficiency that was determined with kinetic constants obtained from pooled 
female human liver microsomes.
QUANTIFICATION OF COMPOUNDS AND GLUCURONIDE CONJUGATES
Samples of the incubation experiments with phenol, propofol and serotonin as substrate 
were centrifuged at 14,000 rpm for 5 min. Subsequently 3.5 µl were analysed by UPLC-PDA 
(Waters Acquity) according the method for phenol and phenylglucuronide described previously 
by Strikwold et al. (2013). Phenylglucuronide was quantified by its peak area using a linear 
calibration curve (R2 > 0.999) made using a commercially available reference compound. 
Chromatogram peaks of propofol glucuronide and serotonin glucuronide from samples of the 
incubation experiments were identified using commercially available reference standards. 
The RAFs were calculated based on the peak areas of the glucuronides that were formed 
after incubating the probes.
ENZYME KINETIC PARAMETERS
Kinetic parameters describing enzymatic conversions were defined based on the in vitro 
metabolism data obtained in the present study using GraphPad (GraphPad Prism 5.0 
software, San Diego, CA, USA). The best model fit was selected from the Michaelis-Menten 
model, substrate inhibition model, and linear curve fitting based on visual inspection of the 
curves. Subsequently, the relevant enzyme kinetic parameters (Vmax for the maximum enzyme 
reaction rate, Michaelis-Menten constant Km, inhibition constant Ki or k representing the first-
order kinetic rate constant) were estimated. In vitro derived Vmax(app) values were scaled to the 
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in vivo situation using a protein yield of 32 mg/g liver (Barter et al. 2007) for in vitro studies 
with microsomes and SupersomesTM and 143 mg/S9 (Medinsky et al. 1994) for in vitro 
studies with S9. In vivo Km values were assumed to be the same as Km values obtained from 
the in vitro experiments. The catalytic efficiencies of the enzyme were defined by Vmax/Km.
PBK MODELS, MONTE CARLO SIMULATIONS AND SENSITIVITY ANALYSIS
Our previously developed PBK model for phenol in humans (Strikwold et al. 2013) was used 
as starting point in the present study to evaluate the effect of human interindividual variation 
in kinetics for phenol induced developmental toxicity. The kinetic constants derived in the 
present study from incubations with the pooled human female liver samples were used in the 
PBK model. Subsequently a sensitivity analysis was performed using the same approach as 
described by Strikwold et al. (2013) to determine parameters that influenced the model 
outcome.
Then, interindividual variability in phenol glucuronidation was assessed using a population 
of ten female individuals. To this purpose, the kinetic constants (Vmax and Km) for liver 
glucuronidation obtained from incubations with individual female human liver S9 
homogenates were included in the PBK model for phenol (Strikwold et al. 2013). With the 
PBK models, maximum phenol plasma concentrations (Cmax) at an oral dose level of 25 mg/
kg bw were calculated for each individual.
To enable prediction of kinetic variation in a larger human population, interindividual 
variability was assessed by linking the PBK model of phenol (Strikwold et al. 2013) with 
Monte Carlo simulations. To this end, a PBK model was developed in which the kinetic 
constants for glucuronidation of phenol were described with the kinetic constants obtained 
in the present study from incubations with recombinant UGT enzymes. Together with literature 
reporting human variation in expression of these UGT enzymes, Monte Carlo simulations 
could be performed on interindividual human differences in glucuronidation of phenol in the 
liver. The Monte Carlo simulations were performed in connection with the PBK model to 
simulate phenol plasma concentrations that could occur in the human female population at 
an oral dose of 25 mg/kg bw, when taking interindividual human variation in the maximum 
glucuronidation rate (Vmax) of phenol in the liver into account. The predicted variation in the 
Cmax of phenol at an oral dose level of 25 mg/kg bw obtained with the Monte Carlo simulation 
was compared to the Cmax values of phenol predicted by the individual PBK models for the ten 
individuals at an oral dose level of 25 mg/kg bw. So far, only variation in phenol glucuronidation 
was taken into account in both approaches, next to the use of average values for the other 
model parameters.
In addition to the analysis above, a Monte Carlo simulation was performed that in addition 
to variation in UGT expression, also included the interindividual human variation in the oral 
absorption coefficient (ka), because the sensitivity analysis revealed this to be another 
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parameter of major influence (Strikwold et al. 2013). No interindividual human variation in 
the remaining model parameters was included since they were shown by the sensitivity 
analysis to be of limited influence.
For the Monte Carlo modelling, a total of 10,000 simulations were performed. The 
distributions were truncated at ±3 SD by excluding individuals with a Vmax value for UGT1A6 
and/or UGT1A9 and/or a ka value higher or lower than three times the SD of the geometric 
mean values from the Monte Carlo simulation. This resulted in a final population of 9956 and 
9907 individuals for respectively simulations with variation in UGTs and simulations with 
variation in both UGTs and ka. In each simulation, the values of the model parameters Vmax for 
UGT1A6 and UGT1A9 and the ka were randomly taken from the log-normal distribution. The 
log-normal distribution of a parameter was defined by the mean (µW) and the standard 
deviation (σW) according the equations defined by Zhang et al. (2007):
and
where µX represents the average of Vmax_UGT or ka and CVx is the coefficient of variation for each 
of the values. In the simulation, the parameters were allowed to vary independently from one 
another. The average ka value was 7.62/h which was obtained from the rat in situ intestinal 
perfusion study of Humphrey et al. (1980) and assumed to be applicable for human. The 
average value for the apparent Vmax of UGT1A6 and UGT1A9 were experimentally obtained in 
the present study amounting 7.3 and 9.7 nmol/min/mg protein, respectively. The coefficients 
of variation (CV) representing interindividual variation in the glucuronidation activity by 
UGT1A6 and UGT1A9 amounting to 76% and 55% respectively, were taken from the literature 
(Court 2010) and attributed to the Vmax values of these UGTs in the PBK model. The CV for ka 
was assumed to be 30% representing a moderate level of variation (Covington et al. 2007).
Model predictions with Monte Carlo simulations were performed with Berkeley Madonna 
(version 8.3.18, UC Berkeley, CA, USA). The population distribution generated with the Monte 
Carlo simulation was statistically analysed with GraphPad (GraphPad Prism 5.0 software, 
San Diego, CA, USA) to calculate the geometric mean, and different percentiles of the Cmax 
values of phenol obtained from the Monte Carlo analysis. The population distribution enabled 
the prediction of the CSAF, which was obtained by dividing the percentile (90th and 99th of the 
population) of Cmax by the geometric mean of Cmax (IPCS 2005).
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REVERSE DOSIMETRY AND DOSE-RESPONSE ANALYSIS 
In analogy to our previous study (Strikwold et al. 2013), reverse dosimetry was applied using 
the maximum plasma concentration (Cmax) as appropriate dose metric. To this end each 
concentration tested in the EST (ECx), was set equal to the maximum plasma concentration 
of unconjugated phenol in the PBK model for the average female that used kinetic constants 
determined using pooled female liver samples, providing effective external oral dose levels 
(EDx) (Strikwold et al. 2013). From these EDx values, an in vivo dose-response curve was 
derived and a 95% lower confidence limit of the benchmark dose at 5% benchmark response 
(BMDL05) using the Benchmark Dose Software (BMDS) version 2.6 from the Environmental 
Protection Agency (EPA). Calculations were performed with the logProbit model because this 
model provided the best fit for our previous predicted dose-response curve for phenol in 
humans (Strikwold et al. 2013). Subsequently, the dose-response curve of a sensitive individual 
in the population, represented by the 99th percentile obtained from the Monte Carlo 
simulations, was visualised by applying the CSAF (99th percentile of Cmax) to the dose-response 
curve of the average population, assuming linear kinetic processes at these dose levels.
RESULTS
FORMATION OF PHENYLGLUCURONIDE BY POOLED FEMALE HUMAN LIVER
MICROSOMES AND INDIVIDUAL FEMALE HUMAN LIVER S9
Table 1 presents the kinetic constants Km, Vmax and the scaled catalytic efficiencies for 
glucuronidation as obtained in incubations with pooled female human liver microsomes and 
individual female liver S9 preparations. The Km and Vmax for the glucuronidation of phenol 
obtained with pooled female microsomes were 771 µM and 64 µmol/h/g liver, respectively.
The average Vmax and Km of the ten individuals amounted to 976 µM and 78 µmol/h/g liver, 
respectively. The difference between the highest and lowest Km value predicted for the ten 
females is 4.8-fold. Interestingly, the Km value of individual H_217 is 257 µM which is relatively 
low compared to the Km values obtained with the pooled females (Km = 771 µM) and the Km 
values obtained with the other individual liver samples (mean Km = 976 µM). The difference 
between the highest and lowest scaled Vmax values of the individuals is 2.3-fold. The mean 
scaled Vmax of the ten individuals is reasonably in accordance with the scaled Vmax obtained from 
incubations with pooled female liver microsomes, namely 78 versus 64 µmol/h/g liver 
respectively. The kinetic constants obtained for the ten females were used in the PBK models 
for the individuals, of which the model predictions were used to assess the consequences of 
interindividual differences in glucuronidation of phenol for the resulting Cmax values.
The coefficients of variation (CVs) of the in vitro determined Vmax and Km of the ten 
individuals were 32% and 30%, respectively and the resulting CV for the scaled catalytic 
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efficiency (Vmax/Km) of the ten females was 79%. This relative high CV for the scaled catalytic 
efficiency is caused by female H_217 which has a relative low Km value of 257 µM, but a Vmax 
value comparable to the other individuals. Removing this subject from the dataset provides a 
CV of 36% for the scaled catalytic efficiency, hence providing a moderate variation in 
glucuronidation activity for the individuals.
Table 1 Kinetic constants Km, Vmax ± SD and catalytic efficiencies for the formation of the metabolite
phenylglucuronide of phenol in incubations with pooled and individual female human liver fractions.
Human 
source
Km(app)a Vmax(app)b In vitro 
catalytic 
efficiencyc
Scaled 
Vmax(app)d
Scaled 
catalytic 
efficiency 
livere
Age Racef
Pooled 
microsomes
771 ± 147 33.4 ± 1.9 43.3 64.1 83.2 33-78 C, AA, H
Individual S9
H_120 842 ± 190 6.3 ± 0.46 7.5 54.4 64.6 57 C
H_251 1213 ± 337 13.0 ± 1.3 10.7 111.4 91.8 42 C
H_280 1098 ± 433 11.8 ± 1.6 10.8 101.2 92.2 36 C
H_291 1224 ± 437 5.6 ± 0.73 4.5 47.7 39.0 18 C
H_393 1024 ± 426 11.0 ± 1.6 10.8 94.6 92.3 30 C
H_428 1115 ± 105 11.5 ± 0.39 10.3 98.7 88.5 57 C
H_177 1169 ± 376 6.1 ± 0.73 5.2 52.3 44.7 45 C
H_205 786 ± 200 10.7 ± 0.87 13.7 92.2 117.3 48 C
H_217 257 ± 72 9.2 ± 0.54 36.0 79.2 308.4 66 C
H_220 1035 ± 451 5.7 ± 0.86 5.5 49.1 47.5 33 C
Statistics
Mean ± SD  976 ± 292 9.1 ± 2.9 11.5 78.1 98.6
CV (%) 30 32 79
a µM.
b nmol/min/mg protein in tissue fraction.
c µl/min/mg protein in tissue fraction.
d µmol/h/g liver.
e ml/h/g liver.
f C=Caucasians; AA=African American; H=Hispanic.
FORMATION OF PHENYLGLUCURONIDE BY RECOMBINANT UGT ENZYMES
Incubations with cDNA recombinant expressed UGT enzymes were performed to determine 
which UGT enzymes are able to glucuronidate phenol. Figure 1 presents the formation of 
phenol glucuronide for each tested UGT during 45 min of incubation under similar conditions. 
Especially UGT1A6 and UGT1A9 were able to form phenylglucuronide, followed by UGT2B7. 
Binnenwerk Proefschrift Marije Strikwold def.indd   119 05-04-16   16:32
120
Chapter 5
Extrahepatic UGT1A7, UGT1A8 and UGT1A10, which are amongst others differentially 
expressed in oesophagus, stomach, small intestine, colon, bile duct, lung and kidney (Tukey 
and Strassburg 2000; Ohno and Nakajin 2009), were also able to glucuronidate phenol, as 
well as UGT1A1 and UGT2B15. Each of these extrahepatic UGTs and UGT1A1 and 2B15 
showed a conversion that was lower than 5% of the sum of phenylglucuronide formed by all 
individual tested UGTs, under similar screening conditions. Glucuronidation of phenol was 
not detected for UGT1A3, UGT1A4, UGT2B4, UGT2B10 and UGT2B17 during the 45 min of 
incubation.
 
Figure 1 Activity of human UGT isoenzymes for the glucuronidation of phenol tested with SupersomesTM 
(baculovirus expressed insect microsomal preparations). UGT isoenzyme activity is expressed as the percentage of 
the sum of the individual UGT isoenzyme activities tested under similar screening conditions (see section Materials 
and methods). Isoenzyme activities are average values obtained from 2 or 3 independent experiments.
Determination of the contribution of each individual UGT in vivo required a correction of Vmax 
of each UGT by the respective RAF. To determine the Vmax and other kinetic values, the rate of 
glucuronidation by UGT1A6, UGT1A7, UGT1A8, UGT1A9, and UGT2B7 with increasing 
concentrations of phenol was determined of which the results are presented in Figure 2. The 
kinetic constants Vmax, Km, Ki and k, together with the RAFs and the (scaled) catalytic 
efficiencies of the UGTs are presented in Table 2. The RAFs determined in the present study 
for UGT1A6 and UGT1A9 were 3.4 and 0.57 respectively. The RAF for UGT2B7, which is an 
average of three RAF values from literature is 1.7 (Al-Subeihi et al. 2015; Kato et al. 2012; 
Saabi et al. 2013). At present no specific probes for UGT1A7, UGT1A8 and UGT1A10 are 
available, which hampers determination of RAFs for these enzymes. As the metabolic 
conversion by these enzymes is observed to be lower than for UGT1A6 and UGT1A9 (i.e. lower 
catalytic efficiency) and as UGT1A7, UGT1A8 and UGT1A10 are only present in extrahepatic 
tissues these enzymes were not included in the PBK model to evaluate interindividual 
differences using Monte Carlo simulations. UGT2B7 did not show saturation kinetics, and 
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showed a linear increase in the rate of glucuronidation with an increasing phenol concentration 
up to at least 8000 µM. Taking into account the relatively low scaled catalytic efficiency of 
1.44 ml/h/g liver for UGT2B7 compared to the scaled catalytic efficiencies of 43.2 and 20.8 
ml/h/g liver for UGT1A6 and UGT1A9 respectively, together with the relative low glucuronidation 
activity of UGT2B7 at phenol concentrations below 1000 µM (Figure 2) which are 
physiologically relevant, no major contribution of UGT2B7 towards the glucuronidation of 
phenol in the female human liver was expected. 
a     b
   
c     d
   
e
 
Figure 2 Concentration dependent formation of phenylglucuronide by cDNA recombinant expressed UGT enzymes: 
a UGT1A6 (n=3 ± SD), b UGT1A7 (n=2 ± SD), c UGT1A8 (n=2 ± SD), d UGT1A9 (n=2 ± SD), e UGT2B7 (n=3 ± SD).
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Both, UGT1A6 and UGT1A9 have a much higher affinity (reflected by a lower Km) for phenol 
compared to the other UGT enzymes. Incubations with UGT1A9 with phenol concentrations 
above 900 µM resulted in substrate inhibition, but this concentration is above phenol plasma 
concentrations at relevant dose levels. When taking into account the kinetic plots of the UGTs 
and the scaled catalytic efficiencies which are corrected by the RAF, UGT1A6 and UGT1A9 are 
estimated to be the UGTs predominantly contributing to the glucuronidation of phenol in the 
female human liver and these UGTs were thus included in our PBK model to evaluate 
interindividual differences using Monte Carlo simulations.
To evaluate the performance of the RAF approach to estimate phenol glucuronidation in 
female human liver, the sum of the scaled catalytic efficiencies of the individual enzymes 
UGT1A6 and UGT1A9 was compared to the scaled catalytic glucuronidation efficiency that 
was measured with pooled female human liver microsomes. It can be concluded that the RAF 
approach performed reasonably well with the sum of the scaled catalytic efficiencies of the 
individual enzymes UGT1A6 and UGT1A9 predicting 77% of the total catalytic glucuronidation 
efficiency that was measured with pooled female human liver microsomes. 
Table 2 Kinetic constants Vmax, Km ± SD, Ki, k, RAF values and catalytic efficiencies of the formation of the
metabolite phenylglucuronide of phenol in SupersomesTM.
Enzyme Vmax(app)a Km(app)b Ki(app)c k(app)d In vitro 
catalytic 
efficiencye
RAFf Scaled 
Vmax(app)g
Scaled 
catalytic
efficiency 
liverh
UGT1A6 7.3 ± 0.6 1108 ± 239 N/A N/A 6.6 3.4 47.8 43.2
UGT1A7 2.5 ± 0.6 5565 ± 1985 N/A N/A 0.45 - j
UGT1A8 4.6 ± 1.5 6475 ± 3096 N/A N/A 0.71 - j
UGT1A9 9.7 ± 3.3 509 ± 288 1529 ± 834 N/A 19.0 0.57 10.6 20.8
UGT2B7 -i -i N/A 0.44E-3 0.44 1.7 k 1.44
a nmol/min/mg protein.
b µM.
c µM.
d nmol/min/mg protein/µM substrate.
e µl/min/mg protein. In case of UGT2B7 the catalytic efficiency is defined by the slope of the linear relation 
between the rate of formation as a function of the substrate concentration.
f -
g µmol/h/g liver.
h ml/h/g liver.
i Could not be derived because of linear kinetics.
j No specific probe available.
k Average of three RAF values from literature (Al-Subeihi et al. 2015; Kato et al. 2012; Saabi et al. 2013).
N/A: not applicable.
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PBK MODELLING, MONTE CARLO SIMULATIONS AND CSAF
Given that in the present study the phenol PBK model was defined with some updated kinetic 
parameters an updated sensitivity analyses was performed (See supplementary data A). This 
analysis confirmed that especially the kinetics for glucuronidation of phenol in the liver and 
the oral absorption coefficient ka were parameters that influenced the maximum predicted 
phenol plasma concentration (Cmax). 
Two methods were applied to evaluate the influence of interindividual variation in glucuro-
nidation on phenol plasma concentrations in the female human population. At first, variation 
in phenol plasma levels was determined for a group of ten human females. With the kinetic 
constants obtained in the present study for the ten female subjects, PBK models were 
developed for each individual female. Figure 3 presents the predicted phenol plasma Cmax for 
each female at an oral dose of 25 mg/kg bw obtained with the PBK model. The geometric 
mean phenol plasma Cmax of the ten females is predicted to be 152 µM and the difference 
between the highest and the lowest Cmax of phenol is 3.2-fold. The geometric CV of the 
predicted Cmax values is 36%. 
 
 
Figure 3 Box and whisker plot representing the distribution of maximum plasma concentrations of phenol (Cmax) at 
an oral dose of 25 mg/kg bw predicted with the PBK models for the ten females (dots represent values for 
individual females) and distributions predicted with PBK models linked with Monte Carlo (MC) simulation for 9956 
individuals with a PBK model with interindividual variation in the Vmax of UGT1A6 and UGT1A9 and for 9907 
individuals with interindividual variation in the Vmax of UGT1A6 and UGT1A9 and in the ka for oral absorption. The 
whiskers represent the minimum and maximum phenol plasma Cmax of each population.
Secondly, a Monte Carlo simulation (n=9956) was performed at an oral dose of 25 mg/kg bw 
to evaluate the interindividual variation in phenol plasma concentrations that could occur in 
a larger female human population, taking interindividual variation in phenol glucuronidation 
by UGT1A6 and UGT1A9 into account. The distribution of parameters used in the Monte Carlo 
simulations is included in Table 3. Figure 3 presents a box and whisker plot visualising the 
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spread in the Cmax of phenol for this population. The geometric mean phenol plasma Cmax is 
202 µM, which is 1.3-fold higher than the geometric mean for the ten individuals. The 
difference between the highest and the lowest phenol plasma Cmax predicted with the Monte 
Carlo simulations is 6.8-fold, is larger than the difference in Cmax of 3.2-fold observed for the 
10 individuals. The geometric CV of the predicted Cmax values is 31%, which is comparable to 
the geometric CV of the 10 individuals. Comparing the phenol plasma Cmax predicted for the 
ten individuals and the Monte Carlo simulations with variation in UGT, indicates that the small 
group of ten individuals reasonably represents the geometric mean phenol plasma kinetics 
of a large population, but that for defining the outer boundaries of the population distribution 
which are relevant to identify sensitive individuals, a Monte Carlo simulation appears more 
appropriate.
Table 3 Distribution of parameters used in the Monte Carlo simulations.
Parameter Mean CV (%) Min-max simulation values Fold-variation
Vmax_UGT1A6(app)a 7.3 76 0.76 - 43.8 57
Vmax_UGT1A9(app)a 9.7 55 1.81 - 39.6 22
kab 7.62 30 3.0 - 17.6 5.8
a nmol/min/mg protein.
b /h, value obtained from the rat in situ intestinal perfusion study of Humphrey et al. (1980).
In a subsequent step, Cmax of phenol in the female population at an oral dose of 25 mg/kg bw 
was calculated with the PBK model linked with the Monte Carlo analysis (n=9907) that 
included not only variation in UGT1A6 and UGT1A9 activity but also variation in ka. A box and 
whisker plot visualising the spread of Cmax of this analysis is included in Figure 3, and Figure 
4 presents the frequency distribution of the predicted Cmax of phenol. The geometric mean of 
the Cmax of phenol in the simulated population is 194 µM and the median Cmax in this 
population is 202 µM. The difference between the highest and the lowest Cmax value in the 
simulated population at the dose of 25 mg/kg bw is 15.8-fold. Comparing the Monte Carlo 
predictions with and without ka as a variable parameter indicates that introducing variation 
in ka in the Monte Carlo analysis increased the difference between the highest and lowest 
predicted Cmax value in the population distribution from 6.8-fold to 15.8-fold. This result also 
demonstrates that variation in ka provides an important contribution to variation in the 
population distribution of the Cmax of phenol. Overall, the Monte Carlo simulation including 
variation in Vmax of the UGTs and ka provides the best insight in interindividual differences in 
the kinetics of phenol.
The data now obtained for the distribution of the plasma Cmax of phenol in the population 
can be used to obtain a chemical specific adjustment factor (CSAF) for the interindividual 
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variation in the kinetics of phenol. Such a CSAF can be defined based on the ratio of the 90th 
or the 99th percentile of the population distribution divided by the mean value (IPCS 2005). 
For this analysis the results obtained with Monte Carlo simulations that included variation in 
UGT1A6, UGT1A9 and ka were used. The geometric mean, the 90th and the 99th percentiles 
of the plasma Cmax of phenol are 194, 303 and 391 µM, respectively. The CSAF thus obtained 
amounted to 1.6 when using the 90th percentile, while the CSAF amounted to 2.0 when the 
99th percentile was used thus including even the most sensitive individuals. The CSAF of 2.0 
could replace the default uncertainty factor of 3.16 that accounts for interindividual human 
kinetic differences (IPCS 2005). 
 
Figure 4 Frequency distribution for the maximum predicted plasma concentration (Cmax) of phenol in 9907 
individuals after Monte Carlo simulation including variation in Vmax of UGT1A6, UGT1A9 and ka with our PBK model 
for phenol at an oral dose of 25 mg/kg bw. The GM, P90 and P99 represent the geometric mean, the 90th and the 
99th percentile of the distribution corresponding to 194, 303 and 391 µM phenol in plasma.
DOSE-RESPONSE ANALYSIS
In an additional step the PBK models were used to analyse the consequences of the detected 
interindividual variation in Cmax values for the predicted in vivo dose-response curves for the 
developmental toxicity of phenol in human. To this end, the in vitro effect concentrations that 
were previously obtained with the EST (Strikwold et al. 2012) were converted to in vivo 
effective doses applying PBK-based reverse dosimetry. First reverse dosimetry was applied 
using the PBK model for the average female human based on the average kinetic constants 
derived from the incubations with pooled female human liver microsomes in the present 
study. The resulting dose-response curve is presented in Figure 5. The BMDL05 derived from 
this dose-response curve of the average female was 27 mg/kg bw and can serve as a PoD for 
the risk assessment. In a next step the interindividual variation in Cmax and ka values was 
taken into account by dividing the dose-response curve data with the CSAF obtained for the 
99th percentile. The curve thus obtained (Figure 5) reflects the consequences of the 
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interindividual variability in phenol kinetics for the ultimate dose-response curve for human 
developmental toxicity presenting the curve for the most sensitive females in the population. 
 
Figure 5 Dose-response curve (95% lower confidence limit) predicted with the in vitro PBK approach, visualising 
the average (solid black line) and the susceptible (dashed black line) individuals of the human population. The 
curve for the susceptible individuals in the population is derived by applying the CSAF (99th percentile of Cmax) to 
the dose-response curve of the average population.
DISCUSSION
The present study aimed to demonstrate an approach that combines in vitro toxicity data, 
PBK modelling and Monte Carlo simulations to assess the consequences of human 
interindividual variation in kinetics for phenol induced developmental toxicity. The sensitivity 
analysis of the PBK model of phenol for the average female population as predicted in the 
present study revealed that especially the oral absorption coefficient (ka) and glucuronidation 
of phenol in the liver were parameters that influenced the maximum predicted phenol plasma 
concentration (Cmax) and these parameters were therefore included in the evaluation of 
interindividual variation in the present study. At first, glucuronidation of phenol was 
determined with ten individual human female liver fractions and the kinetic constants 
obtained were used to define individual PBK models of phenol for each female which were 
used to predict phenol plasma levels. Secondly, to enable prediction of interindividual 
variation in a larger human population, Monte Carlo simulations were performed in connection 
with our PBK model for phenol, simulating interindividual human variation on the basis of the 
conversion of phenol by UGT enzymes and literature reported information on variation in 
expression of these enzymes. In a final step also variability in the oral absorption coefficient 
was included in the analyses.
UGT enzymes involved in glucuronidation of phenol have not been fully characterised 
before. Our studies with SupersomesTM revealed that UGT1A1, UGT1A6, UGT1A7, UGT1A8, 
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UGT1A9, UGT1A10, UGT2B7 and UGT2B15 are intrinsically able to glucuronidate phenol. The 
present study revealed that UGT1A6 is the primary UGT responsible for the glucuronidation of 
phenol in the liver followed by UGT1A9. The scaled catalytic efficiency of the other enzymes 
capable to glucuronidate phenol was lower than that of UGT1A6 and UGT1A9, which implies 
that these UGT enzymes will not contribute to the in vivo glucuronidation of phenol to a 
significant extent. The importance of UGT1A6 and UGT1A9 in the glucuronidation of phenol is 
in line with the involvement of these UGT enzymes in the glucuronidation of a series of 
p-substituted phenols (Ethell et al. 2002).
In the present study variability in phenol glucuronidation was assessed based on in vitro 
kinetic data obtained with experiments using UGT isoforms and human variation in expression 
of these UGT derived from the literature from a human liver bank of 54 people (man and 
woman) (Court 2010). Court (2010) did not find any significant effect of gender, age (when 
age > 20 years) and smoking on the glucuronidation activity in the liver by UGT1A6 and 
UGT1A9. However, consuming alcohol was associated with an increased glucuronidation of 
the specific probes serotonin (UGT1A6) and propofol (UGT1A9). Additionally, drug intake, diet 
or environmental factors (Guillemette 2003) may also influence the activity of UGT enzymes 
as well as genetic polymorphisms. As no gender differences were observed for UGT1A6 and 
UGT1A9 (Court 2010) the reported CVs were considered adequate and used to simulate 
developmental toxicity in the female population in the Monte Carlo modelling.
Within the present study the focus was on including variability in the most sensitive 
parameters that influence the model outcome. For this reason, the kinetic constants for 
glucuronidation of phenol and the oral uptake rate constant were varied in the Monte Carlo 
simulations. Little information exists on variation in uptake of compounds from the intestine, 
whereas from our Monte Carlo analysis with and without variation in ka it can be concluded 
that variation in ka provides an important contribution to variation in the population 
distribution of Cmax of phenol. It is expected that oral absorption of the phenols is driven by 
passive diffusion. Factors like gastric emptying time, gastrointestinal motility, bile secretion 
and pH may in general influence passive diffusion (Martinez and Amidon 2002), but it is 
unknown if these factors give rise to the CV of 30% that was applied in the present study 
representing a moderate level of variation (Covington et al. 2007), or whether the CV of 30% 
should be considered a worst case approach to model interindividual variability in ka. Further 
research towards interindividual variation in the oral uptake rate may be undertaken to define 
a CV representing variation in the human population for this parameter. 
For phenol, the population distribution of the phenol plasma concentration generated by 
the Monte Carlo simulation including variation in UGT1A6, UGT1A9 and ka provided 
information to predict a CSAF, which was calculated by the ratio of Cmax of phenol at the 99th 
percentile and the geometric mean, resulting in a CSAF of 2.0. Comparing the CSAF of 2.0 
derived in the present study to the default uncertainty factor of 100.5 (=3.16) for interindividual 
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human kinetic differences shows that for phenol the default safety factor is adequately 
protective. The CSAF could replace the default uncertainty factor for interindividual kinetic 
differences of 3.16 when one would derive a human health-based guidance value for phenol.
Reverse dosimetry was applied with the PBK model for the average individual providing an 
in vivo dose-response curve from which a BMDL05 of 27 mg/kg bw for the average female in 
the population was derived. When this BMDL05 is used as a PoD for deriving a health-based 
guidance value, in addition to the CSAF of 2.0 for interindividual human kinetic differences, 
also other uncertainty factors may be needed. This includes first of all an uncertainty factor 
of 100.5 (=3.16) accounting for human variability in toxicodynamics. Furthermore, one could 
argue that because the extrapolation was based on in vitro toxicity data obtained with cells of 
animal origin (mouse ES-D3 cells) an additional uncertainty factor of 100.4 (=2.5) should be 
applied for interspecies differences in toxicodynamics. The default uncertainty factor of 100.6 
(=4.0) accounting for interspecies kinetic differences (IPCS 2005) can be omitted because 
the PBK model of phenol describes the kinetics directly for humans. The total uncertainty 
factor thus obtained amounts 15.9 and applying this factor to the PoD of 27 mg/kg bw that 
was derived from the in vivo dose-response curve of phenol for the average female population 
predicted with in vitro PBK-based reverse dosimetry would provide a guidance value of 1.7 
mg/kg bw/d. This values is 3.4-fold higher than the TDI of 0.5 mg/kg bw/d derived from a 
BMDL10 of 52 mg/kg bw for maternal toxicity obtained from a developmental toxicity study 
(Argus 1997) using an overall uncertainty factor of 100 (EFSA 2013). This difference is mainly 
due to the use of a CSAF of 2.0 instead of the default value of 3.16 and not applying the 
uncertainty factor of 4.0 accounting for interspecies kinetic differences because the PBK 
model for phenol directly applies for humans. Thus, the difference is not caused by the fact 
that the PoD was derived from an in vitro-PBK based alternative approach, instead of taken 
from an in vivo developmental toxicity study.
It can be argued whether an additional uncertainty factor should be applied to account for 
uncertainties regarding the use of the in vitro PBK approach, for example regarding 
differences in sensitivity between an in vitro toxicity assay and an in vivo system toward a test 
compound and uncertainties that may result from PBK models that are just defined by in vitro 
and silico predicted input parameters. So far, PoDs for developmental toxicity predicted with 
the in vitro PBK approach are within a 10-fold difference compared to in vivo reported 
developmental toxicity PoDs (Louisse et al. 2010; Louisse et al. 2014; Strikwold et al. 2013; 
Strikwold et al. 2016). Based on these data it might be advocated to replace the default 
uncertainty factor of 2.5 for interspecies toxicodynamic differences by a factor of 10 when a 
PoD is used that is derived with the in vitro PBK approach (when cells from animal origin are 
used). Applying this uncertainty factor of 10 together with the CSAF of 2.0 for interindividual 
differences in human kinetics and the uncertainty factor of 3.16 that accounts for 
interindividual human dynamic differences, provides a total uncertainty factor of 63.2, 
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resulting in a guidance value of 0.43 mg/kg bw/d for phenol which closely resembles the 
current TDI of 0.5 mg/kg bw/d.
Finally, it is of importance to stress that during pregnancy, biochemical and physiological 
changes occur which may possibly affect phenol plasma levels. In humans, glucuronidation is 
controlled by a wide array of nuclear receptors of which some are influenced by sex specific 
hormones (i.e. estradiol, progesterone) (Jeong 2010), which change during the course of 
pregnancy and may possibly lead to an increased glucuronidation. The present study did not 
explicitly take into account variation in UGT activity during pregnancy, because refining model 
predictions is not straightforward when the glucuronidation activity changes during the course 
of pregnancy. However, since results indicate that glucuronidation in humans may increase 
during pregnancy (Miners et al. 1986), phenol plasma levels may be lower than predicted in 
the current study where the kinetic parameters for the PBK model were determined for the 
non-pregnant female population for which data and microsomal samples were available. 
Given that increased glucuronidation will result in lower and thus less toxic plasma levels of 
phenol it can be concluded that the results obtained are adequately protective.
In conclusion, this study exemplifies a modelling approach to integrate in vitro toxicity 
data, PBK modelling and Monte Carlo simulations to predict safe human guidance values 
taking into account interindividual human kinetic variation. The strength of this approach is 
that it provides a risk assessment that is directly relevant to the human situation, based on 
only in vitro and in silico data.
 
 
SUPPLEMENTARY DATA A
 
Figure S1 Normalised sensitivity coefficient for parameters of the PBK model of phenol in human based on Cmax 
values obtained after a single oral dose of 1.5 mg/kg bw (black bars) and 150 mg/kg bw (grey bars). Normalised 
sensitivity coefficients ≥ 0.2 are presented. VL=fraction liver tissue, ka=oral absorption coefficient, MPL=liver 
microsomal protein yield, CPL=liver cytosolic protein yield, VmaxLPS=unscaled maximum rate of sulfation of 
phenol in liver, VmaxLPG= unscaled maximum rate of glucuronidation of phenol in liver, KmLPG=Michaelis-Menten 
constant for glucuronidation of phenol in liver.
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OVERVIEW
Alternatives to animal testing are increasingly important for toxicological safety assessments 
of chemicals. Especially a number of recent regulatory shifts within the European Union (EU) 
have made the development of non-animal based approaches in chemical risk assessment 
more important (EC 2007; EC 2009), as well as economical limitations, ethical objections 
and concerns about the predictivity of animal based safety tests. During the past decades, 
many in vitro assays have been developed to test the toxicity of compounds, but until now 
they are mainly used for screening and prioritising chemicals with limited applications in 
quantitative risk assessment. An important reason for the limited use of in vitro data in 
current risk assessment practice is that in vitro toxicity outcomes are not directly applicable 
to the in vivo situation. More specifically, in vitro derived concentration-response curves 
cannot provide an in vivo dose-response curve from which a point-of-departure (PoD) for the 
risk assessment can be derived. Converting in vitro effective toxicity concentrations into in 
vivo effective dose levels by applying physiologically based kinetic (PBK) modelling was the 
major aim of the present thesis. In the present thesis we demonstrated the potential of a 
combined in vitro PBK-based modelling approach to translate in vitro toxicity data to in vivo 
toxicity values for rat and human predicting in vivo dose-response curves that allow definition 
of a PoD for risk assessment. We used in silico and in vitro defined PBK model parameters, 
and assessed interindividual variability by combining the in vitro PBK approach with Monte-
Carlo simulations.
The present thesis focussed on predicting developmental toxicity using the murine 
embryonic stem cell differentiation test (EST) as a representative in vitro assay for this endpoint. 
Phenol and a series of p-substituted phenols were selected as the model compounds, 
representing a series of compounds that have not been evaluated before in the EST. The 
selected phenols have different chemical properties regarding lipophilicity and reactivity.
 In chapter 2 we first evaluated the applicability of the EST to test the potential 
embryotoxicity for the selected series of phenols. To this purpose, toxicity data obtained with 
the EST for the phenols were compared to potency data reported for these compounds in the 
literature in the whole embryo culture (WEC) assay, being another in vitro assay for 
developmental toxicity. Next, the in vitro potency data generated with the EST were also 
compared to literature data reporting results from in vivo developmental toxicity tests. We 
found that the potency ranking of the EST was identical to the potency ranking of the WEC 
assay. However, the compound p-heptyloxyphenol was relatively more potent in the EST 
compared to the WEC assay, which may possibly result from the different endpoints that were 
used to define embryotoxicity and differences in the kinetic behaviour of the test compound 
in both assays. Furthermore, we found that the EST did not provide a similar potency ranking 
for the phenols when compared to in vivo developmental toxicity data obtained from literature. 
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The reason for the observed disparities may be diverse, and insight into the causes of these 
disparities is necessary to ultimately enhance the applicability of the EST in practice 
(Spielmann et al. 2006). For the present set of phenols, we hypothesised that combing in 
vitro derived toxicity values with kinetic data describing the absorption, distribution, 
metabolism and excretion (ADME) of the phenols in vivo may (partly) explain the disparities 
observed between the in vitro and the in vivo relative embryotoxic potencies. Such an 
integration of in vitro toxicity data with kinetic modelling may improve predictions of in vitro 
derived embryotoxic potency data of the test compounds, and theoretically may also be 
applied to quantitatively predict in vivo effective dose levels as well as PoDs enhancing the 
applicability of in vitro assays for quantitative risk assessment purposes.
In chapter 3 of the present thesis we demonstrated that combining in vitro embryotoxicity 
data derived from the EST with PBK modelling based reverse dosimetry, could indeed 
adequately translate in vitro effect concentrations to in vivo effective dose levels from which 
a PoD could be derived, with phenol as the model compound of interest. We developed PBK 
models for phenol in rat and human based on data obtained from in silico and in vitro 
experiments and data from the literature. Important parameters describing the ADME of 
phenol in vivo were the oral absorption coefficient and the metabolism of phenol. 
Glucuronidation and sulfation of phenol in different organs were included in the PBK models 
for rat and human based on in vitro data obtained from incubations with rat and human 
subcellular organ fractions. In vitro effect-concentrations obtained with the EST were 
translated to in vivo effective dose levels applying PBK-based reverse dosimetry, from which 
an in vivo dose-response curve and a PoD was derived. The predicted PoD for phenol fell 
within the variation of PoDs obtained from studies reported for developmental toxicity of 
phenol in the rat, indicating the applicability of this approach for quantitative hazard and risk 
assessment purposes.
After providing a proof-of-principle for the extrapolation of in vitro toxicity data to the in vivo 
situation using PBK-based reverse dosimetry for the compound phenol, it was investigated in 
chapter 4 of this thesis whether the in vitro PBK-based reverse dosimetry approach would 
also be successful for predicting in vivo potential developmental toxicity of the p-substituted 
phenolic congeners tested in the EST. Furthermore it was investigated whether the approach 
could overcome the difference observed between the in vitro and in vivo derived relative 
embryotoxic potencies for the phenols, particularly for p-heptyloxyphenol. The PBK model for 
phenol in the rat was used as a starting point to construct PBK models for the phenols that 
were included in this study. Adjustments that were made consisted of modelling 
glucuronidation in the liver as the sole route of metabolism as this was found to be the 
principle metabolic pathway and addition of a fat compartment because of the relatively high 
lipophilicity of p-heptyloxyphenol. Moreover, we also included in vitro transport experiments 
to predict the relative oral absorption of the phenols, and added a placental/foetal 
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compartment to quantify transfer of the compounds from mother to foetus and vice versa. 
With the in vitro PBK-based reverse dosimetry approach we could overcome the disparities 
that were observed between the in vitro and the in vivo relative potencies of the phenols, also 
for the compound p-heptyloxyphenol for which relative toxicity compared to phenol was more 
than three orders of magnitude higher in the EST while differed less than one order of 
magnitude in vivo (chapter 2). The most important parameter underlying the improved 
prediction for p-heptyloxyphenol, when combining the results of the EST with PBK modelling 
based reverse dosimetry, was the relatively rapid metabolism of this compound by 
glucuronidation. Moreover, the relatively low placental transport of heptyloxyphenol and the 
relatively high tissue:plasma partition coefficient of p-heptyloxyphenol compared to those for 
the other phenols were factors that contributed to an improved prediction.
In chapter 3 we have applied the in vitro PBK approach to predict developmental toxicity 
of phenol for the average human. In this chapter we did not take into account the variation in 
the population that might occur in sensitivity to developmental toxicity of phenol, as a result 
of interindividual human variation in kinetics, while such information may be valuable for risk 
assessors to derive human guidance values. In chapter 5 of this thesis we demonstrated an 
approach that combines in vitro toxicity data, physiologically based kinetic (PBK) modelling 
and Monte Carlo simulations to assess the effects of human interindividual variation in 
kinetics for phenol induced developmental toxicity. We used two approaches to obtain insight 
in interindividual differences in phenol glucuronidation. One approach involved in vitro 
quantification of the kinetic constants for glucuronidation of phenol using subcellular liver 
samples from ten individual females. The kinetic constants obtained for each female were 
included in our previously developed PBK model for phenol (Strikwold et al. 2013). The 
predicted difference between the maximum phenol plasma concentrations (Cmax) of the ten 
individual females was limited (3.2-fold). The other approach involved quantification of 
glucuronidation of phenol by UGT enzymes. The UGT specific kinetic constants obtained were 
included in the PBK model of phenol (Strikwold et al. 2013) together with information about 
the variation in activity of these UGTs in the population. Subsequently, Monte Carlo simulations 
were performed generating a population distribution of the Cmax of phenol, which showed a 
6.8-fold difference between the highest and the lowest predicted Cmax value, which is higher 
than the difference in Cmax observed for the ten females. In a next step interindividual variation 
for the oral absorption coefficient, which according to the sensitivity analysis (Strikwold et al. 
2013) also highly influenced the model outcome, was included in the Monte Carlo simulations 
as well providing a 15.8-fold difference between the highest and the lowest predicted Cmax 
value. Based on the results obtained from the latter Monte Carlo simulation a chemical 
specific adjustment factor (CSAF) of 2.0 was derived, that covers interindividual human 
kinetic variation. Based on this outcome, it was concluded that the default safety factor of 
3.16 applied for interindividual human kinetic differences in the safety assessment of 
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chemicals seems adequate protective. Then, PBK-based reverse dosimetry was applied in 
which the vitro effect concentrations obtained from the EST were set equal to in vivo plasma 
concentrations using Cmax as an appropriate dose metric, generating effective dose levels. 
Benchmark dose modelling provided a dose-response curve and a PoD (BMDL05) for the risk 
assessment. Dividing the dose-response curve data obtained with in vitro PBK-based reverse 
dosimetry, with the CSAF obtained for the 99th percentile of the population provided a dose-
response curve that reflects the consequences of the interindividual variability in phenol 
kinetics for the developmental toxicity of phenol presenting the dose-response curve for the 
most sensitive individuals. Altogether, we demonstrated an approach that provided a toxicity 
estimate that is directly relevant to the human situation including interindividual variation, 
which can be applied for the risk assessment of chemicals, without the need for animal 
testing.
 
Overall, this thesis demonstrated the potential of the combined in vitro PBK approach to 
translate in vitro toxicity data to in vivo toxicity values for rat and human and to predict in vivo 
dose-response curves and define a PoD for risk assessment. The next sections discuss the 
most critical steps in the presented approach in some more detail, together with some 
important future perspectives. Topics discussed include especially: 
• The use of the EST for predicting developmental toxicity in vitro 
• PBK modelling considerations
• The use of different kinetic reverse dosimetry approaches to perform in vitro to in vivo 
extrapolations (IVIVE)
• The possibility to take interindividual variations into account and
• Future perspectives
THE USE OF THE EST FOR PREDICTING 
DEVELOPMENTAL TOXICITY IN VITRO
A first topic to discuss in some more detail is the use of the EST for predicting developmental 
toxicity, both in comparison to the WEC assay, being another in vitro assay for developmental 
toxicity as well as in comparison to in vivo developmental toxicity.
COMPARISON EST AND WEC ASSAY
For the series of phenols included in the present thesis, the toxic potency data obtained 
with the EST were close to the toxic potency data reported in the WEC assay, except for 
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p-heptyloxyphenol which was much more potent in the EST compared to the WEC assay. 
Reasons for the difference in the observed toxicity between the assays for p-heptyloxyphenol 
may be multiple, of which some may be related to the lipophilic nature of p-heptyloxyphenol 
(logD7.0 = 4.4 (ACD/Labs 2015)). Inconsistent in vitro results between the EST and the WEC 
assay have also been observed for the lipophilic compound retinoic acid (logD7.0 = 4.0 (ACD/
Labs 2015)), for which the EC50 in the EST was 80-fold lower than the EC50 in the WEC assay 
(Louisse et al. 2011). Moreover, the EST appeared also to be up to 11-fold more sensitive 
than the WEC assay towards a series of six triazoles (de Jong et al. 2011) which have 
moderately high logD7.0 values varying between 2.7 and 3.9 (ACD/Labs 2015).
As discussed in chapter 2, the lower albumin fraction in the EST compared to the WEC 
assay may result in a higher free fraction of p-heptyloxyphenol in the EST, which may enhance 
toxicity. In addition, it was reported that phenols easily reach the conceptus and especially 
p-heptyloxyphenol was found to accumulate in the WEC assay (Fisher et al. 1993), indicating 
that the yolk sac hardly forms any barrier for compounds to move from the medium to the 
conceptus in the WEC assay and that the affinity for the conceptus is high, especially for the 
lipophilic compound p-heptyloxyphenol (Fisher et al. 1993). Such an accumulation of the 
compound may also occur in the embryonic stem cells and/or embryonic bodies of the EST 
and enhance the toxicity of p-heptyloxyphenol. In addition, it may be hypothesised that the 
embryonic stem cells and the embryonic bodies of the EST have a larger surface area-to-
volume ratio than the rat conceptus in the WEC assay, enhancing uptake of lipophilic 
compounds from the culture medium into the cells. As a result the cells of the EST may be 
more exposed to lipophilic compounds that have a large affinity for the cellular content/
membrane and hence may be more vulnerable for toxicity than the conceptus in the WEC 
assay. Moreover, it has been shown that cell density may impact the free concentration; more 
cells would result in a lower amount of chemical per cell, diminishing toxicity (Gülden et al. 
2010). Additionally it has been proposed that expressing toxicity as moles per cell would 
facilitate the comparison between assays carried under different experimental conditions 
(Doskey et al. 2015). However, providing such a dose metric is difficult for the EST, because 
of significant changes in cell number during the course of the assay.
Another difference between the assays that may result in a more sensitive outcome of the 
EST compared to the WEC assay, is the different exposure window. In the EST applied in the 
present study (De Smedt et al. 2008), chemical exposure of the embryonic cells started at 
single cell suspension and continued ten days in which the cells developed into an embryoid 
body, subsequently forming contracting cardiomyocytes after plating on non-adherent petri-
dishes. In the rat WEC assay, the conceptus (including decidual tissue and an intact yolk sac) 
(ECVAM 2010) is placed in culture medium containing the test compound at gestational dag 
(GD) 9.5 (ECVAM 2010) or GD10 (Oglesby et al. 1992), and generally cultured for 48-h. Thus, 
the EST and the WEC assay may encompass different events in the developing embryo, with 
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possibly different sensitivity windows for exposure. Another important difference between the 
assays is the in vitro endpoint tested, which in the EST is differentiation of stem cells into 
beating cardiomyocytes, while the test outcomes of the WEC assay also include morphological 
endpoints, which on first sight may better reflect adverse outcomes of developmental toxicity 
in vivo. In spite of this, the EST appeared to work well also for compounds known to induce 
malformations in vivo (de Jong et al. 2009).
Overall, for most of the phenolic test compounds included in this thesis comparison of the 
EST with the WEC assay did not reveal large differences in the toxicity outcome between the 
assays, except that the EST was more sensitive towards the lipophilic compound 
p-heptyloxyphenol. Considering that the EST is a sensitive test, it may be regarded a suitable 
assay to study embryotoxicity. Nonetheless, it is recommended to further explore how in vitro 
kinetic processes i.e. related to lipophilicity should be accounted for when applying the EST 
in the hazard or quantitative risk assessment of chemicals.
PREDICTIVE CAPACITY OF THE EST FOR IN VIVO DEVELOPMENTAL TOXICITY
FOR THE PHENOLS
Another issue to discuss when considering the use of the EST for predicting developmental 
toxicity in vitro is the predictivity of the EST for the model compounds used for the present 
studies. The phenols studied in the present thesis, may be regarded as weak embryo toxicants 
in vivo as developmental effects were reported to occur at relatively high oral dose levels 
(developmental NOAEL or BMD10 > 40 mg/kg bw) (chapter 2). Our studies showed a limited 
ability of the EST to correctly predict the relative embryotoxic potency of the phenols, 
especially regarding p-heptyloxyphenol. Two validation studies using a diverse set of 
compounds, tested the performance of the EST and provided variable results regarding the 
ability of the assay to correctly predict in vivo developmental toxicity (Genschow et al. 2004; 
Marx-Stoelting et al. 2009).
One very important aspect that may limit the predictive capacity of the EST is the lack of 
metabolic capacity of the assay. This was clearly demonstrated in the present thesis, in which 
metabolism was an important parameter describing the in vivo kinetics of the phenols in the 
PBK models and which revealed that, when translating vitro toxicity data to in vivo 
developmental toxicity values applying PBK-based reverse dosimetry, the predictive 
performance of the EST for the phenols improved. Apart from metabolism, other reasons that 
might explain the poor predictivity of the EST may be related to the absence of a well defined 
applicability domain for the EST which is further discussed below. 
APPLICABILITY DOMAIN OF THE EST
When using the EST for predicting in vivo developmental toxicity it is also important to consider 
its applicability domain. The applicability domain of a bioassay may involve the chemical 
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structure, and/or biological space for which it is applicable to make predictions for new 
compounds (Hartung et al. 2004; Judson et al. 2013). Thus, the applicability domain of an 
assay may include a statement about the toxicity endpoint that is being predicted and 
physico-chemical properties or structural fragments of compounds for which the test is 
applicable. Carefully defining an applicability domain may be difficult for in vitro toxicity 
assays, because the number of compounds tested is often relatively small (Judson et al. 
2013). This especially holds for the classical EST, which is not a high-throughput assay. At 
present, the applicability domain of the EST is not well defined. Considerations about the 
developmental toxicity endpoints that might be detected by the EST are discussed in some 
more detail below.
 
DEVELOPMENTAL TOXICITY ENDPOINTS IN RELATION TO THE EST
In the classical EST, differentiation of the embryonic stem cells into beating cardiomyocytes 
is evaluated after 10 days of chemical exposure. This is a simplified endpoint of 
embryogenesis/developmental toxicity. It has been shown that embryoid bodies, which are 
formed during the assay, can generate cells from the three different germ layers (ectoderm, 
endoderm and mesoderm) (Keller 1995), suggesting similarities with in vivo cellular 
processes for cardiac differentiation (van der Laan et al. 2012). Additionally, the EST 
resembles the functional interaction between different cells types like sinus node, ventricular 
and atrial cells (Tandon and Jyoti 2012). The EST may cover early events in development and 
differentiation, but lack the ability to test for morphological effects (Spielmann et al. 2006; 
van der Laan et al. 2012). Moreover, the EST is not able to mimic all complex pathways of 
developmental toxicity, which may limit its applicability. For example, it has been stated that 
the murine EST roughly covers a time window of the first GD5-10 in the rat (Ozolinš. 2010). 
Adverse effects of chemicals on embryonic developments that occur after this period, such 
as neural differentiation, may possibly remain undetected in the classical EST as has been 
observed for the compound methylmercury (He et al. 2012; Stummann et al. 2008).
From the example of methylmercury, and as has been outlined by others (Dreisig et al. 
2013; Piersma et al. 2013), it may become clear that the EST cannot function as a stand-
alone assay to test developmental toxicity. Enlarging the applicability domain to predict 
toxicity that reflect a wide array of developmental toxic effects can be achieved by testing 
additional in vitro endpoints (using embryonic stem cells), for example on neurodevelopmental 
toxicity (Theunissen et al. 2013), developmental bone toxicity measured by osteoblast 
formation and calcification of osteoblasts (Kuske et al. 2012) and endocrine disruptive 
endpoints (Jomaa et al. 2014). Toxicity could be identified using a combination of different 
read-outs like transcriptomic and proteomic profiles and flow cytometric, functional, 
physiological and morphological biomarkers (Garcia-Käufer et al. 2014; Louisse et al. 2012).
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In addition, (in vitro) assays testing placental transport of compounds (i.e. with BeWo cells in 
a so-called transwell system) and effects of compounds on the functioning of the placenta 
should be considered, because an altered placenta function may affect the wellbeing of the 
foetus (Myllynen et al. 2005). Current in vitro assays however, do not cover the variety of 
endpoints of the placenta, requiring the development of biomarkers for placental toxicity 
(Vähäkangas et al. 2014).
Altogether, different in vitro assays each covering a different sensitive aspect of foetal and 
embryonic development, could be applied in combination with the EST in a tiered approach 
to optimise the strategy for in vitro developmental toxicity testing (Kroese et al. 2015; Piersma 
et al. 2013).
 
PBK MODELLING CONSIDERATIONS
In chapter 3, 4 and 5 we translated in vitro outcomes of the phenols obtained in the EST to in 
vivo toxicity values applying PBK-based reverse dosimetry. PBK modelling forms an essential 
link in this extrapolation step, describing the ADME of a compound. Important steps that 
determine the quality of the PBK model are the definition of the PBK model structure and the 
selection of input parameters of the PBK model. These topics affecting the quality of the 
predictions made will be discussed in some more detail.
SELECTION AND PREDICTION OF RELEVANT INPUT PARAMETERS OF THE PBK 
MODELS FOR THE PHENOLS
To comply with the replacement, reduction and refinement (3Rs) principle in the most optimal 
way in the present thesis, all the parameters required for the PBK models, except the oral 
absorption coefficient in the PBK model of phenol (chapter 3), were predicted with in vitro 
and in silico approaches. Selecting such an in vitro approach to predict the kinetic properties 
of interest may not be straightforward. For instance, in the present thesis, transport across 
the small intestine to ultimately predict the oral absorption of the phenols (chapter 4) was 
quantified with transport studies using Caco-2 cells, but other approaches like the parallel 
artificial membrane permeability assay (PAMPA)(Kansy et al. 2004), or the use of MDCK cells 
(Volpe 2011; Wang et al. 2014) could also have been considered. For the phenols, for which 
passive diffusion is likely to be the most dominant transport route, selecting a different 
approach would probably provide comparable results. However, when transfer is facilitated by 
transporters, a more specific selection of the cellular system to be used may be required. 
Clearly, the applicability and the performance may differ per assay and depends on the 
physico-chemical properties of the test compound, and the species to be modelled. However, 
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for many in vitro tests the applicability domain is not (well) defined yet and efforts need to be 
undertaken to achieve this. Defining the applicability domain for in vitro ADME assays, in 
analogy to Quantitative Structure-Activity Relationships (QSARs) (Fjodorova et al. 2008), may 
therefore be valuable.
Evaluating the PBK models with a sensitivity analysis revealed that, apart from the oral 
absorption coefficient, glucuronidation of phenol in the liver is an influential parameter on the 
model outcome, both for phenol as well as for the p-substituted phenols. The capacity of the 
liver to glucuronidate the phenols was derived from in vitro assays with subcellular fractions 
from rat and human livers. The metabolic constants obtained from these experiments were 
extrapolated to in vivo relevant values and included in the PBK model. The resulting PBK 
model predictions provided adequate phenol plasma levels, which were quantitatively 
evaluated by comparing the values of the compound phenol to in vivo plasma levels reported 
for this compound in the literature. From these results, it is believed that the approach 
applied in the present thesis to predict metabolism of phenols in vivo was appropriate, not 
only for phenol, but also for the p-substituted phenols.
 Metabolic formation of hydroquinone was not selected as a parameter to be included in 
the PBK models of the phenols. In literature, it has been hypothesised that some of the 
adverse effects of phenol might be due to its hydroxylated metabolite hydroquinone (Bruce et 
al. 2001). In vivo, only at higher oral doses of phenol (150 mg/kg bw) hydroquinone was 
present in elevated levels in urine being excreted as the corresponding glucuronide conjugate 
(Hiser et al. 1994). A developmental NOAEL of 100 mg/kg bw was established for hydroquinone 
in rats (Health Council of the Netherlands 2012; Krasavage et al. 1992) that received 
hydroquinone orally during GD6-16. Developmental NOAELs of phenol, derived by studies 
that used comparable species and dosage regimens as used for deriving the NOAEL of 
hydroquinone, were 60 and 120 mg/kg bw (Argus 1997; Jones-Price et al. 1983). Given that 
the in vivo embryotoxic effects were only observed at relatively high oral dose levels of 
hydroquinone comparable or higher than embryotoxicity values reported for phenol, it seems 
unlikely that the adverse effects of phenol detected in vivo can be ascribed to the (limited) 
formation of hydroquinone in the metabolic pathway of phenol.
It is also of interest to note that when phenol and hydroquinone were added together in 
the WEC assay, a synergistic toxic effect was observed (Chapman et al. 1994). The authors 
hypothesised that this effect might be due to the fact that phenol enhances the reaction of 
hydroquinone to benzoquinone providing free radical intermediates (Chapman et al. 1994). 
Chapman et al. (1994), however, did not report addition of antioxidants to the WEC assay, 
while hydroquinone is unstable due to auto-oxidation. Considering that the antioxidant GSH 
may prevent auto-oxidation of hydroquinone (Moridani et al. 2002) and is present in rat and 
human blood and tissues up to millimolar concentrations (Jain and Flora 2012; Pastore et al. 
2003), we do not expect that synergism has an (important) role on phenol induced 
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developmental toxicity in vivo. Moreover, the metabolic profile reported for an in vivo kinetic 
study in rat with low to high oral doses of phenol (1.5, 15 and 150 mg/kg bw) did not report 
formation of benzoquinone (metabolites) (Hiser et al. 1994). Taken together, it is assumed 
that the parent compound phenol itself is responsible for the developmental toxicity observed 
and that its plasma and/or tissue concentrations can be expected to provide an adequate 
descriptor for prediction of the toxic effects that are observed in vivo. 
As illustrated for phenol, defining metabolism, both qualitatively and quantitatively is an 
essential step when developing a PBK model. For phenol, the major metabolic pathways are 
well known and reported in literature, but, when extending the approach to other compounds, 
it is good to realise that for many compounds such kinetic information is lacking. A first step 
is then elucidating the reactions involved in metabolism of the compound and the products 
that are formed. In silico tools, like the expert systems Meteor (Lhasa Ltd., Leeds, UK), 
StarDrop (Optibrium Ltd., Cambridge, UK), and MetaSite (Molecular Discovery Ltd., Middlesex, 
UK) (T’Jollyn et al. 2011) may be helpful to identify molecular sites liable to metabolism and 
the type of metabolites expected to be formed. Subsequently, in vitro metabolic assays, 
followed by chemical metabolic profiling can be applied to confirm and/or refine these 
predictions and define the pathways quantitatively in vitro as well as to define the related 
kinetic constants required for the PBK models. It should be recognised that this may be 
labour intensive, but as was clear from the proof-of-principle provided in the present thesis, 
it is an indispensable aspect to define and parameterise the PBK models required to translate 
in vitro toxicity values to in vivo dose levels.
PBK MODELLING OF A PLACENTAL/FOETAL COMPARTMENT
In the PBK models described in chapter 4, we included a newly developed placental/foetal 
compartment that models placental transfer based on in vitro transport experiments with 
BeWo cells and partitioning of the compound in the embryo/foetus using partition coefficients. 
This approach comprises an important but currently lacking aspect in the extrapolation of in 
vitro derived embryotoxicity values to the in vivo situation. The measured transfer of the 
phenols across the BeWo cells was rapid, except for p-heptyloxyphenol for which transport in 
vitro was less rapid compared to the other phenols possibly due to binding to albumin in the 
apical compartment of the transport assay as discussed in chapter 4. The transport of p-heptylo-
xyphenol may be somewhat larger in vivo, because of prevailing dynamic fluid conditions in vivo, 
opposed to the static situations in the BeWo assay (Li et al. 2013), although such a relation 
should be further explored. The predicted foetal plasma concentrations for all phenols were 
close to maternal levels, except for p-heptyloxyphenol, for which the foetal concentrations were 
predicted to be lower than maternal plasma levels. This result seems to be in line with data 
reported in the literature for phenol and p-nitrophenol for which foetal and maternal plasma 
levels were reported to be similar indeed (Abu-Qare et al. 2000; Gray and Kavlock 1990). 
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An additional feature of the placental/foetal compartment in our PBK model is that it may 
aid in elucidating whether the embryotoxic effect is a result of a direct action of the compound 
or maternally mediated, although this was not the scope of the present thesis. For some 
of the phenols, embryotoxicity in vivo occurred at a similar or somewhat higher dose level 
than maternal weight changes, which may raise the question whether embryotoxic effects 
observed in vivo are due to indirect maternal effects or are induced by a more direct action 
of the compound. Disentangling whether embryotoxic effects observed in vivo are due to a 
direct action of the compound or mediated by maternal toxicity is difficult (Daston et al. 
2010), but it may be important for the risk assessment (Spielmann et al. 2006). This aspect 
can be especially of importance when defining the most sensitive endpoint for risk assessment 
or for classification and labelling of a compound. With respect to phenol, for which both foetal 
and maternal toxicity has been reported, it is of interest to note that our experiments with the 
EST indicate that the phenols have the potency to cause embryotoxic effects. The transport 
studies with BeWo cells showed that the phenols may readily pass placental cells facilitating 
foetal exposure. Including a placental/foetal compartment in the PBK model provided foetal 
systemic concentrations that were close to maternal concentrations (except for p-heptylo-
xyphenol). Thus, it may be hypothesised that embryotoxicity observed in vivo at maternally 
toxic doses could still be mediated by a direct action of the compound since we predicted that 
the embryo/foetus itself is exposed to the compound, even at concentrations similar to those 
in maternal plasma in the case of phenol, p-fluorophenol and p-methylketophenol. For 
p-heptyloxyphenol in vivo dose levels causing maternal toxicity were lower than the dose 
levels causing embryotoxic effects (Kavlock 1990), which is in line with the difference in 
maternal and foetal circulating concentrations predicted with our in vitro PBK approach. 
Altogether, including a placental/foetal compartment in PBK modelling may provide valuable 
information to refine the toxicological assessment of developmental toxicants.
Taken together, the definition of the PBK model structure and the selection of input 
parameters of the PBK model are aspects that can greatly affect the quality of the PBK model 
and the PBK-based reverse dosimetry prediction, especially regarding input parameters that 
are influential on the model outcome. Developing and applying in silico and in vitro tools to 
predict in vivo kinetic processes that have a well defined applicability domain is essential. 
This holds especially true for approaches in predictive toxicology, where in vivo kinetic data 
are lacking for most compounds to be tested.
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THE USE OF DIFFERENT KINETIC REVERSE
DOSIMETRY APPROACHES TO PERFORM IN
VITRO TO IN VIVO EXTRAPOLATIONS (IVIVE)
Another aspect that determines the quality and applicability of the in vivo toxicity predictions 
using in vitro toxicity data is the choice for the approach that is applied to perform kinetic 
reverse dosimetry. To illustrate this, the in vitro PBK approach is briefly compared other in 
vitro in vivo extrapolation approaches, and the different characteristics of the approaches are 
discussed. In addition, the selection of the dose metric used in kinetic reverse dosimetry is 
also addressed.
COMPARISON OF KINETIC REVERSE DOSIMETRY APPROACHES
The present thesis used PBK models to translate in vitro toxicity data to in vivo toxicity values. 
Recently, other approaches have been reported which also apply reverse dosimetry modelling 
to link the in vitro effect concentration to an in vivo oral effective dose level (Rotroff et al. 
2010; Wetmore et al. 2012; Wetmore et al. 2013; Wetmore et al. 2015). These authors 
described a high throughput-in vitro in vivo extrapolation (HT-IVIVE) approach for risk 
assessment, in which at least two in vitro kinetic parameters were measured, namely protein 
binding and hepatic metabolic clearance. These data were included in the simple kinetic 
equation of Wilkinson and Shand (1975) to calculate the steady state concentration of a 
parent compound (Css (µM)) in plasma at a low dose exposure level of 1 mg/kg bw/d. 
Subsequently, this relation is used to calculate an oral equivalent dose of EC50 values 
obtained from in vitro kinetic (toxicity) studies.
In general, the in vitro PBK approach applied in the present thesis describes the ADME 
processes in more detail than the HT-IVIVE. Important differences between the models are 
related to the description of the kinetics of the metabolic processes, the selection of 
(additional) compartments (i.e. a foetal compartment), the description of the distribution of 
a compound within an organism and the selection of the dose metric. An overview of the 
main differences between the in vitro PBK approach applied in the present thesis and the HT-
IVIVE approach (Rotroff et al. 2010; Wetmore et al. 2012; Wetmore et al. 2013) is presented 
in Table 1.
In general, the HT-IVIVE approach may provide a more conservative toxicity estimate 
(Thomas et al. 2013). It should be realised, however, that this may not always be the case and 
depends on the kinetic processes to be modelled in connection with model characteristics 
and the model input parameters. For example, in the in vitro PBK approach we included 
Michaelis-Menten kinetics (or substrate inhibition when applicable) to describe the 
metabolism of the phenols, while the HT-IVIVE approach assumes linear metabolic kinetic 
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processes and uses a metabolic clearance that was derived with the substrate depletion 
method at a low concentration of either 1 or 10 µM. When a similar clearance value is applied 
for situations where higher plasma concentrations prevail than the 1 or 10 µM, the HT-IVIVE 
approach will underestimate the metabolic turnover, resulting in a higher internal (plasma) 
concentration of the parent compound, but lower concentrations of a metabolite than actually 
is the case. This provides a conservative toxicity estimate when the parent compound is 
responsible for toxicity but would lead to an underestimation of the risk when the metabolite 
is the toxic entity. With this respect it is important to note that the HT-IVIVE approach is not 
able to predict toxicity values induced by metabolites of the parent compound that is 
modelled, as it only makes predictions based on the parent compound and not based on the 
metabolites. With in vitro PBK-based reverse dosimetry, however, it is possible to model the 
formation of metabolites and predict in vivo toxicity values based on the metabolites formed 
(Louisse et al. 2010). Another example which may lead to under prediction of the risk is 
bioaccumulation of the toxic compound in a target organ, which is not modelled with the HT-
IVIVE approach. This was, however, also not included in our PBK model, because the phenols 
were not expected to accumulate.
Overall, the characteristics of the in vitro PBK and the HT-IVIVE approaches affect the 
applicability of each approach for the risk assessment of chemicals. The HT-IVIVE approach 
is a generic model especially suitable to provide a first tier toxicity estimate that can be 
characterised by a higher degree of uncertainty, and predictions are based on more 
conservative assumptions (Thomas et al. 2013). The PBK model developed in the present 
thesis is applicable for a higher tier toxicological assessment, although PBK models may also 
be applied in the first tier when they have more generic characteristics, for example modelling 
only a limited number of compartments.
 
Binnenwerk Proefschrift Marije Strikwold def.indd   146 05-04-16   16:32
147
General discussion and future perspectives
6
Table 1 Overview of differences in the characteristics of the kinetic models applied in the in vitro PBK and the HT-
IVIVE reverse dosimetry approaches.
Model characteristic In vitro PBK approach 
present thesisa
HT-IVIVE approacha,b
Absorption
Oral uptake First order (but can be adjusted)
100% bioavailability, but can be 
adjusted based on Caco-2
Zero-order
100% bioavailability, but can 
be adjusted based on Caco-2
Distribution
Partition coefficients Y N
Target organs for safety testing Y N
Placental/foetal compartment Y N
Blood-brain-barrier Can be implemented N
Binding to specific target molecules Can be implemented N
Prediction target organ concentration Y (i.e. concentrations in liver or in 
foetus)
N
Metabolism
Hepatic metabolism In vitro derived kinetic constants 
from enzyme kinetic studies 
considering different models (i.e. 
Michaelis-Menten, substrate 
inhibition model)
Clearance value determined 
in vitro at a low concentration 
assuming linear metabolic 
kinetics (See text for details)
Non-specific binding to microsomes Y N
Prediction of target specific formation 
and levels of reactive metabolites 
Y N
Excretion
Glomerular filtration rate Not included, because regarded 
quantitatively not relevant for 
phenol
Included
Other
Dose metric for reverse dosimetry Cmax, AUCc 
Can be adjusted to Css for 
comparison
Css
Time Time dependent analysis 
i.e. to see when Css is established
One time (data) point  
(steady state)
Inter- and intraspecies modelling Y N
Route-to-route extrapolations Can be implemented N
Evaluation repeated dosing regimens Can be implemented N
a Included (Y) or not included (N) in the kinetic reverse dosimetry approach.
b Approach presented by Rotroff et al. (2010) and Wetmore et al. (2012, 2013, 2015).
c Maximum test concentration (Cmax); area under the concentration-time curve (AUC); steady state concentration 
(Css). For more details, see section Selection of dose-metric for the in vitro to in vivo extrapolation.
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SELECTION OF DOSE-METRIC FOR THE IN VITRO TO IN VIVO EXTRAPOLATION
The choice of an adequate dose metric to be used, for example the maximum test 
concentration (Cmax) or the area under the concentration-time curve (AUC), is an important 
step when performing extrapolations from in vitro toxicity data to in vivo toxicity values. It has 
been advocated that for reversible (toxic) reactions the peak concentration may be the 
appropriate metric but that for irreversible toxic actions the AUC may be preferred due to an 
increase in effect over time (Groothuis et al. 2015).
Daston (2010) reported that developmental toxicity is likely to be dependent on the peak 
concentration. For the present set of phenols, the PBK model based reverse dosimetry 
predicted in vivo toxicity values corresponded better to the in vivo toxicity values obtained 
from the literature when extrapolations were based on Cmax values instead of the AUC (chapter 
3 and 4). This dose-metric corresponds to the observation that toxicity of the phenols is 
associated with a polar narcosis mechanism (Hansch et al. 2000; Yi and Liu 2005) for which 
Cmax is regarded an appropriate dose metric (Groothuis et al. 2015). 
It has been suggested by some authors (Daston et al. 2010) to multiply the applied test 
concentration by the duration of the assay to obtain an AUC. This approach may be used as a 
first screening to assess differences between the dose metrics i.e. Cmax or AUC on the model 
predictions when applying PBK-based reverse dosimetry. However, an important next step 
may be characterisation of the behaviour of the test compound in the in vitro assay, as in vitro 
kinetic processes may influence the AUC as was shown in the present thesis (chapters 2 and 
3). It is likely that the test design of the EST, by using the hanging drop technique in the first 
three days of the assay, attributes to evaporation of (semi)-volatile compounds, as phenol 
disappeared rapidly during the first culturing day, while evaporation was much less after 3 
days when phenol was present in petri dishes and 24-well plates. Moreover, it remains also 
to be seen how the dose metrics Cmax and AUC will affect toxicity predictions when considering 
different in vitro assays such as the EST and the WEC assay which have large differences in 
the test duration, namely 10 days versus 48 hours. 
An additional step in establishing the appropriate dose metric, may be investigating the 
behaviour of the concentration-response curves at different durations of exposure to evaluate 
whether a change in the AUC in vitro results in a change in the prediction of toxicity. It should 
be kept in mind, however, that changes in concentration-response curves may also be 
induced by a specific window of heightened susceptibility of cells towards the test compound 
during an assay, especially when the in vitro assay encompasses different processes 
regarding proliferation and differentiation like the EST.
Thus, identifying an appropriate dose metric for the PBK model based in vitro to in vivo 
translation is not straightforward, especially not in predictive toxicology when no information 
about the in vivo effect is available. Therefore, further insight in the relation of different dose 
metrics and toxic effects, preferably mechanistically based, is required. 
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THE POSSIBILITY TO TAKE INTERINDIVIDUAL
VARIATIONS INTO ACCOUNT
Another aspect that is discussed in some detail in this chapter concerns the possibility to 
take interindividual variations into account to predict variation in toxicity. PBK models provide 
the opportunity to evaluate the effect of interindividual kinetic differences in toxicity. This can 
be achieved by defining PBK models for different individuals using (experimentally derived) 
kinetic constants from different humans, or by modelling variation in a (larger) population 
linking PBK modelling with Monte Carlo simulations using information on the level of variation 
of the kinetic parameters of interest in the human population, as was demonstrated for 
phenol in the present thesis. 
The sensitivity analysis of the model performance revealed that especially glucuronidation 
and the oral absorption coefficient mainly influenced the predicted levels of phenol in plasma, 
hence interindividual variation in these kinetic processes was simulated. Individuals with a 
reduced UGT1A6 and UGT1A9 activity together with an increased oral absorption are regarded 
a sensitive subgroup for phenol induced developmental toxicity. However, our results indicate 
that when the oral absorption and glucuronidation by UGT1A6 and UGT1A9 are predominant 
kinetic processes, the default uncertainty factor of 3.16 which is applied in the risk 
assessment of chemicals to account for human kinetic differences (IPCS 2005; IPCS 2010) 
may be adequately protective for phenol induced developmental toxicity. 
Multiple factors may influence the sensitivity of individuals towards a chemical, for 
example life-stage, gender, life style factors, disease status, environmental exposure, drug 
intake, as well as the genetic make up (Guillemette 2003). A number of these factors are 
expressed in the coefficients of variation of the activity of UGT enzymes that were used in the 
present thesis to predict variability in phenol glucuronidation using Monte Carlo simulations. 
Nonetheless, it should be recognised that the databank of 54 individuals (Court 2010) from 
which this information originates may not cover the full spectrum of variability in UGT enzyme 
activity in the population, including the variation caused by genetic variations in the 
population. With the increasing use of molecular techniques, more and more genetic 
variations are discovered (UGT Alleles Nomenclature Home Page 2015), but the effect of 
specific alleles on the UGT activity has only been defined for a selective number of variants. 
Further defining the influence of polymorphisms on the glucuronidation activity as well as the 
allele frequency in the population, may refine predictions of interindividual human variation 
in toxicity as presented in this thesis.
A topic that needs further attention in the prediction of interindividual human variation in 
toxicity is the variability between humans in the response of a chemical at the target site, 
such as receptor binding or signal transduction. This so called toxicodynamic difference may 
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result from factors like disease-status, genetic variability and drug or environmental exposure. 
At present, information about variations in responses caused by interindividual toxicodynamic 
differences is scarce. However, using a range of human cell lines from different individuals 
for instance obtained from biobanks and using in vitro disease models in toxicological 
research, which are becoming more and more available, may generate information about 
interindividual differences in dynamic toxicological responses. Variation in toxicological 
responses can for example be included in the in vitro in silico approach to further refine 
population based predictions on the toxicity of a chemical.
Overall, integrating in vitro toxicity data, PBK modelling and Monte Carlo simulations 
provided a unique approach to predict interindividual differences in developmental toxicity. 
The approach may provide a reliable basis to derive human guidance values and support 
population health based risk assessment, which is one of the goals outlined by the next 
generation (NexGen) framework for risk science (Krewski et al. 2014).
FUTURE PERSPECTIVES
The present thesis demonstrated that the in vitro PBK approach was able to predict in vivo 
PoDs for a series of phenols that are close to in vivo derived toxicity values and appeared to 
be a promising strategy to extrapolate in vitro toxicity values to in vivo relevant levels. The 
ultimate goal may be to apply the in vitro PBK approach in predictive toxicity for compounds 
for which no or little in vivo toxicity data are available for the endpoint of interest. Reaching 
that point requires sufficient confidence in the prediction together with regulatory acceptance, 
which may partly go hand-in-hand. This can be achieved by providing more examples, for 
different substances and different toxicity endpoints.
Based on this consideration, it would be interesting to test the validity of the in vitro PBK 
approach for other toxicity endpoints. Subsequently, a complete toxicological risk assessment 
for a set of compounds could be evaluated to see if the critical toxicological endpoint defined 
in vivo is picked up by the in vitro PBK approach. Within this context, phase I and II of the 
ToxCast program of the US-EPA (Dix et al. 2007), in which about 1000 unique compounds are 
being tested in several hundred in vitro tests including toxicity assays, may generate valuable 
information in the upcoming years. At present a subset of the in vitro toxicity data has been 
extrapolated to in vivo toxicity values using the method of Wilkinson and Shand (1975) 
(Wetmore et al. 2012; Wetmore et al. 2013; Wetmore et al. 2015), but this may possibly be 
extended in the future. Extrapolations generated so far including our approach, may support 
the definition of endpoints and groups of compounds for which IVIVE extrapolations are 
promising, but may also define bottlenecks and/or uncertainties that need to be eliminated.
Furthermore, to enlarge the future applicability of the presented in vitro PBK approach, 
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the method should also be tested for compounds that enter the body via the dermal or the 
inhalation route, in conjunction with in vitro assays that quantify uptake via these ports of 
entry. Moreover, we demonstrated a new non-animal based approach to quantify placental 
transfer using BeWo cells together with predicting the partitioning of the chemical in the 
foetus with PBK modelling, which provided adequate predictions for the phenols. However, 
more research is required to define the applicability domain for this method, focussing on 
changes in the developing embryonic/foetal compartment during pregnancy and the influence 
of physico-chemical properties of the compounds for which the method would be applicable. 
At present extrapolating in vitro toxicity values to in vivo toxicity levels has predominantly 
been performed using in vitro toxicity data generated by in vitro models using cells from 
animal origin. A next step can be the use of human cells, which in potential may closer mimic 
human biological responses than animal cells (Tandon and Jyoti 2012), and may perhaps, 
eventually, eliminate the interspecies safety factor that accounts for differences in inter-
species toxicodynamics in the risk assessment of chemicals. Within this context, the use of 
induced pluripotent stem cells (iPSC) may have an advantage over immortalised human cells 
because iPSC may better mimic essential features of primary humans cells and may 
circumvent ethical concerns regarding the use of embryonic stem cells (Yap et al. 2015). 
Furthermore, three-dimensional (3D) cell cultures in addition to two-dimensional (2D) 
cultures may be considered as 3D cultures potentially may represent more tissue functions 
that are present in the in vivo micro environment like cellular communication (Fey and 
Wrzesinski 2012), and provide opportunities to include various cell types in one model (Roth 
and Singer 2014). Moreover, it has been shown that 3D microtissues with liver cells had a 
prolonged life-time and viability, extending possibilities to test chronic chemical exposure 
(Messner et al. 2013), which is an important bottleneck in current in vitro toxicity testing. 
Moreover, the organ-on-a-chip which is a microdevice for culturing living cells that are 
continuously perfused, may encapture many advantages that were outlined above for the 
different cell culture technologies, like multicellular architecture, tissue-tissue interaction, 
together with simulating the tissue and organ physiology (Bhatia and Ingber 2014). Taken 
together, the developments in in vitro cell culture technology of which some are briefly 
discussed have the potential to improve in vitro toxicity testing in the (near) future, hence 
refining the extrapolation of in vitro effect concentrations to in vivo toxicity values.
A final factor that needs to be considered in the further development of the in vitro PBK 
approach for predicting PoDs and using them in a subsequent risk assessment is the way in 
which related uncertainties can be taken into account. To account for the extra uncertainties 
associated with the in vitro PBK-based in vivo predictions, an additional safety factor may be 
introduced when deriving safe exposure levels for the risk assessment of chemicals. Such a 
safety factor may specify uncertainties related to the in vitro toxicity assay selected, as well 
as uncertainties implicit in the in silico toxicokinetic methods. Applying such an additional 
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safety factor may be a starting point to enhance the use of the in vitro PBK model approach 
in practice, while determining the size of such an uncertainty factor may have to await the 
development and evaluation of more proofs of principle.
FINAL CONCLUSIONS
The present thesis showed that combining in vitro toxicity data with kinetic processes is 
indispensible to improve in vivo toxicity predictions, which are based on in vitro toxicity data. 
We demonstrated that combining in vitro toxicity data with PBK-based reverse dosimetry 
adequately predicted in vivo developmental toxicity values for a series of phenols. The results 
obtained demonstrate the possibility of the approach to improve toxic potency estimates as 
well as to provide quantitative toxicity estimates like a PoD, the latter solving a major 
bottleneck hampering the application of in vitro approaches in the risk assessment of 
chemicals. Moreover, this thesis is an important step forward to ultimately implement the 
envisioned paradigm shift away from studying apical endpoints in animal studies for the 
safety testing of chemicals, towards an approach that is cheaper, non-animal based and 
more directly relevant for humans.
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Many efforts have been undertaken over the past decades to develop in vitro tests for a wide 
range of toxicological endpoints as an alternative to animal testing. The principle application 
of in vitro toxicity assays still lies in the hazard assessment and the prioritisation of chemicals 
for further toxicity testing. The in vitro toxicity outcomes are hardly used in quantitative risk 
assessment of chemicals, for example to predict health-based guidance values like an 
acceptable or tolerable daily intake (ADI or TDI). An important reason for this limited use is 
that an in vitro toxicity assay cannot provide a complete in vivo dose-response curve from 
which a point of departure (PoD) for risk assessment, like a no observed adverse effect level 
(NOAEL) or a 95% lower confidence limit of the benchmark dose (BMDL) can be derived. 
Translation of in vitro toxicity data to the in vivo situation is of paramount importance to 
overcome these constraints. Physiologically based kinetic (PBK) models, which mathematically 
describe the absorption, distribution, metabolism and excretion (ADME) of a compound in an 
organism, can be used to extrapolate in vitro derived toxicity data to in vivo toxicity values.
The aim of the present thesis was to demonstrate the potential of a combined in vitro PBK- 
based approach to translate in vitro toxicity data to in vivo toxicity values for rat and human 
predicting in vivo dose-response curves that allow definition of a PoD for risk assessment. 
This translation was carried out by applying PBK-based reverse dosimetry, using in silico and 
in vitro defined kinetic parameters, and by combining the in vitro PBK approach with Monte 
Carlo simulations to assess interindividual variability. The present thesis focused on the 
prediction of in vivo developmental toxicity. The ES-D3 differentiation assay of the embryonic 
stem cell test (EST) was selected as a representative in vitro assay for this toxicity endpoint. 
Phenol and a series of para-substituted phenols being p-fluorophenol, p-heptyloxyphenol, 
p-mercaptophenol and p-methylketophenol were chosen as model compounds.
Chapter 1 introduces the methods and concepts that are used in the present thesis, 
namely in vitro developmental toxicity testing, PBK modelling and Monte Carlo simulations. 
Also the general outline of the in vitro PBK approach using reverse dosimetry is presented. 
Furthermore, a brief description of the ADME properties of each phenol that is included in the 
present thesis is given.
In chapter 2 the applicability of the EST as an alternative assay to predict developmental 
toxicity for the selected phenols was evaluated. The embryotoxic potencies of the phenols 
obtained with the EST were compared with potency data reported in the literature for the WEC 
assay, providing a similar potency ranking. The results suggest that the EST can identify the 
intrinsic embryotoxic potency of the phenols. However, when comparing the potency ranking 
of the EST to in vivo reported potency data on developmental toxicity of the phenols, it was 
concluded that the EST was not able to correctly rank the phenols according these in vivo 
potency data. Only phenol was correctly ranked, being the least potent congener, while the 
relative toxic potency of p-heptyloxyphenol was overestimated in the EST, when compared to 
the in vivo derived relative potency value. It was hypothesised that combining in vitro toxicity 
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data with kinetic modelling could improve the in vivo toxicity prediction.
In chapter 3 we combined in vitro toxicity data from the EST with PBK-based modelling for 
the compound phenol. For this purpose, PBK models were developed that describe the ADME 
of phenol in rat and human. The PBK models were parameterised with in vitro and in silico 
data and data taken from the literature. Evaluation of the PBK models pointed out that the 
oral absorption coefficient and phenol glucuronidation are influential model parameters for 
the predicted phenol plasma concentration. PBK-based reverse dosimetry was applied to 
translate the in vitro effect concentrations obtained from the EST to in vivo effective dose 
levels from which an in vivo dose-response curve was generated allowing the prediction of a 
PoD for risk assessment. The predicted PoD thus obtained for the rat lies within the range of 
PoDs for phenol obtained from in vivo developmental toxicity data from the literature. The 
results demonstrate the potential of PBK-based reverse dosimetry to translate in vitro toxicity 
data to in vivo toxicity values that can be used for quantitative hazard and risk assessment 
purposes, like deriving safe exposure levels.
In chapter 4 it was explored whether PBK-based reverse dosimetry could also successfully 
extrapolate in vitro toxicity data obtained in the EST to in vivo developmental toxicity values 
for a series of para-substituted phenols. It was of interest if this approach could overcome the 
differences observed between the in vitro and in vivo derived relative embryotoxic potencies 
for the phenols, especially for p-heptyloxyphenol. For each phenol, a PBK model for the rat 
was developed. In silico methods were selected and applied to predict input values for a 
number of PBK model parameters. In vitro assays were performed to predict metabolism of 
the test compounds and transport across the intestinal and the placental barrier. After 
completing the PBK models, reverse dosimetry was applied generating in vivo developmental 
toxicity data for each of the phenols from which a PoD was derived. These PoDs appeared to 
differ less than 3.8-fold from PoDs derived for the phenols from in vivo toxicity data available 
in the literature. The large difference that was observed between the in vitro and the in vivo 
relative embryotoxic potency for the phenols, especially for p-heptyloxyphenol, was reduced 
to a large extent after applying the in vitro PBK-based reverse dosimetry approach. Our 
modelling approach pointed towards metabolism by glucuronidation as the most important 
factor underlying the relative low toxic potency for p-heptyloxyphenol in vivo compared to the 
relatively high observed embryotoxic potency in vitro. Altogether, the results showed the 
feasibility of the PBK-based reverse dosimetry approach to properly extrapolate in vitro 
toxicity outcomes to in vivo toxicity values.
In chapter 5 we demonstrated a modelling approach that integrates in vitro toxicity data, 
PBK modelling and Monte Carlo simulations to predict the effects of human interindividual 
variation in kinetics for phenol induced development toxicity. Incubations with recombinant 
uridine diphosphate glucuronyltransferases (UDPGTs) revealed that the enzymes UGT1A6 
and UGT1A9 were mainly responsible for glucuronidation of phenol. Kinetic constants 
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describing the glucuronidation of phenol by UGT1A6 and UGT1A9 were included in the PBK 
model of phenol together with information about the variation in activity of these UGTs in the 
population and information on the interindividual variation for the oral absorption coefficient. 
Monte Carlo simulations in connection with PBK modelling provided a population distribution 
of phenol plasma concentrations, from which chemical specific adjustment factors (CSAFs) 
were calculated that cover interindividual human kinetic variation. It was concluded that the 
default safety factor of 3.16 applied for interindividual human kinetic differences in the safety 
assessment of chemicals is adequate protective, given that the predicted CSAF lies within 
this value. Dividing the dose-response curve data obtained with in vitro PBK-based reverse 
dosimetry with the CSAF provided a dose-response curve that reflects the consequences of 
the interindividual variability in phenol kinetics for the developmental toxicity of phenol. 
Altogether, this chapter presented a non-animal based approach to predict interindividual 
human variation in sensitivity to phenol induced developmental toxicity.
Chapter 6 discusses prominent aspects of the in vitro PBK-based reverse dosimetry 
approach. The items discussed encompass the selection of the EST as an alternative in vitro 
assay to predict developmental toxicity, different considerations regarding PBK modelling, 
the use of different kinetic reverse dosimetry approaches to perform in vitro toxicity to in vivo 
toxicity extrapolations (IVIVE) and the possibility to take interindividual variations into account. 
Finally, future perspectives related to the application of the PBK-based reverse dosimetry to 
predict in vivo toxicity values from in vitro toxicity data are outlined.
In conclusion, this thesis demonstrated that the approach of combining in vitro toxicity 
data with PBK-based reverse dosimetry has the potential to overcome a major bottleneck in 
the hazard and risk assessment of chemicals, since it was not only able to improve in vitro 
toxic potency estimates but more importantly it provided adequate quantitative toxicity 
estimates such as a PoD. Altogether this thesis contributes to the replacement of apical 
endpoints in animal studies for the safety testing of chemicals, towards an approach that is 
cheaper, non-animal based and more directly relevant for humans.
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